[(' As previously described (,), genotyping was performed in patients of European ancestry at the Center for Genotyping and Analysis at the Broad Institute (MAYO, VUMC, and NU) and the Center for Inherited Disease Research at the Johns Hopkins University (MC and GHC) using the Illumina Human660W-Quadv1_A genotyping platform, consisting of 561,490 SNPs and 95,876 intensity-only probes.', {'entities': [(338, 345, 'Total SNPs')]}),
 (' SNPs imputed in all datasets were not included in the analysis sample; only SNPs genotyped on at least one of the arrays (1,195,878 SNPs) were considered for inclusion in the analysis.', {'entities': [(123, 132, 'Total SNPs')]}),
 (' The kinship matrix used was constructed from 413,669 LD pruned SNPs (LD <0.', {'entities': [(46, 53, 'Total SNPs')]}),
 (' The association between the genome-wide significant SNPs and CHD were examined from results in 22,233 cases and 64,762 controls from the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study.', {'entities': [(96, 102, 'Total SNPs')]}),
 (' With 530,565 variants (491,553 SNPs and 39,012 indels) across 479 controls and 481 patients after the quality control, each individual carried a mean of 7566 synonymous, 6452 missense, and 103 protein truncating variants.', {'entities': [(6, 13, 'Total SNPs')]}),
 ('To estimate the total number of newly associated loci selected for the iCOGS replication stage, we identified a set of 22,662 SNPs selected for replication of the GWAS and not selected for fine mapping to exclude previously known loci that were uncorrelated (r _2  < 0.', {'entities': [(119, 125, 'Total SNPs')]}),
 ('For BAS in the discovery stage, a total of 509 cases of MI and 1,034\ncontrols were genotyped with the Affymetrix GeneChip_®  Human\nMapping 500K Array Set, including 500,568 SNPs.', {'entities': [(165, 172, 'Total SNPs')]}),
 (' Using the 1000 Genomes Project phase I integrated variant set as the reference panel (October 2011 release), 20,109,249 SNPs were imputed.', {'entities': [(110, 120, 'Total SNPs')]}),
 (' The resulting genotype data for 14,598,181 SNPs were subjected to further quality control checks and selected for high imputation accuracy ( > 0.', {'entities': [(33, 43, 'Total SNPs')]}),
 (' In addition to this GWAS providing a broad atheoretical test of the effect of all 527,829 SNPs, we tested 1,180 SNPs identified from a variety of publications that examined SNPs in relation to various disorders such as schizophrenia, depression, substance use, etc.', {'entities': [(83, 90, 'Total SNPs')]}),
 (' The resulting 105,291 SNPs were used to generate the principal components.', {'entities': [(15, 22, 'Total SNPs')]}),
 (' The chip also contains around 3,000 SNPs added as part of the WTCCC2 project replication phase.', {'entities': [(31, 36, 'Total SNPs')]}),
 ('  In two large cohorts included in the meta-analysis, the Netherlands Twin Register (NTR, N = 3,599 unrelated individuals) cohort and the QIMR Berghofer Medical Research Institute (QIMR, N= 3,369) adult cohort, Genomic-relatedness-matrix Restricted Maximum Likelihood (GREML) analysis in the GCTA software was applied to estimate the proportion of variance in neuroticism that can be explained by common SNPs.', {'entities': [(94, 99, 'Total SNPs')]}),
 (' Most self-reported African Americans (N=290) and self-reported Caucasians (N=549) were also genotyped at 196,726 SNPs using the Cardio-MetaboChip [] in separate batches.', {'entities': [(106, 113, 'Total SNPs')]}),
 (' Participants who did not consent to genetic analyses or who had no usable genetic material were excluded, resulting in a combined sample of 7,914 participants comprising the MESA SNP Health Association Resource (SHARe) sample.', {'entities': [(141, 146, 'Total SNPs')]}),
 (' Imputation was performed using IMPUTE () or MACH () for roughly 2.5 million SNP', {'entities': [(65, 76, 'Total SNPs')]}),
 (' We used Caucasian samples from the Psychiatric Genomics Consortium for ADHD (4,163 ADHD cases and 12,040 controls) and a bivariate model of analysis [] to estimate the SNP-genetic correlation between Han Chinese and Caucasians for liability to ADHD.', {'entities': [(99, 105, 'Total SNPs')]}),
 (' To estimate the cumulative effect of the 21 heart rate–associated loci, we calculated the GPS in 5,053 adults from the LifeLines2 study and 4,000 12-year-old children from the ALSPAC study by summing the number of heart rate–increasing alleles carried by an individual at the lead SNP of each heart rate locus.', {'entities': [(98, 103, 'Total SNPs')]}),
 (' After data cleaning, there were 656,051 SNPs for the association analyses.', {'entities': [(33, 40, 'Total SNPs')]}),
 (' Population stratification was adjusted for using the first three principal components of the genomic kinship matrix, as estimated using 28,494 uncorrelated SNPs (r_2 <0.', {'entities': [(137, 143, 'Total SNPs')]}),
 ('00 × 10_−6 ) and included 8,893,347 common SNPs in the single-variant association test.', {'entities': [(26, 35, 'Total SNPs')]}),
 (' After quality control filtering, data from 1,024,001 SNPs were available.', {'entities': [(44, 53, 'Total SNPs')]}),
 (' The significance of SNP–probe associations was assessed using a non-parametric permutation P -value, based on 10,000 permutations, and P  values <0.', {'entities': [(111, 117, 'Total SNPs')]}),
 ('01 exclusion, and Hardy-Weinberg equilibrium p-value <1E-06 exclusion, a total of 584,060 genotyped autosomal SNPs remained for use in the imputation.', {'entities': [(82, 89, 'Total SNPs')]}),
 (' After quality control, 214,705 SNPs were pre-phased with SHAPEIT v2 (r790), and genotypes were imputed with a publicly available reference panel (https://imputation.', {'entities': [(24, 31, 'Total SNPs')]}),
 ('html) () and the Centre d’ Étude du Polymorphisme Humain study population of Utah residents with ancestry from northern and western Europe (CEU) 1000 Genomes reference set (version 37), containing whole-genome sequence data from 629 individuals including 19,097,376 SNP variants ().', {'entities': [(255, 265, 'Total SNPs')]}),
 (' GOLDN-FamHS participants were genotyped on one of three Illumina platforms: (i) Illumina HumMap 550K chip with 547,353 SNP markers, (ii) Illumina Human 610-Quadv1 chip with 576,888 SNP markers, or (iii) Illumina Human 1M-Duov3 chip with 1,111,639 SNP markers [].', {'entities': [(112, 119, 'Total SNPs'), (238, 247, 'Total SNPs')]}),
 (' In total, 161,689 SNPs with poor imputation quality (info score\u2009<\u20090.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' In the absence of an South Asian specific haplotype map, the primary analysis tested the association with T2D of the 568,976 autosomal SNPs that had been directly genotyped and passed QC, amongst the South Asian GWA participants.', {'entities': [(118, 125, 'Total SNPs')]}),
 ('We imputed additional SNPs in the 1,962 samples that passed quality control standards in the GWAS, using Impute 2 version 2.', {'entities': [(34, 39, 'Total SNPs')]}),
 (' The final list comprised 220,123 SNPs.', {'entities': [(26, 33, 'Total SNPs')]}),
 (' 1,484 SNPs were removed.', {'entities': [(1, 6, 'Total SNPs')]}),
 (' After SNP quality control, 11,632 SNPs were considered to be of high genotyping quality in at least 1 country and were analyzed in stage 2.', {'entities': [(28, 34, 'Total SNPs')]}),
 (' In the initial stage, 909,622 SNPs were genotyped for the Chinese subjects.', {'entities': [(23, 30, 'Total SNPs')]}),
 (' A total of 9,966,893 SNPs were included in the meta-analysis.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' For the symmetrical analysis, we obtained 725\xa0SNPs that were significantly associated (p < 5\xa0× 10_−5 ) with\xa0SHR from a GWAS of 21,590 individuals of European ancestry.', {'entities': [(128, 134, 'Total SNPs')]}),
 ('There were 500,568 SNPs on the Affymetrix 500K chips and 164,871 on the\nPerlegen custom chip (665,439 SNPs in total).', {'entities': [(11, 18, 'Total SNPs')]}),
 (' VEGAS (versatile gene-based association study) analysis software () was used to assess the degree to which SNPs in 17,601 autosomal genes and their surrounding regions were associated with antisaccade error.', {'entities': [(116, 122, 'Total SNPs')]}),
 (' This resulted in 711,589 SNPs used for imputation in European-American subjects and 806,416 in African-American subjects.', {'entities': [(18, 25, 'Total SNPs')]}),
 (' A total of 2,072,428 SNPs were imputed, with 2,028,122 high-confidence SNPs remaining after removal of SNPs with low imputation quality (r _2\u2009 <0.', {'entities': [(12, 21, 'Total SNPs')]}),
 ('0 (containing probes for 906,600 SNPs).', {'entities': [(25, 32, 'Total SNPs')]}),
 (' After these filters, a total of 7,261 SNPs remained.', {'entities': [(33, 38, 'Total SNPs')]}),
 (' After removal of low quality imputed SNPs, 6,844,888 imputed SNPs remained for further analysis.', {'entities': [(44, 53, 'Total SNPs')]}),
 (' The following criteria were used to exclude 102,896 unreliable SNPs: minor allele frequency (MAF) < 1% (50,322 SNPs), info < 0.', {'entities': [(45, 52, 'Total SNPs')]}),
 (' Following this, linear regression was used to evaluate whether any of the 527,829 SNPs were individually associated with any of the EDA indices.', {'entities': [(75, 82, 'Total SNPs')]}),
 ('0 (574,519 single-nucleotide polymorphisms [SNPs]), and 6602 SardiNIA volunteers were genotyped with four Illumina arrays (OmniExpress, ImmunoChip, Cardio-MetaboChip, and ExomeChip; 890,542 SNPs in total).', {'entities': [(182, 189, 'Total SNPs')]}),
 (' While 735,843 SNPs were analyzed, multiple testing correction for 735,843 SNPs would be highly conservative, due to the extensive linkage disequilibrium (LD) between SNPs.', {'entities': [(7, 14, 'Total SNPs')]}),
 (' Polygenic profiles were created in PRSice  using the UK Biobank neuroticism SNP-based association results, for 7,388 unrelated individuals in GS.', {'entities': [(112, 117, 'Total SNPs')]}),
 (' A total of 13,276 SNPs proposed by the combined ER-negative GWAS yielded high-quality genotype data (5,738 from BPC3, 4,628 from TNBCC and 2,910 from C-BCAC).', {'entities': [(12, 18, 'Total SNPs')]}),
 (' This last selection step led to a final number of 7,055,881 SNPs in stage 1 analysis.', {'entities': [(51, 60, 'Total SNPs')]}),
 (' After quality control, 1,885 individuals who were genotyped at 739,284 SNPs were available for imputation.', {'entities': [(24, 29, 'Total SNPs')]}),
 (' In total, 73,355,677 SNPs, short indels and large structural variants were imputed.', {'entities': [(11, 21, 'Total SNPs')]}),
 (' Analysis here is based on the 527,829 autosomal SNPs remaining following these data cleaning steps.', {'entities': [(31, 38, 'Total SNPs')]}),
 (' The final analytic data set included 2350 gastric cancer cases and 2708 controls with genotypes for a total of 556,896 SNPs.', {'entities': [(112, 119, 'Total SNPs')]}),
 ('5 million SNP markers was performed with 669,450 high-quality genotyped SNPs and the MACH program (version 1.', {'entities': [(41, 48, 'Total SNPs')]}),
 (' Population stratification was assessed by principal component analysis (PCA) over the sample correlation matrix, based on 16,842 independent (LD-pruned) SNPs.', {'entities': [(123, 129, 'Total SNPs')]}),
 (' We generated 1,000 random SNP sets, each of the same size (n =722) as the original list of LD-pruned top signals (r _2 >0.', {'entities': [(14, 19, 'Total SNPs')]}),
 (' Across all samples 39,235,157 SNPs were imputed, with the actual number of SNPs imputed for each individual varying based on the regional density of array genotypes available.', {'entities': [(20, 30, 'Total SNPs')]}),
 (' The association P- value (on -log_10  scale) for each of up to 22,434,434 SNPs (y  axis) is plotted against the genomic position (NCBI Build 37; x  axis).', {'entities': [(64, 74, 'Total SNPs')]}),
 (' Genotypes from genome-wide, high-density SNP genotyping arrays for 16,175 AD cases and 17,176 cognitive-normal individuals were imputed.', {'entities': [(68, 74, 'Total SNPs')]}),
 (' A total of 909,622 autosomal SNPs across the entire genome were genotyped using the Affymetrix 6.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('3, thus leaving a total of 20,370,935 SNPs across chromosomes 1–22 and chromosome X.', {'entities': [(27, 37, 'Total SNPs')]}),
 (' A total of 704,409 and 706,040 SNPs passed quality control in the NHS and HPFS sets, respectively, and were used to impute the genotypes of other SNPs by means of MACH.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('0 × 10_−7  and obtained genotype data of 480,103 SNPs for 26,620 subjects.', {'entities': [(41, 48, 'Total SNPs')]}),
 (' After data cleaning and quality control, 5,697 individuals and 889,659 SNPs remained for imputation.', {'entities': [(42, 47, 'Total SNPs')]}),
 (' Both genotyped and imputed SNPs were included in these analyses, which yielded 1,211,988 million SNPs after QC procedures.', {'entities': [(80, 89, 'Total SNPs'), (86, 97, 'Total SNPs')]}),
 ('3) or low allele frequency (MAF <2 %), resulting in ∼2.24 million SNP', {'entities': [(53, 65, 'Total SNPs')]}),
 ('We tested for multiplicative SNPxMHT interactions on the genome-wide level (2.5 million SNP', {'entities': [(76, 87, 'Total SNPs')]}),
 (' Genotyping of 500,568 SNPs was attempted in each sample.', {'entities': [(15, 22, 'Total SNPs')]}),
 ('0 () with a genetic relatedness matrix (GRM) constructed from 413,669 LD pruned SNPs and 10 principal components used as covariates in a) the full cohort, b) the adversity-exposed cohort, and c) the unexposed cohort.', {'entities': [(62, 69, 'Total SNPs')]}),
 (' After the exclusion of SNPs showing logistic regression coefficient |β| > 5 or P  value equal to 0 or 1, the maximum number of SNPs in any data set was 8,131,643.', {'entities': [(153, 162, 'Total SNPs')]}),
 (' Samples were genotyped using the Illumina Human1M-Duo BeadChip (1,199,187 SNPs) as described previously ().', {'entities': [(65, 74, 'Total SNPs')]}),
 (' Application of the same quality control filters described above to the 46,180,700 imputed SNPs, with the addition of excluding SNPs with Hardy-Weinberg equilibrium P  values < 0.', {'entities': [(72, 82, 'Total SNPs')]}),
 ('[] The GERA cohort comprises a sample of 110,266 adult members of Kaiser Permanente Medical Care Plan, Northern California Region (KPNC) with high-density single nucleotide polymorphism (SNP) markers linked to comprehensive electronic health records (EHR) containing information on pharmacy utilization, laboratory test results, clinical diagnoses, and other clinical utilization.', {'entities': [(41, 48, 'Total SNPs')]}),
 (' We have approximately 550,000 SNP data from the entire human genome.', {'entities': [(23, 30, 'Total SNPs')]}),
 ('As study participants were of more than one race, we selected 22,863 SNPs with >99% call rates that were spaced at approximately 100kb intervals and used these SNPs in the principal components (PC) implemented in the Eigenstrat software package to assess population structure ().', {'entities': [(62, 68, 'Total SNPs')]}),
 (' Subjects were excluded from the US cohort if not of Caucasian or African-American ancestry as determined by STRUCTURE, or had high SNP missing rates, or if values for covariates were missing; this resulted in a total of 1,008 subjects (895 Caucasians and 113 African Americans, ).', {'entities': [(221, 226, 'Total SNPs')]}),
 (' Principal-components analyses were carried out separately for the European, Asian and African-American subgroups, on the basis of a subset of 37,000 uncorrelated SNPs.', {'entities': [(143, 149, 'Total SNPs')]}),
 (' After removing SNPs with low quality imputation, 13,519,496 SNPs were included in the discovery GWAS; and only the top 10,000 most significant SNPs (http://www.', {'entities': [(120, 126, 'Total SNPs'), (50, 60, 'Total SNPs')]}),
 (' Initially, 1.2 million SNP', {'entities': [(12, 23, 'Total SNPs')]}),
 ('8) in all the African-American and European-American cohorts resulting in a total of 10,250,422 and 6,655,203 SNPs for each ancestry group, respectively.', {'entities': [(85, 95, 'Total SNPs')]}),
 (' After quality control as described previously, 474,231 directly genotyped SNPs (MAF ≥5%) in 1,616 subjects (842 cases and 774 controls) from 1,850 total subjects were available for association testing.', {'entities': [(48, 55, 'Total SNPs')]}),
 (' Of these, 293,633 SNPs had minor allele frequencies of 1% or greater.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' Meta-analyses of linear regression slope β with 369,771 SNPs that were shared in all studies from 4 European American populations (SARP, CSGA, TENOR, and ACRN) were performed, with weights proportional to the inverse variance of β using METAL software (http://www.', {'entities': [(49, 56, 'Total SNPs')]}),
 (' Significant SNPs from the discovery stage with satisfactory imputation qualities were assessed for replication in a Norwegian case-cohort study (CONOR()) comprising 1,496 prostate cancer cases of which 791 died due to prostate cancer during follow-up.', {'entities': [(166, 171, 'Total SNPs')]}),
 (' Imputation of over 2.5 million SNP', {'entities': [(20, 31, 'Total SNPs')]}),
 (' A two-step imputation process was performed using SHAPEIT for haplotype phasing and IMPUTE2 for imputation, yielding a total of 39,345,920 imputed SNPs.', {'entities': [(129, 139, 'Total SNPs')]}),
 ('Approximately 2,000 SNPs out of the total 200,000 SNPs were selected to be included in the ImmunoChip array based on the initial association results of the bacteremia analyses.', {'entities': [(14, 19, 'Total SNPs')]}),
 (' This resulted in 257,768 SNPs.', {'entities': [(18, 25, 'Total SNPs')]}),
 (' After completion of QC and PCA, our sample consisted of 3814 African-American individuals genotyped for 883,511 SNPs.', {'entities': [(105, 112, 'Total SNPs')]}),
 ('6 Mb, NCBI build 36), which encompasses 13,516 SNPs.', {'entities': [(40, 46, 'Total SNPs')]}),
 (' We also tested the association of SNPs most significantly associated with indexed urinary uromodulin with eGFR by querying these in publicly available meta-analysis results of 67,093 individuals of European ancestry from the CKDGen Consortium.', {'entities': [(177, 183, 'Total SNPs')]}),
 (' A total of 1,922 subjects were genotyped, of which two-thirds were processed and genotyped at the Finnish Genome Center in Helsinki and one-third at the SNP Technology Platform, Uppsala University, Uppsala, Sweden (www.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' After a careful quality review, a total of 4,058,415 SNPs were used for association analysis.', {'entities': [(44, 53, 'Total SNPs')]}),
 ('0 Chip data for additional 643,600 SNPs were also obtained for the same cell lines.', {'entities': [(27, 34, 'Total SNPs')]}),
 ('  The Immunochip contains 3,120 SNPs that were part of a bipolar disease replication effort and other non-immune-related studies.', {'entities': [(26, 31, 'Total SNPs')]}),
 ('  We determined all the most significantly associated SNPs (or an appropriate surrogate) in the GWAS results from METASTROKE, a study of 12,389 individuals with ischemic stroke and 62,004 controls with imputation to the Hapmap2 reference panel.', {'entities': [(137, 143, 'Total SNPs')]}),
 ('9 using the Beagle genetic analysis software package [15] for the PGC samples), 110,942 autosomal SNPs were selected, with a linkage disequilibrium (r_2 ) <0.', {'entities': [(80, 87, 'Total SNPs')]}),
 ('1–6.6 million SNP', {'entities': [(2, 13, 'Total SNPs')]}),
 (' In total, 8,020,965 autosomal SNPs and 538,222 markers on the X-chromosome were meta-analyzed in stage 1.', {'entities': [(40, 47, 'Total SNPs'), (11, 20, 'Total SNPs')]}),
 (' The totals of 2,305,461, 2,305,682 and 2,305,640 SNPs were available for traits of agreeableness, conscientiousness and openness (respectively) in GPC-1, as well as 6,941,603 SNPs for extraversion and 6,949,614 SNPs for neuroticism in GPC-2.', {'entities': [(15, 24, 'Total SNPs')]}),
 (' A list of 19,532 SNPs was submitted to a devoted Illumina website to develop an iSelect microarray.', {'entities': [(11, 17, 'Total SNPs')]}),
 ("The Affymetrix GeneChip Mapping 100K Set (split into 2 array sets referred to as 50K Xba I and 50K Hin dIII) was used to examine 116,204 SNPs according to the manufacturer's protocol (Affymetrix, Santa Clara, Calif.", {'entities': [(129, 136, 'Total SNPs')]}),
 (' The number of SNPs after quality control and exclusion was 2,485,435 SNPs; our genome-wide interaction analysis was performed using these SNPs.', {'entities': [(60, 69, 'Total SNPs')]}),
 (' Principal components (PCs) were produced with EIGENSTRAT [] among 1,522 unrelated individuals using 116,867 tag-SNPs where in advance any SNPs with MAF < 5%, HWE-p  < 1e–6 with missing genotypes were excluded.', {'entities': [(67, 72, 'Total SNPs')]}),
 (' After applying previously implemented quality control procedures (), we performed GWA analyses of 729,454 single nucleotide polymorphism (SNP) markers using 1001 European American bipolar cases and 1034 mentally healthy European American controls, genotyped on the Affymetrix Genome-Wide Human SNP Array 6.', {'entities': [(99, 106, 'Total SNPs')]}),
 (' A total of 205,598 independent SNPs were used in the MDS analysis, with independence being determined with the “— indep” function in PLINK as previously described ().', {'entities': [(12, 19, 'Total SNPs')]}),
 (' In addition, genome-wide joint linkage and association analysis was performed using 944,565 SNPs.', {'entities': [(85, 92, 'Total SNPs')]}),
 (' A total of 517,480 SNPs satisfy all of these criteria.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('The association between the 559,977 SNPs and risk of glioma was estimated by the odds ratio (OR) and 95% confidence interval (CI) using unconditional logistic regression assuming a trend effect genetic model with 1 degree of freedom.', {'entities': [(28, 35, 'Total SNPs')]}),
 ('P-values for the most significant SNPs for the association with CSF tau and ptau were included here from the previously published GWAS for AD, consisting of 11,840 controls and 10,931 cases ().', {'entities': [(157, 163, 'Total SNPs')]}),
 ('Genotyping in the CHS population was carried out using the Illumina 370CNV chip and genotype calls were done using Bead-Studio software, resulting in 307,655 genotyped SNPs.', {'entities': [(150, 157, 'Total SNPs')]}),
 (' A set of 33,165 SNPs with low pairwise correlation (r_2  < 0.', {'entities': [(10, 16, 'Total SNPs')]}),
 (' Clinical characteristics of study populations from the Moroccan family-based and case–control studiesA full GWA scan was conducted across all 550,352 SNPs under the additive, recessive and dominant models using three sets of configurations of the family-based study population.', {'entities': [(143, 150, 'Total SNPs')]}),
 (' Briefly, samples were genotyped for 539,473 SNPs on the Illumina HumanCore+Exome array.', {'entities': [(37, 44, 'Total SNPs')]}),
 (' SAGE samples were genotyped on the Illumina Human 1M array containing 1,069,796 total SNPs.', {'entities': [(71, 80, 'Total SNPs')]}),
 (' Single SNP association tests were conducted using logistic regression for all 729,454 available SNP markers, assuming a log-additive genetic model.', {'entities': [(79, 86, 'Total SNPs')]}),
 (' Using the KORA study as reference, we corrected for tests on 655,658 SNPs and 37,455 metabolic traits, thus obtaining a Bonferroni-adjusted p-value of p = 2.', {'entities': [(62, 69, 'Total SNPs')]}),
 (' Of the 248,535 genotyped SNPs with unique positions on National Center for Biotechnology Information (NCBI) build 34, the genotyping call rate was >80% for 220,143 SNPs, including 205,031 SNPs that were polymorphic within the study sample.', {'entities': [(8, 15, 'Total SNPs')]}),
 (' Genotyping was performed with Illumina chips and >2.5 million SNP', {'entities': [(51, 62, 'Total SNPs')]}),
 (' Quality control filters were subsequently applied to reduce the number of SNPs to a highly informative set of ~9.8 million SNP', {'entities': [(112, 123, 'Total SNPs')]}),
 (' A total of 23,481 SNPs were excluded from analyses.', {'entities': [(12, 18, 'Total SNPs')]}),
 (' After excluding SNPs based on minor allele frequency < 1%, SNP call rate < 95% (<99% if MAF < 5%), and Hardy-Weinberg equilibrium p < 1\xa0× 10_−10 , 143,100 SNPs remained for the further analyses.', {'entities': [(148, 155, 'Total SNPs')]}),
 ('As described previously (), we genotyped DNA samples from the LCLs in the Genotype Shared Resource (GSR) at Mayo Clinic using Illumina HumanHap 550K and 510S BeadArrays, which contained 561,298 and 493,750 SNPs, respectively.', {'entities': [(186, 193, 'Total SNPs')]}),
 (' After QC, 17,148 SNPs and 2 individuals (1 cases and 1 control) were excluded for low call rates.', {'entities': [(11, 17, 'Total SNPs')]}),
 ('01 for non-Hispanic white, East Asian, Latino, and African-American men, respectively (19,977,088 unique SNPs).', {'entities': [(87, 97, 'Total SNPs')]}),
 ('We implemented a conditional-random-field-based approach, RFMix, to infer local ancestry at a set of 236,456 SNPs in common between the HCHS/SOL and reference-panel datasets.', {'entities': [(101, 108, 'Total SNPs')]}),
 ('01 (n=57,382); 371,951 SNPs were retained for analysis.', {'entities': [(15, 22, 'Total SNPs')]}),
 (' In all, 6,237 autosomal SNPs were flagged for potential deviation from HWE (p < 0.', {'entities': [(9, 14, 'Total SNPs')]}),
 (' In stage 2, the MassARRAY System by Agena Bioscience (San Diego, CA) was utilized at the Institute for Molecular Medicine Finland (FIMM) to genotype single-nucleotide variants in Nordic cohorts (STHLM2, 544 cases/541 controls; Gothenburg, 1,903 cases/258 controls; HUNT, 1,168 cases/1,147 controls; Estonia, 257 cases/259 controls; and FINRISK, 198 cases/172 controls), as well as 1,038 individuals from the FIN cohort who had also been genotyped with SNP arrays (925 with the HumanOmni2.', {'entities': [(240, 245, 'Total SNPs')]}),
 (' This table shows that 555,254 of the 1,298,078 SNPs remained after quality control, and that most SNPs were deleted because they appeared only on the 1M and 1M Omni chips that were used to type only 227 controls.', {'entities': [(23, 30, 'Total SNPs'), (38, 47, 'Total SNPs')]}),
 (' The chip contains approximately 2.5 million SNP', {'entities': [(33, 44, 'Total SNPs')]}),
 (' Therefore, the final SNP set maintained in the subsequent analyses contained 689,368 SNPs, yielding an average marker spacing of ~4 kb throughout the human genome.', {'entities': [(78, 85, 'Total SNPs')]}),
 (' Before imputation, 452,154 SNPs for 3,772 individuals (1,208 cases and 2,564 controls) were in the German dataset, and 494,760 SNPs for 3,134 individuals (1,118 cases and 2,016 controls) were in the Dutch dataset.', {'entities': [(20, 27, 'Total SNPs')]}),
 (' After these QC procedures, 580,086 SNPs for 971 individuals (474 cases and 497 controls) remained in the Shanghai-1 dataset; 515,701 SNPs for 485 individuals (254 cases and 231 controls) remained in the Shanghai-2 dataset; 522,096 SNPs for 641 cases and 435,925 SNPs for 972 controls remained in the Guangzhou-1 dataset; and 478,246 SNPs for cases and 443,065 SNPs for controls remained in the Aichi-1 dataset.', {'entities': [(28, 35, 'Total SNPs')]}),
 (' This resulted in genotype calls for a total of 38,066,487 SNPs and insertion/deletion polymorphisms (indels), but only the 9,427,497 variants with a Minor Allele Frequencies (MAF) > 0.', {'entities': [(48, 58, 'Total SNPs')]}),
 (' After pruning, a set of 231,649 autosomal SNP markers in approximate linkage equilibrium was used to estimate the relationship measures.', {'entities': [(25, 32, 'Total SNPs')]}),
 ('We used a case-control design to investigate EOBC risk among Caucasian women in relation to 1,265,546 single-nucleotide polymorphisms (SNPs) included in the HapMap3 project (http://hapmap.', {'entities': [(92, 101, 'Total SNPs')]}),
 (' The resulting dataset, containing 370,404 SNPs for 3,307 individuals, was subsequently imputed across ∼2.54 million SNP', {'entities': [(35, 42, 'Total SNPs'), (104, 116, 'Total SNPs')]}),
 (' After sample and SNP QC, 1,536 case subjects and 2,677 control subjects were analyzed at 787,861 genotyped autosomal SNPs.', {'entities': [(26, 31, 'Total SNPs')]}),
 (' To estimate IBD, we phased intersected genotypes for the ‡Khomani and Nama populations both separately (number of SNPs = 300,370 in ‡Khomani, 525,934 in Nama) and jointly (number of SNPs = 241,929) using Beagle (v4.', {'entities': [(122, 129, 'Total SNPs')]}),
 (' We also excluded 125,308 SNPs with minor allele frequency (MAF) less than 5% in the present study.', {'entities': [(18, 25, 'Total SNPs')]}),
 (' The number of unique SNPs available for meta-analysis was 7,480,565.', {'entities': [(59, 68, 'Total SNPs')]}),
 (' The first SNP-based analysis consisted of SNP-specific logistic regressions for each of the 1,265,548 typed or imputed HapMap3 SNPs using BEAGLE ().', {'entities': [(93, 102, 'Total SNPs')]}),
 (' To generate the principal components we used a set of 79,974 SNPs that were imputed with R_2 >0.', {'entities': [(55, 61, 'Total SNPs')]}),
 (' Merging these files on the SNPs that were called in every project yielded 532,566 variants in common.', {'entities': [(75, 82, 'Total SNPs')]}),
 (' There were 3,717 subjects genotyped on 542,585 SNPs (526,123 on autosomes) before QC.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' Both genotyped and imputed SNPs were included in these analyses, which yielded 1,211,988 million SNP', {'entities': [(80, 89, 'Total SNPs'), (86, 97, 'Total SNPs')]}),
 (' We have also provided summary statistics for the first 10,000 LD pruned SNPS for the three GWAS analyses (males-only, females-only, and non-stratified) as .', {'entities': [(56, 62, 'Total SNPs')]}),
 (' The combined discovery data set (comprised of all meta-analysed SNPs with data from at least 5,000 subjects) was carried forward for the additional analyses detailed below.', {'entities': [(94, 99, 'Total SNPs')]}),
 (' After frequency and genotyping pruning, there\nwere 449,540 SNPs.', {'entities': [(52, 59, 'Total SNPs')]}),
 (' Final meta-analysis results were obtained for 2,449,806 SNPs.', {'entities': [(47, 56, 'Total SNPs')]}),
 ('Genetic (kinship) and shared environmental (household) effects were estimated from a variance-component analysis that used all genotyped SNPs with MAF > 1% (∼1.7 million', {'entities': [(158, 169, 'Total SNPs')]}),
 (' For GWAS, a total of 803,323 QC-passed SNPs were selected for analysis.', {'entities': [(22, 29, 'Total SNPs')]}),
 (' Initially, 2,053 participants and 370 SNPs with > 90% call rates were retained, including the 119 AIMs.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' Samples of European ancestry or unknown ancestry were analyzed using the Illumina Human660W-Quadv1_A genotyping platform, consisting of 561,490 SNPs and 95,876 intensity-only probes.', {'entities': [(137, 144, 'Total SNPs')]}),
 (' In total, 1,047 SNPs with p≤0.', {'entities': [(11, 16, 'Total SNPs')]}),
 (' Thus, 512,226 SNPs were analyzed in the association studies reported here.', {'entities': [(7, 14, 'Total SNPs')]}),
 ('_,  A much denser genetic map (up to 13.6 million SNP', {'entities': [(37, 49, 'Total SNPs')]}),
 (' A total of 224,826 genotyped SNPs passed QC criteria across each of the samples.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' Imputations were performed in chunks with 5,000 SNPs blocks and 1,000 SNPs overlap from our data.', {'entities': [(43, 48, 'Total SNPs')]}),
 (' An FDR framework was used to determine the α level\n– assuming that ~25 of 492,900 GWAS SNPs have true effects\n(i.', {'entities': [(75, 82, 'Total SNPs')]}),
 ('genotyped SNPs and 10.3 million ', {'entities': [(19, 31, 'Total SNPs')]}),
 ('0 and 169,521 SNPs on the Exome Beadchip were interrogated in the initial GWAS.', {'entities': [(6, 13, 'Total SNPs')]}),
 (' For the OncoArray data set, principal-components analysis was performed using data for 33,661 SNPs (which included the 2,318 markers of continental ancestry) with MAF ≥0.', {'entities': [(88, 94, 'Total SNPs')]}),
 ('  Associations of SNPs with T2D amongst Europeans were tested in silico  using results from the GWA phase of the DIAGRAM+ study, which comprises 8,130 T2D cases and 38,987 controls of European ancestry.', {'entities': [(145, 150, 'Total SNPs')]}),
 (' Monomorphic SNPs were excluded, as were those with minor allele frequency (MAF) of <10% (n  = 175,153), a call rate of <95% (n  = 19,986) or Hardy-Weinberg disequilibrium in controls (n  = 2,054 with P  < 1 × 10_−4  when testing for Hardy-Weinberg equilibrium).', {'entities': [(190, 195, 'Total SNPs')]}),
 (' Four hundred and eighty-one UCSD subjects were genotyped at 592,312 SNPs using the Illumina 610-Quad genotyping array (Illumina Inc.', {'entities': [(61, 68, 'Total SNPs')]}),
 (' Each of the five clinical phenotypes was regressed on each of the 527,828 autosomal SNPs, using the demographic and principal component scores described above as covariates.', {'entities': [(67, 74, 'Total SNPs')]}),
 ('9939, respectively, in the remaining 13,412,051 imputed SNPs.', {'entities': [(37, 47, 'Total SNPs')]}),
 (' Within each population, approximately 4.6 million SNP', {'entities': [(39, 50, 'Total SNPs')]}),
 (' SNPs are binned into as many as 17,787 gene sets when they are in genes or within 50kb of genes.', {'entities': [(33, 39, 'Total SNPs')]}),
 (' After quality control (), we used 472,862 autosomal SNPs and 10,029 X-chromosomal SNPs for analyses.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' After quality control a total of 2,356,032 SNPs from RS-I and 1,956,891 SNPs from RS-II were available for GWAS and meta-analysis.', {'entities': [(34, 43, 'Total SNPs')]}),
 ('A genetic risk score (GRS) was computed using data from 88,251 European-ancestry individuals to model the increase in fibrinogen levels according to number of fibrinogen-raising alleles for each of the lead SNPs.', {'entities': [(56, 62, 'Total SNPs')]}),
 (' In the SCN5A -SCN10A  region (NCBI build 36 positions 38,490,026 - 38,818,967), 654 MetaboChip SNPs were directly genotyped and passed QC filters (SNP and sample call rate\u2009>\u200990%, concordance among blind duplicates\u2009>\u200998%, HWE P -value\u2009>\u20090.', {'entities': [(55, 65, 'Total SNPs')]}),
 (' Briefly, the French and Swiss primary cohorts were genotyped for ~350,000 SNPs and ~1,000,000 SNPs, respectively, using Illumina HumanCNV370-Duo and Human1M-Duo beadchips (Illumina, San Diego, USA).', {'entities': [(85, 94, 'Total SNPs')]}),
 ('13\u2009ms (estimated from 2,845 CHS subjects of European ancestry after application of exclusion factors described above), African-ancestry index SNP effect size, and the previously reported SNP coded allele frequency in populations of European descent ().', {'entities': [(22, 27, 'Total SNPs')]}),
 (' In order to examine the third-effect SNP rs2027498 in TNFSF4,  an independent Korean cohort including 1,254 RA cases [average age=53.', {'entities': [(103, 108, 'Total SNPs')]}),
 ('01 (excluded 46,562), and non-autosomal SNPs (excluded 61,087); a total of 2,077,308 SNPs in 1576 individuals were retained and carried forward for discovery GWAS analyses.', {'entities': [(75, 84, 'Total SNPs')]}),
 (' For the 330,775 tested random sets, at most six overlapping SNPs were found (8 times), and in over half of the cases no overlapping SNPs were present in the sampled dataset (see Table below).', {'entities': [(9, 16, 'Total SNPs')]}),
 (' Analytic work flow Next, results were combined in a meta-analysis using 1,811,026 SNPs shared between the asthma and COPD datasets (meta-analysis1).', {'entities': [(73, 82, 'Total SNPs')]}),
 ('We used a random sample of 19,059 autosomal SNPs with frequency ≥ 2% over the five racial/ethnic group samples to estimate principal components of ancestry.', {'entities': [(27, 33, 'Total SNPs')]}),
 ('01 (n = 57,382); 371,951 SNPs were retained for analysis.', {'entities': [(17, 24, 'Total SNPs')]}),
 ('8 and Dʹ\u2009=\u20091) using HapMap and 1,000 Genomes datasets to establish whether the SNP was near a cis- eQTL SNP.', {'entities': [(31, 36, 'Total SNPs')]}),
 ('0 chip and were imputed to ≈ 2.5 million SNP', {'entities': [(29, 40, 'Total SNPs')]}),
 ('Genotypes for ~21 million SNP', {'entities': [(15, 25, 'Total SNPs')]}),
 (' A set of 274,604 SNPs that were common to all of the genotyping chips were used for imputation, which was performed using the program MACH .', {'entities': [(10, 17, 'Total SNPs')]}),
 (' After these quality control steps, 935 cases, 946 controls, and 779,326 SNPs remained and were included in the statistical analysis.', {'entities': [(65, 72, 'Total SNPs')]}),
 (' Further quality control procedures were applied after imputation, yielding a total of 8,268,322 SNPs for further analyses.', {'entities': [(87, 96, 'Total SNPs')]}),
 (' We applied GCTA to identify “index SNPs” for distinct association signals attaining genome-wide significance (P <5x10-8 ) in the European ancestry meta-analysis using a reference sample of 5,000 individuals of white British origin, randomly selected from UK Biobank, to approximate patterns of linkage disequilibrium (LD) between variants in these regions.', {'entities': [(190, 195, 'Total SNPs')]}),
 (' HAPI Heart Study participants were genotyped using the Affymetrix GeneChip_®  Human Mapping 500K Array Set which consisted of 500,568 SNP genotyping calls on each participant using the BRLMM genotype-calling algorithm.', {'entities': [(127, 134, 'Total SNPs')]}),
 (' All samples used in stage 3 were imputed to the HRC haplotype reference panel_, , which includes 64,976 haplotypes with 39,235,157 SNPs that allows imputation down to an unprecedented MAF=0.', {'entities': [(98, 104, 'Total SNPs'), (121, 131, 'Total SNPs')]}),
 (' The average number of SNPs filtered out in each dataset was 1.47 million ', {'entities': [(61, 73, 'Total SNPs')]}),
 (' We then drew 1,000,000 sets of 37 SNPs at random (with replacement) from this sampling dataset.', {'entities': [(14, 23, 'Total SNPs')]}),
 (' After filtering rare and monomorphic variants and applying stringent quality-control filters, high-quality genotypes for 386,731 common SNPs were obtained ().', {'entities': [(122, 129, 'Total SNPs')]}),
 (' European ancestry in both cases and controls was determined using a panel of 2,440 SNPs (intermarker r _2  <0.', {'entities': [(78, 83, 'Total SNPs')]}),
 ('The 5,955 SNPs obtained in the MHC after all QCs were used for the imputation process.', {'entities': [(4, 9, 'Total SNPs')]}),
 (' In total, 526,014 SNPs were successfully genotyped and further analyzed in 229 samples of the discovery series.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' In the end, 2,501,352 autosomal SNPs were used for the GWAS analysis.', {'entities': [(13, 22, 'Total SNPs')]}),
 (' The Immunochip contains 3,120 SNPs that were part of a bipolar disease replication effort and other non-immune-related studies.', {'entities': [(25, 30, 'Total SNPs')]}),
 (' The 1000 Genomes control loci were calculated using 24,000 matched variants based on MAF, gene density, distance to nearest gene, and number of nearby variants in linkage disequilibrium determined by the SNPsnap tool.', {'entities': [(53, 59, 'Total SNPs')]}),
 (' Analysis of neonatal genotypes was performed on 916 cases, 935 controls, and 797,196 SNPs after all of the QC steps.', {'entities': [(78, 85, 'Total SNPs')]}),
 (' Analyses were confined to the 595,692 autosomal\nSNPs that were common across the SNP genotyping arrays.', {'entities': [(31, 38, 'Total SNPs')]}),
 (' During the Illumina production process, 2,287 SNPs failed oligonucleotide synthesis, leading to a final number of 14,445 SNPs for which genotyping was attempted.', {'entities': [(41, 46, 'Total SNPs')]}),
 (' Including imputed SNPs, the numbers were increased to 1,216,189 and 1,216,074, respectively.', {'entities': [(55, 64, 'Total SNPs')]}),
 (' A total of 2,232,944 SNPs passed filters for both quality and informativeness (polymorphic and unduplicated) and became candidates for imputation and association testing.', {'entities': [(12, 21, 'Total SNPs')]}),
 ('01 in any of the cohorts, leaving 2,017,629 SNPs available for analysis.', {'entities': [(34, 43, 'Total SNPs')]}),
 (' Genotypes were obtained for 1,020,596 autosomal SNPs.', {'entities': [(29, 38, 'Total SNPs')]}),
 (' This resulted in 530,683 SNPs.', {'entities': [(18, 25, 'Total SNPs')]}),
 ('We tested for association of the 42 lead SNPs and 3 secondary associations in data from up to 88,823 individuals of European descent from 37 in silico  replication studies with heart rate in stage 2.', {'entities': [(94, 100, 'Total SNPs')]}),
 (' We assumed additive model for each SNP (ie, 0,1,2 for 0,1,2 copies of the minor allele, respectively).', {'entities': [(45, 50, 'Total SNPs')]}),
 (' SNPs were further filtered by comparing the allele frequency of an additional 6,450 Chinese samples.', {'entities': [(79, 84, 'Total SNPs')]}),
 ('01) were removed, resulting in 8,466,825 SNPs for analysis.', {'entities': [(31, 40, 'Total SNPs')]}),
 ('01 in either cases or controls,\nHardy-Weinberg equilibrium P  < 1 ×\n10_−5  in controls, and significantly different missing\ngenotype rates between cases and controls (P  < 1\n× 10_−5 ), a total of 1,532,051 genotyped and imputed\nautosomal SNPs from the BAS, 2,042,781 from the CAS, and 2,228,999 SNPs from the\ncombined two GWAS samples were retained for subsequent association analysis.', {'entities': [(196, 205, 'Total SNPs')]}),
 ('A total of 868,158 autosomal SNPs across the entire genome were genotyped using the Affymetrix 6.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' An additional 224 subjects from these 118 families had been genotyped in a previous case-control GWAS by the Center for Inherited Disease Research (CIDR) at John Hopkins University using the Illumina Human 1M-Duo BeadChip technology (1,041,465 SNPs; Illumina, San Diego, CA, USA; ).', {'entities': [(235, 244, 'Total SNPs')]}),
 ('025 were excluded, leaving 8,036,255 SNPs for analysis.', {'entities': [(27, 36, 'Total SNPs')]}),
 (' The analysis included 1,131,426 SNPs and 2,239 samples.', {'entities': [(42, 47, 'Total SNPs'), (23, 32, 'Total SNPs')]}),
 (' SNPs were removed from the analysis if any of the following criteria were not satisfied: (1) SNPs on chromosome 1–22; (2) call rate per SNP ≥ 95%; (3) minor allele frequency ≥ 5% (1,845,510 SNPs were removed based on Criteria 1, 2 and 3); and (4) Hardy-Weinberg equilibrium (HWE) test of p ≥ 10_−6  using CN subjects only (198 SNPs were removed).', {'entities': [(181, 190, 'Total SNPs')]}),
 ('We genotyped 582,892 SNPs for each subject, producing approximately 15 billion genotypes.', {'entities': [(13, 20, 'Total SNPs')]}),
 (' After imaging QC, our final sample included 239 participants (162 males, 77 females; 126 HC, 113 patients with SCZ) and 1,067,955 autosomal SNPs.', {'entities': [(121, 130, 'Total SNPs')]}),
 (' In total 137,532 SNPs with an estimate of the squared correlation between imputed and true genotypes, ≤0.', {'entities': [(10, 17, 'Total SNPs')]}),
 (' 10,996,499 imputed autosomal SNPs that passed the QC were analyzed for additive and genotypic models using SNPTEST2, taking the imputed genotype uncertainty (frequentist score test) and the first two principal components (PCs) of genetic structure into account.', {'entities': [(1, 11, 'Total SNPs')]}),
 (' All GWA study SNPs and their p-values were included in the analysis, resulting in 17,744 autosomal genes and the corresponding gene-based and lowest SNP p-values (for more information, see also ).', {'entities': [(83, 89, 'Total SNPs')]}),
 (' Genotyping was performed at the Mind Research Network (MRN) Neurogenetics Core Lab using the Illumina HumanOmni-Quad BeadChip interrogating 1,140,419 SNPs.', {'entities': [(141, 150, 'Total SNPs')]}),
 (' In particular, among the total analyzed SNPs, 149,817 were genotyped, and the remaining SNPs were imputed based on their LD with the observed SNPs and are thus not independent.', {'entities': [(47, 54, 'Total SNPs')]}),
 (' Using the software simpleM with a window size of 5000 SNPs [], we estimated that approximately 54,000 independent SNPs were included in the analysis, suggesting a significance threshold of 9.', {'entities': [(96, 102, 'Total SNPs')]}),
 (' Within each cohort, the association between approximately 2.5 million SNP', {'entities': [(59, 70, 'Total SNPs')]}),
 (' To increase genome coverage, genotypes were imputed for un-typed SNPs and in-dels using the 1kG multi-ethnic reference panel, yielding a total of 6,378,483 variants, and of these 5,904,251 with MAF≥ 5% were analyzed in the current investigation for association analysis.', {'entities': [(147, 156, 'Total SNPs')]}),
 (' For each of the landmark SNPs in the loci confirmed to be associated with BMI, gene–gene interactions were evaluated with all of the genome-wide SNPs (7 × 2,178,018 SNP pairs; ), and genomic control corrections were applied.', {'entities': [(156, 165, 'Total SNPs')]}),
 (' For the imputation, we additionally excluded SNPs with a MAF<1% and a call rate <98% and SNPs that could not be linked to the 1000 genomes reference or differed significantly in frequency from the 1000 genomes (European frequency) and a further 1,128 SNPs where the cluster plot was judged to be inadequate.', {'entities': [(246, 251, 'Total SNPs')]}),
 ('In GOLDN, a total of 906,600 single nucleotide polymorphisms (SNPs) were genotyped using the Affymetrix Genome-Wide Human 6.', {'entities': [(21, 28, 'Total SNPs')]}),
 ('_*  To standardize genotyping across cohorts and allow for meta-analysis, participant-level genotype data were imputed to more than 2.5 million SNP', {'entities': [(132, 143, 'Total SNPs')]}),
 (' After filtering, 300,895 SNPs remained for analysis.', {'entities': [(18, 25, 'Total SNPs')]}),
 ('  Meta-analysis of the 2016 IHGC migraine GWAS and 2016 23andMe MDD GWAS (for the top 10,000 SNPs) was performed using the METASOFT (URL: http://genetics.', {'entities': [(86, 92, 'Total SNPs')]}),
 ('01, and genotype call rates >95%, leaving 352,228 SNPs.', {'entities': [(42, 49, 'Total SNPs')]}),
 (' The resulting dataset, containing 370,404 SNPs for 3,307 individuals, was subsequently imputed across ∼2.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' A total of 1,145,510 SNPs were genotyped for both Afro-Caribbean and Hispanic study subjects on Illumina Human1M microarrays and 598,821 SNPs for European ancestry subjects on Illumina Human610 microarrays.', {'entities': [(130, 137, 'Total SNPs'), (12, 21, 'Total SNPs')]}),
 (" The V3 platform was based on the Illumina OmniExpress+ BeadChip, with custom content to improve the overlap with 23andMe's V2 array, with a total of about 950,000 SNPs.", {'entities': [(156, 163, 'Total SNPs')]}),
 ('05 error / 247,463 SNPs) for meta-analysis of both discovery and replication studies and a P-value of less than 0.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' Our GWAS analysis used 10,109,774; 9,283,528; 10,776,138; and 17,141,436 SNPs with r_2 ≥0.', {'entities': [(24, 34, 'Total SNPs')]}),
 ('A principal-component analysis of all 254,145 autosomal SNPs that pass the highest standards of quality control (i.', {'entities': [(38, 45, 'Total SNPs')]}),
 ('4 or Hardy-Weinberg Equilibrium P -value<10_−5 ; this yielded ~6.6 million SNP', {'entities': [(63, 74, 'Total SNPs')]}),
 (' This completed QC for EAS and LAT, resulting in 653,943 and 678,790 SNPs, respectively.', {'entities': [(49, 56, 'Total SNPs')]}),
 (' Genotypes of 39,164 chromosome 3 SNPs that were not monomorphic in the CAP Caucasians or triallelic in dbSNP and were not A/T or C/G SNPs were used for imputation using the 1000G PhaseIv3 EUR haplotypes [] as a reference.', {'entities': [(14, 20, 'Total SNPs')]}),
 ('8 based on linkage disequilibrium information of 1,000 Genomes African Ancestry population, to assess evidence that SNPs were located in regulatory regions.', {'entities': [(49, 54, 'Total SNPs')]}),
 (' We imputed SNPs, classic HLA  alleles (at both 4-and 2-digit resolution), and their amino acid polymorphisms in the 1,962 individuals from our GWAS, using Beagle software as previously described ().', {'entities': [(117, 122, 'Total SNPs')]}),
 (' There were between 2,127,883 (SBP) and 2,166,286 (hypertension) SNPs for analysis after quality control.', {'entities': [(20, 29, 'Total SNPs')]}),
 ('We performed a meta-analysis on directly genotyped and imputed SNPs from individuals of European ancestry in seven studies, with a total of 17,248 individuals (stage 1).', {'entities': [(140, 146, 'Total SNPs')]}),
 (' In total, 1,590 SNPs were identified through this process and these 1,590 SNPs comprised the basis for the present meta-analysis.', {'entities': [(11, 16, 'Total SNPs')]}),
 ('_–  BeadChip, which measures nearly 2.4 million SNP', {'entities': [(36, 47, 'Total SNPs')]}),
 (' Participants and SNPs passing basic quality control thresholds were imputed to >2.2 million ', {'entities': [(81, 92, 'Total SNPs')]}),
 (' We used as a reference panel for the imputation (1) 2,767 European-descent individuals with four-digit typing of human leukocyte antigen (HLA) class I and II molecules and (2) the genotypes of more than 7,500 common SNPs and indel polymorphisms across the extended MHC (xMHC).', {'entities': [(53, 58, 'Total SNPs')]}),
 ('Genotyping of germline DNA was performed (; Data Supplement) for 5,398 patients with the Affymetrix Genome-Wide Human SNP 6.', {'entities': [(65, 70, 'Total SNPs')]}),
 (' There is an overlap of 435,632 SNPs between the early access and commercial platforms.', {'entities': [(24, 31, 'Total SNPs')]}),
 (' After genetic quality control, the dataset included 735,843 SNPs in 431 PD cases and 427 sibling controls [].', {'entities': [(53, 60, 'Total SNPs')]}),
 (' All 92 lesional samples and all but two of the 82 normal samples were genotyped on the Affymetrix Axiom Biobank Plus Array, which contains a GWAS backbone panel of 260,000 SNPs in addition to exome and custom content.', {'entities': [(165, 172, 'Total SNPs')]}),
 ('025 were selectively excluded to maximize sample size, leaving 4,897,434 SNPs and 464 individuals for variance component analysis.', {'entities': [(63, 72, 'Total SNPs')]}),
 ('SNPs selected from the case-only genome-wide association studies for replication were evaluated using seven population-based studies (five case-control studies (CECILE, GENICA, MARIE, PBCS, SASBAC), one case-cohort (MCCS), and one nested case-control study (UKBGS)), and four non-population-based studies (MCBCS, kConFab/AOCS, OFBCR, pKARMA), including in total 7,689 cases (676 lobular) and 9,266 controls participating in the Breast Cancer Association Consortium (BCAC).', {'entities': [(362, 367, 'Total SNPs')]}),
 ('After excluding single-nucleotide polymorphisms (SNPs) with low call rate, 751,455 SNPs on the SNP 6.', {'entities': [(75, 82, 'Total SNPs')]}),
 ('We used markers of highest quality to impute with Minimac [] approximately 2.5 million SNP', {'entities': [(75, 86, 'Total SNPs')]}),
 ('Participants were genotyped for approximately 580,000 SNPs on an Illumina HumanCoreExome array plus 15,890 SNPs of custom content designed to cover candidate genes and loci implicated by previous genome-wide or candidate gene studies or from animal models with craniofacial anomalies.', {'entities': [(46, 53, 'Total SNPs')]}),
 (' Colon CFR samples were genotyped across three platforms based on chip availability: the Illumina Human1M or Human1M-Duo (CFR Set 1) and the Illumina HumanOmni1-Quad (CFR Set 2), each containing ~1.2 million SNP', {'entities': [(196, 207, 'Total SNPs')]}),
 (' Because not all versions of 1000 Genomes that were used included copy number variations, we only analyzed single nucleotide polymorphisms (SNPs), which totaled 14,227,402.', {'entities': [(161, 171, 'Total SNPs')]}),
 (' In all, 390,619 autosomal markers overlapping between the 500K Affymetrix GeneChip and the AffymetrixGenome-Wide Human SNP Array 6.', {'entities': [(9, 16, 'Total SNPs')]}),
 (' Adding SNPs typed but not used for imputation purposes resulted in a total of 2,587,527 genotyped or imputed SNPs available for association analyses.', {'entities': [(79, 88, 'Total SNPs')]}),
 (' A total of 3,647 SNPs with high Mendelian error rate were dropped.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' Selected SNPs from the serum urate analysis were followed up in 12 studies with in silico  GWAS data totaling 18,821 individuals, as well as 3 studies in which de novo  genotyping was conducted (HYPEST, KORA S2 and Ogliastra Genetic Park, totaling 13,992 individuals).', {'entities': [(111, 117, 'Total SNPs')]}),
 ('30, MAF<1%, or HWE P<1×10_−6  were removed, and a total of 2,216,774 SNPs, with fractional values ranging from 0 to 2, remained for the analysis.', {'entities': [(59, 68, 'Total SNPs')]}),
 (' A total of 1,718 triple-negative cases from 11 studies (ABCTB, BBCC, DFCI, FCCC, GENICA, HEBCS, MARIE, MCBCS, MCCS, POSH and SBCS) were genotyped for the TNBCC GWAS using Illumina SNP arrays.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' Both Set 1 and Set 2 samples were genotyped on all 317,000 SNPs.', {'entities': [(52, 59, 'Total SNPs')]}),
 ('4% over a total of 20,853,552 genotypes and 100% over the 174 genotypes corresponding to the 3 associated SNPs.', {'entities': [(19, 29, 'Total SNPs')]}),
 (' Among the 293 unrelated European Caucasian (EC) participants in the discovery cohort, 136 samples were genotyped on the Illumina HumanHap550 SNP array (Illumina, San Diego, CA, USA); and 157 samples were genotyped on the Illumina Human610-Quad version 1 SNP array, overlapping in 535,752 common SNPs.', {'entities': [(281, 288, 'Total SNPs')]}),
 (' After these QC steps, the maximum number of SNPs in the analysis was 9,657,952.', {'entities': [(70, 79, 'Total SNPs')]}),
 (' After quality control, a total of 820,017 genotyped SNPs remained for genotype imputation.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' Additionally, 7.2 million SNP', {'entities': [(15, 26, 'Total SNPs')]}),
 (' Genotypes were obtained using high-density SNP arrays, and then imputed for ~2.4 million ', {'entities': [(78, 89, 'Total SNPs')]}),
 (' For this purpose, the algorithm generates 5,000 sets of genes, by randomly selecting SNPs until a list of n tagged genes is formed.', {'entities': [(43, 48, 'Total SNPs')]}),
 (' After quality control of imputation data, 2,731,086 SNPs in PanScan and 2,307,550 SNPs in ChinaPC were available for analysis.', {'entities': [(43, 52, 'Total SNPs')]}),
 (' For the 22 previously reported QRS loci, 3,526 independent SNPs were identified and a Bonferroni-based significance threshold of 1.', {'entities': [(42, 47, 'Total SNPs')]}),
 (' The association between tHcy SNPs on CAD were tested in 2 ways: ) Each of the 18 SNPs that were associated with tHcy concentrations was tested for association with risk of CAD in a case-control study with the use of data from the CARDIoGRAM consortium (22,233 CAD cases and 64,762 controls) and in 3 separate CAD cohorts: the WGHS () (758 CAD cases and 22130 controls), which was also used in the discovery stage; the LOLIPOP (24) study, which contributed 2793 CAD cases and 3756 controls from South Asia; and the PROCARDIS study (), which contributed a total of 5616 CAD cases and 2279 controls.', {'entities': [(275, 281, 'Total SNPs')]}),
 (' Imputations were based on 537,371 genotyped SNPs in common with the reference data (G-C and A-T SNPs were excluded).', {'entities': [(27, 34, 'Total SNPs')]}),
 (' We removed 53,530 monomorphic loci and 82,462 SNPs with a call rate below 96% (1,556 SNPs overlapped on these two criteria).', {'entities': [(12, 18, 'Total SNPs')]}),
 (' The assay interrogates 906,600 SNPs.', {'entities': [(24, 31, 'Total SNPs')]}),
 (' A total of 1,134,514 SNPs were released with genotype and intensity data.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' π̂   Following quality control, 484,724 SNPs were available in all data sets for analysis.', {'entities': [(33, 40, 'Total SNPs')]}),
 (' The quality control and filtering criteria for all 2,462,060 imputed SNPs were the same as for the genotyped SNPs, and 1,672,517 imputed SNPs were retained for the GWAS analysis ().', {'entities': [(52, 61, 'Total SNPs')]}),
 (' Replication of associated SNPs was conducted in four independent cohorts, three of white European descent and one of black African descent, totaling 7,766 subjects.', {'entities': [(150, 155, 'Total SNPs')]}),
 ('To replicate association findings in Hispanic/Latino samples, we used 1000 Genomes imputed GWAS data available in three additional Hispanics/Latinos samples, including 3,454 from the Women’s Health Initiative (WHI) SNP Health Association Resource (SHARe) project, 782 from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort,_,   and 2,854 from Mount Sinai BioMe Biobank.', {'entities': [(168, 173, 'Total SNPs')]}),
 (' For example, 2,346 SNPs selected from conditional and joint multiple-SNP analysis with P  < 5 × 10_−3  explained 6.', {'entities': [(14, 19, 'Total SNPs')]}),
 (' Summary of SNPs that showed genome-wide significant (P  < 5 × 10_−8 ) association with disc area in the combined analysis (n  = 24,089 subjects with European and Asian descent) We tested for heterogeneous effects, for which P -values and I_2  are shown.', {'entities': [(129, 135, 'Total SNPs')]}),
 (' After quality control, there were 925 Sydney MAS participants (417 males, 508 females) with data for 734,550 SNPs, with a mean genotyping call rate of 99.', {'entities': [(102, 109, 'Total SNPs')]}),
 (' A consensus set of 6,036,699 high quality SNPs from each imputed dataset was analyzed by PLINK using a generalized linear model controlling for the genotyping platform and genetic ancestry based on principal component analysis by EIGENSOFT.', {'entities': [(20, 29, 'Total SNPs')]}),
 (' Each study imputed their genotype data to the ~2.5 million SNP', {'entities': [(48, 59, 'Total SNPs')]}),
 (' Using an acceptance threshold call rate > 98% per marker, we identified 83,774 SNPs with a lower call rate including 1,188 SNPs with high Mendelian error rate.', {'entities': [(73, 79, 'Total SNPs')]}),
 (' A total of 771,842 SNPs on the autosomal chromosomes with MAF greater than equal to 5% were used for further analysis.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' In the case-control subgroup, logistic regression was used to test for association under the additive genetic model while including 18 principal components of ancestry (generated via principal component analysis [PCA] of 67,000 SNPs in low linkage disequilibrium across all ancestry groups) to adjust for population structure ().', {'entities': [(222, 228, 'Total SNPs')]}),
 (' Therefore, the final genome-wide association marker set includes 880,959 autosomal SNPs.', {'entities': [(66, 73, 'Total SNPs')]}),
 ('\xa0Approximately 23,700,000 markers (including SNPs and\xa0INDELS) were assessed for association.', {'entities': [(15, 25, 'Total SNPs')]}),
 (' Assuming an additive genetic model with 1 degree of freedom, we related each of the 2.5 million SNP', {'entities': [(85, 96, 'Total SNPs')]}),
 (' A total of 2,546 ancestry-informative SNPs from the Illumina array were selected based on low inter-marker correlation and ability to differentiate between samples of African and European descent.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' Genotyping was attempted for a total of 5,568 samples on the Illumina 660W SNP microarray at the CGR.', {'entities': [(41, 46, 'Total SNPs')]}),
 ('05/2,668,805 SNPs).', {'entities': [(3, 12, 'Total SNPs')]}),
 (' After quality control, an imputation to 2.5 million SNP', {'entities': [(41, 52, 'Total SNPs')]}),
 (' After quality control, 609,508 SNPs were checked for alignment against the 1000 Genomes Project phase I integrated reference panel (released June 16, 2014) () and used for haplotype phasing with SHAPEIT2 software ().', {'entities': [(24, 31, 'Total SNPs')]}),
 ('A list of 1,391 SNPs was generated based on the lowest P _int  (cut-off P _int  <3.', {'entities': [(10, 15, 'Total SNPs')]}),
 (' First, chromosomal segments of no more than 10,000 genotyped SNPs, with overlaps of 200 SNPs, were phased using Beagle (version 3.', {'entities': [(45, 51, 'Total SNPs')]}),
 (' Briefly, we combined summary statistics from 24 studies for up to 2,766,983 autosomal single nucleotide polymorphisms (SNPs) using an inverse-variance fixed-effects meta-analysis for each QRS trait.', {'entities': [(67, 76, 'Total SNPs')]}),
 (' We were able to annotate 19,684 genes with one or more putative functional SNPs, 11,040 of which were annotated with at least one e-QTL SNP.', {'entities': [(26, 32, 'Total SNPs')]}),
 (" From these, we removed 123,000 intensity-only probes, 10,000 SNPs failed CIDR's technical filter, 55,000 were monomorphic, and 22,000 showed high SNP missingness rates (>2%).", {'entities': [(24, 31, 'Total SNPs')]}),
 ('2) and 1,070 healthy individuals from Japan (1KJPN panel, which contains > 20 million SNPs) () as a reference dataset.', {'entities': [(7, 12, 'Total SNPs'), (75, 85, 'Total SNPs')]}),
 (' Genome-wide SNP genotyping data that met quality control standards were available on 2,812 COPD cases and 2,534 control subjects in the non-Hispanic white group and 821 COPD cases and 1,749 control subjects in the African American group.', {'entities': [(86, 91, 'Total SNPs')]}),
 (' For the PCA we used 100,000 representative SNPs from the GWAS panel and analyzed them using 2 PC’s [].', {'entities': [(21, 28, 'Total SNPs')]}),
 (' 531,025 genotyped SNPs passed all the filters and were included for dfs_SM  analysis and 531,230 for dfs_PF  analysis.', {'entities': [(1, 8, 'Total SNPs')]}),
 (" SNPs rs4552569, rs13210693 and rs 17095830 were genotyped in 2,998 East Asian cases and 5,547 East Asian controls using TaqMan probes according to the manufacturer's instructions.", {'entities': [(62, 67, 'Total SNPs')]}),
 ('0001, we retained 459 samples and 332,290 SNPs from the GPA case group, 382 samples and 336,887 SNPs from the Canadian historical control group, and 1,124 samples and 312,412 SNPs from the US historical control group.', {'entities': [(34, 41, 'Total SNPs')]}),
 ('  To estimate IBD, we phased intersected genotypes for the ‡Khomani and Nama populations both separately (number of SNPs = 300,370 in ‡Khomani, 525,934 in Nama) and jointly (number of SNPs = 241,929) using Beagle (v4.', {'entities': [(123, 130, 'Total SNPs')]}),
 (' Genome-wide SNP imputation using inferred haplotypes was performed with IMPUTE2, generating data for 9,237,809 SNPs ().', {'entities': [(102, 111, 'Total SNPs')]}),
 (' This resulted in a dataset of 17,842 subjects containing 6,305 duos and 465,740 SNPs (112 were removed during liftover and 234 were out of HWE after combination).', {'entities': [(31, 37, 'Total SNPs')]}),
 (' After removal of the 64,908 SNPs with MAF<1%, 654,634 SNPs were available for imputation.', {'entities': [(22, 28, 'Total SNPs')]}),
 (' Following filters for genotype imputation, including no ambiguity in strand alignment and ability to be mapped to NCDB build 37, 2,018,833 SNPs were selected as the basis for imputation.', {'entities': [(130, 139, 'Total SNPs')]}),
 (' A total of 1,112,545 SNPs in 749 individuals were included in the meta-analysis.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' There were ∼7.3 million SNP', {'entities': [(13, 24, 'Total SNPs')]}),
 ('As different genotyping platforms were used across studies, we imputed to ~2.5 million SNP', {'entities': [(75, 86, 'Total SNPs')]}),
 ('  Following this, linear regression was used to evaluate whether any of the 527,829 SNPs were individually associated with any of the EDA indices.', {'entities': [(76, 83, 'Total SNPs')]}),
 (' SNPs were excluded from analysis if missing in >5% of samples (137,589 SNPs in the discovery dataset; 14 SNPs in the replication dataset), if they had minor allele frequency (MAF) <5% (157,580 SNPs in the discovery dataset), or if they showed deviation from Hardy-Weinberg equilibrium (p-value < 1×10_−5 ; 5,433 SNPs in the discovery dataset).', {'entities': [(307, 312, 'Total SNPs')]}),
 (' After filtering, Z -scores for 7,629,099 SNPs from the 23andMe study were used as input to LDSC.', {'entities': [(32, 41, 'Total SNPs')]}),
 ('01 in Tibetans and retained ∼7.8 million SNP', {'entities': [(29, 40, 'Total SNPs')]}),
 (' Genotyping as part of CORECT was conducted using a custom Affymetrix genome-wide platform (the Axiom CORECT Set) with ~1.3 million SNP', {'entities': [(120, 131, 'Total SNPs')]}),
 (' In brief, a total of 906,600 SNPs were genotyped on the Affymetrix Genome-Wide Human SNP Array 6.', {'entities': [(22, 29, 'Total SNPs')]}),
 (' From the 793,799 autosome SNPs on the Affymetric SNP array 6.', {'entities': [(10, 17, 'Total SNPs')]}),
 (' After quality control exclusions, 402,919 SNPs remained in the children and 287,622 SNPs in the adults.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' Genotyping was performed via hybridization to a custom Affymetrix genome-wide platform (the Axiom® CORECT Set) containing ~1.3 million SNP', {'entities': [(124, 135, 'Total SNPs')]}),
 (' Using a subset of 60,572 uncorrelated SNPs (r_2 <0.', {'entities': [(19, 25, 'Total SNPs')]}),
 ('  1,000 sets of control loci were generated by matching SNPs to sentinel variants from the AF combined-ancestry analysis, with the SNPSnap tool.', {'entities': [(2, 7, 'Total SNPs')]}),
 ('  We used VEGAS () to conduct gene-based tests of all 17,601 genes identified by VEGAS, to parallel our genome-wide scan of individual SNPs.', {'entities': [(54, 60, 'Total SNPs')]}),
 (' Across the three datasets 466,573 SNPs were shared in common.', {'entities': [(27, 34, 'Total SNPs')]}),
 (' the three lead SNPs from the main analysis plus the two additional SNPs from the conditional analyses, rs780094, rs710446, rs4253417, rs4253421 and rs76438938) were tested in the F5Leiden, GAIT2, MARTHA studies (a total of 10,908 subjects) for association with aPTT, adjusting for age, sex, and, if applicable, principal components (model 1), and also with additional adjustment for FXI levels (model 2).', {'entities': [(224, 230, 'Total SNPs')]}),
 ('16 × 10-7 , representing a Bonferroni correction for 430,198 SNPs.', {'entities': [(53, 60, 'Total SNPs')]}),
 (' There were 1,000,559 SNPs released with genotyped and intensity data.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' In areas with long-spanning linkage-disequilibrium, formal conditional analysis was performed in a subset of 12,834 Finnish samples to ensure the independence of the lead-SNPs.', {'entities': [(110, 116, 'Total SNPs')]}),
 (' To increase genome coverage, genotypes were imputed for un-typed SNPs and in-dels using the 1kG multi-ethnic reference panel, yielding a total of 6,378,483 variants, and of these 5,904,251 with MAF≥ 5% were analyzed in the current investigation.', {'entities': [(147, 156, 'Total SNPs')]}),
 (' The final data set contained 8.9 million SNP', {'entities': [(30, 41, 'Total SNPs')]}),
 (' We further filtered out 99,511 SNPs with missing call rate\u2009\u2009>\u2009=\u20092%, 563 SNPs with\u2009>1 discordant calls, 1,078 SNPs with\u2009>1 Mendelian errors and 4,591 SNPs with Hardy-Weinberg equilibrium test P \u2009<\u200910\u2009_− \u2009_4 .', {'entities': [(25, 31, 'Total SNPs')]}),
 (' In our comparisons, we implemented 1,000 iterations for the Monte Carlo procedure across a 300kb window around the associated SNPs in each region.', {'entities': [(36, 41, 'Total SNPs')]}),
 (' 447,040 SNPs passed quality control metrics for the 541 discovery set cases for final analysis.', {'entities': [(1, 8, 'Total SNPs')]}),
 ('We estimated how much phenotypic variance a panel of 319,445 directly genotyped SNPs with MAF > 1% in the autosomes explain using the linear mixed model approach implemented in GCTA (v.', {'entities': [(53, 60, 'Total SNPs')]}),
 (' The final analysis dataset included 1,043,036 SNPs genotyped on 3,016 cases and 2,745 controls, with an average SNP call rate of 99.', {'entities': [(65, 70, 'Total SNPs'), (37, 46, 'Total SNPs')]}),
 (' This conservative choice fully corrects for the ~10 million SNP', {'entities': [(50, 60, 'Total SNPs')]}),
 (' This resulted in 26,226 individuals (3,143 cases and 23,083 controls), 402,748 genotyped SNPs, and 2,184,083 imputed SNPs with r_info _2 ≥0.', {'entities': [(18, 24, 'Total SNPs'), (100, 109, 'Total SNPs')]}),
 (' In GWA analysis for the subsample, we used genetic data of 319,517 SNPs after evaluating SNP call rates (> 95%), the Hardy-Weinberg equilibrium (HWE) test (P > 0.', {'entities': [(60, 67, 'Total SNPs')]}),
 ('30, which resulted in 2,455,927 imputed SNPs.', {'entities': [(22, 31, 'Total SNPs')]}),
 (' After combining imputed genotypes from both cohorts, the final data set contained ∼5.82 million SNP', {'entities': [(84, 96, 'Total SNPs')]}),
 (' The meta-analysis for adiponectin association with ∼2.5 million SNP', {'entities': [(53, 64, 'Total SNPs')]}),
 (' To examine whether the HCC risk–associated SNPs identified in our study were also associated with risk for chronic hepatitis B, 4,585 healthy controls without a history of HBV infection were also recruited from eastern China (Suzhou and Shanghai), northern China (Beijing), central China (Luoyang) and southern China (Fusui and Baise) ( and ).', {'entities': [(129, 134, 'Total SNPs')]}),
 (' An overlapping set of 369,487 autosomal SNPs were present on the 500k, 5.', {'entities': [(23, 30, 'Total SNPs')]}),
 (' A total of 4,058,415 SNPs (MAF > 5%) that passed quality control and Mendelian inheritance checks were used for association analysis.', {'entities': [(12, 21, 'Total SNPs')]}),
 ('000001) leaving a total of 1,197,702 SNPs for analysis.', {'entities': [(27, 36, 'Total SNPs')]}),
 (' After excluding monomorphic SNPs and SNPs with Hardy-Weinberg Equilibrium P<1×10_−6 , missing rate>25% or MAF<1%, a total of 820,017 genotyped SNPs remained for genotype imputation.', {'entities': [(126, 133, 'Total SNPs')]}),
 (' The number of SNPs per collection varied between 290,000 and 780,000.', {'entities': [(50, 57, 'Total SNPs')]}),
 ('Meta-analysis was carried out by using a fixed effect, sample size–weighted approach implemented in METAL using EMMAX association results for European GABC and TSS from a common set of ∼5.82 million SNP', {'entities': [(186, 198, 'Total SNPs')]}),
 (' High-density genotyping results were also available in the FHS and MESA for approximately 50,000 single nucleotide polymorphisms (SNPs) in approximately 2000 cardiovascular candidate genes from the Candidate Gene Association Resource (CARe).', {'entities': [(91, 97, 'Total SNPs')]}),
 ('HCHS/SOL participants were genotyped at 2.4 million SNP', {'entities': [(40, 51, 'Total SNPs')]}),
 (' In addition, DNA samples from 238 CeAD cases were genotyped across the genome, and 1,584 controls were genotyped on a custom chip including the SNPs yielding the most significant associations in the GWAS ().', {'entities': [(84, 89, 'Total SNPs')]}),
 (' The minimum P  value per gene (for genes that an SNP within the 9,830 variants assayed in this meta-analysis mapped to) is provided in .', {'entities': [(65, 70, 'Total SNPs')]}),
 (' SNPs were removed from further analysis if the allele frequency of the controls used in the current study differed from the allele frequency of the additional 6,450 Chinese samples by 0.', {'entities': [(160, 165, 'Total SNPs')]}),
 (' This left about 800,000 SNPs for each disease pair analyzed.', {'entities': [(17, 24, 'Total SNPs')]}),
 ('0\nincluding 906,600 SNPs.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('All of the contributed samples were genotyped on 1 of the Illumina (San Diego, CA, USA) single nucleotide polymorphism (SNP) chips (see ); 254,145 SNPs common across the various SNP genotyping arrays and that passed quality control were analyzed in these cohorts.', {'entities': [(139, 146, 'Total SNPs')]}),
 ('7, and obtained genotype data of 2,178,018 SNPs.', {'entities': [(33, 42, 'Total SNPs')]}),
 (' We excluded SNPs with HWE P ≤10_−6 , dropping 17,562 SNPs in African-Americans and 8,571 SNPs in Hispanics.', {'entities': [(47, 53, 'Total SNPs')]}),
 (' Imputation was based on the HapMap II CEU population and resulted in approximately 2.4 million SNP', {'entities': [(84, 95, 'Total SNPs')]}),
 ('5 array genotyping data, there were 2,376,105 measured SNPs, of which 2,116,447 passed QC.', {'entities': [(36, 45, 'Total SNPs')]}),
 (' For scenarios a) and b), we simulated 1,000 independent replicates of a SNP effect (matching SNPs associated in the unexposed) on a disease with prevalence of 5% in a cohort with adversity exposure, prevalence, and sample sizes matching CONVERGE.', {'entities': [(39, 44, 'Total SNPs')]}),
 (' Following quality control, 10 a priori  loci previously associated with stop signal task performance, 8,762 of the 20,652 HVA SNPs, and 4,873,750 genome-wide SNPs were available for analysis.', {'entities': [(103, 108, 'Total SNPs'), (137, 146, 'Total SNPs')]}),
 (' Quality control filters were applied (see ) which resulted in 18,485,882 imputed SNPs for analysis in 329,821 individuals.', {'entities': [(103, 110, 'Total SNPs'), (63, 73, 'Total SNPs')]}),
 ('; Santa Clara, CA) was used to genotype a total of 868,158 autosomal SNPs among 1,881 GenSalt study participants.', {'entities': [(51, 58, 'Total SNPs')]}),
 ('Genotype data from the FHS SHARe project include approximately 550,000 SNPs that were genotyped using Affymetrix GeneChip Human Mapping 500 k Array Set and the 50 k Human Gene Focused Panel by Affymetrix (Santa Clara, CA).', {'entities': [(63, 70, 'Total SNPs')]}),
 ('SNPs were genotyped using the Illumina HumanOmniExpress BeadChip for REDUCE and CLUE II populations at the Center for Cancer Genomics at Wake Forest University School of Medicine including 730,525 SNPs across the genome.', {'entities': [(189, 196, 'Total SNPs')]}),
 (' DEPICT used 37,427 human gene expression microarray samples to identify tissues and cell types in which genes near BMI-associated SNPs are highly expressed, and then tested for enrichment of specific tissues by comparing results with randomly selected loci matched for gene density.', {'entities': [(13, 19, 'Total SNPs')]}),
 (' 2,048 SNPs showing p<0.', {'entities': [(1, 6, 'Total SNPs')]}),
 (' The ‘adaptive’ mode essentially curtails the run length by removing SNPs that are highly unlikely to attain statistically significance at each permutation, until a user-defined maximum number of permutations (in this case 1,000,000) is reached for SNPs that continue to be statistically significant.', {'entities': [(223, 232, 'Total SNPs')]}),
 (' For 530,951 SNPs association results were available in one cohort only and were discarded, leading to a final 6,949,614 SNPs for which results are reported.', {'entities': [(5, 12, 'Total SNPs'), (111, 120, 'Total SNPs')]}),
 (' 728,129 SNPs remained for\nimputation.', {'entities': [(1, 8, 'Total SNPs')]}),
 ('  We further examined a list of 1,180 candidate SNPs that have been implicated in disorders that are linked to abnormal EDA responses (see  for a list of the sources).', {'entities': [(32, 37, 'Total SNPs')]}),
 (' The associations between these SNPs and ER-positive breast cancer were assessed using 25,227 ER-positive cases of European ancestry in BCAC who had been genotyped as part of the COGS Project.', {'entities': [(87, 93, 'Total SNPs')]}),
 (' The final results submitted to the Coordinating Center for meta-analysis were the per-allele regression coefficients with corresponding standard errors and P -values for the associations of up to 2.5 million SNP', {'entities': [(197, 208, 'Total SNPs')]}),
 (' For the meta-analysis, 18,376 SNPs passed quality control and included in the study.', {'entities': [(24, 30, 'Total SNPs')]}),
 ('0 arrays; 94,552 of those SNPs were not studied because they were monomorphic (n = 31,246) or had minor allele frequency < 5% (n = 63,306) in the Hutterites.', {'entities': [(10, 16, 'Total SNPs')]}),
 ('  We also investigated a specific set of 1,180 endophenotype-general candidate SNPs selected from meta-analyses and related studies of interest examining the molecular genetic bases of disorders and traits likely related to the startle response, such as depression, schizophrenia, and antisocial behavior (see notes for  for a list of the sources used).', {'entities': [(41, 46, 'Total SNPs')]}),
 (' After imputation, ∼10.5 million SNP', {'entities': [(20, 32, 'Total SNPs')]}),
 (' After per-SNP quality control steps, 550,352 autosomal SNPs were retained (See ).', {'entities': [(38, 45, 'Total SNPs')]}),
 (' Subsequently, we evaluated significant SNPs in 8,376 subjects of Asian origin from 5 different studies, and performed a meta-analysis on all studies combined.', {'entities': [(48, 53, 'Total SNPs')]}),
 (' The 1,719 CLHNS offspring were genotyped by the University of North Carolina Mammalian Genotyping using the Metabochip (Illumina, San Diego, CA), a custom high-density genotyping array of SNPs designed to provide a high-density coverage for both overall SNPs and low frequency variants concentrated around GWA loci and/or signals for cardiovascular and metabolic traits ().', {'entities': [(5, 10, 'Total SNPs')]}),
 (' A total of 539,473 SNPs (comprising 96.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('A collection of 7,447 cases and 11,479 controls were selected for low-frequency SNP association analysis.', {'entities': [(16, 21, 'Total SNPs')]}),
 (' We analysed data on chromosomes for which >90% of SNPs passed these filters, thus including 298,782 SNPS from 22 autosomal chromosomes.', {'entities': [(93, 100, 'Total SNPs')]}),
 (' After quality control, genotypes at 457,533 SNPs were available for estimating genetic effects for 1,079 ischemic stroke cases, 400 LAA cases, 288 SVO cases and 226 CE cases.', {'entities': [(37, 44, 'Total SNPs')]}),
 (' Furthermore, of 1,909 independent SNPs (pairwise distance >500 kb and r _2  < 0.', {'entities': [(17, 22, 'Total SNPs')]}),
 (' SNPs and samples with low genotyping call rate (<95%), and SNPs with HWE P-value < 1×10_−6  were excluded, resulting in 1,235 SNPs and 2,121 samples available for analysis.', {'entities': [(121, 126, 'Total SNPs')]}),
 (' To minimize imputation errors, we additionally excluded SNPs with a MAF <1% and a call rate <98% in any study, SNPs that could not be linked to the 1KGP reference, those with MAF for Europeans that differed from that for the 1KGP, and a further 16,526 SNPs for which the cluster plot was judged to be not ideal.', {'entities': [(246, 252, 'Total SNPs')]}),
 ('0 microarray containing 988,306 autosomal SNPs to genotype 2,660 subjects (1,581 AAs and 1,079 EAs); and the Illumina HumanCoreExome array, which contains over 550,000 markers split between common tagging and low-frequency variants, to genotype 1,264 subjects (592 AAs and 672 EAs).', {'entities': [(24, 31, 'Total SNPs')]}),
 (' Samples were genotyped using Illumina’s Human 1M Beadchip, containing 1,072,820 SNPs.', {'entities': [(71, 80, 'Total SNPs')]}),
 (' This platform provided genotype data for 964,193 SNPs of which 2,923 were removed because they were from chromosome Y, mitochondria, or unplaced chromosomes.', {'entities': [(42, 49, 'Total SNPs')]}),
 (' Elimination of SNPs with low call rate (<95%), low MAF (<2%), or out of Hardy-Weinberg equilibrium (p<E-6) resulted in 803,582 high-quality autosomal SNPs available for analysis.', {'entities': [(120, 127, 'Total SNPs')]}),
 (', San Diego, USA), which together covered almost 410,000 non-overlapping SNPs from the entire human genome.', {'entities': [(49, 56, 'Total SNPs')]}),
 (' Only 87 SNPs were excluded due to allele mismatches, 13,276 SNPs were excluded due to allele frequency mismatches from the 1000 genomes phase 3 reference panel, 283,163 were found to be duplicates and excluded, 104 SNPs were found on the HRC reference panel, but not on the 1000 genomes phase 3 reference panel, and 2,723,493 SNPs had sample sizes less 10000 individuals.', {'entities': [(54, 60, 'Total SNPs'), (317, 326, 'Total SNPs')]}),
 (' After excluding the unqualified samples and SNPs in the preimputation process, our final dataset included 734 cases, 3651 controls, and 746,272 autosomal SNPs.', {'entities': [(137, 144, 'Total SNPs')]}),
 (' Genotyping was carried out using Illumina arrays containing a common set of about 575,000 genotyped SNPs.', {'entities': [(83, 90, 'Total SNPs')]}),
 (' Over half of the more than 700,000 SNPs on the IlluminaOmniExpress BeadChip reside within 10 Kb of a RefSeq gene, while only about 15,000 are predicted to cause a non-synonymous amino acid change.', {'entities': [(28, 35, 'Total SNPs')]}),
 (' Study-specific Metabochip results as well as Metabochip meta-analysis results were genomic-control-corrected using 4,425 SNPs included on Metabochip for replication of associations with QT-interval, a phenotype not correlated with BMI, after pruning of SNPs within 500 kb of an anthropometry replication SNP.', {'entities': [(116, 121, 'Total SNPs')]}),
 (' The final data contain 613,218 SNPs from 5615 samples (832 cases and 4783 controls).', {'entities': [(24, 31, 'Total SNPs')]}),
 (' Study-5 (416\u2009BP cases and 2,741 controls) was used as the reference sample here because subjects from Study-5 were genotyped by the high density SNP array (Illumina HumanOmni2.', {'entities': [(27, 32, 'Total SNPs')]}),
 (' After all of the QC filters, we retain 3,381 individuals (3,008 Tibetan and 373 Han) and 287,691 SNPs (279,608 autosomal SNPs).', {'entities': [(40, 45, 'Total SNPs')]}),
 (' After the quality control, 305,811 autosomal SNPs available on 2226 individuals (1046 singletons and 590 DZs) were available and used for imputation.', {'entities': [(28, 35, 'Total SNPs')]}),
 (' We further examined a list of 1,180 candidate SNPs that have been implicated in disorders that are linked to abnormal EDA responses (see  for a list of the sources).', {'entities': [(31, 36, 'Total SNPs')]}),
 (' Genotyping failure led to the further exclusion of an additional 1,999 SNPs as a result of the SNPs (i) having no intensity signal (n  = 559), (ii) not being polymorphic (n  = 1,176), (iii) only being found in a heterozygous state (n  = 248) or (iv) having mismatched alleles compared to 1000 Genomes Project data (n  = 16).', {'entities': [(66, 71, 'Total SNPs')]}),
 (' Each study performed genotyping using genome-wide SNP arrays, and\nconducted QC and imputation of the data to ~2.5 million ', {'entities': [(111, 122, 'Total SNPs')]}),
 (' Allele frequencies were calculated for the resulting 944,565 SNPs using maximum likelihood estimates in SOLAR [].', {'entities': [(54, 61, 'Total SNPs')]}),
 (' After quality control, 1,162 cases and 1,244 controls were available for association analyses at 551,514 SNPs.', {'entities': [(24, 29, 'Total SNPs')]}),
 (' Over 38 million SNP', {'entities': [(6, 16, 'Total SNPs')]}),
 (' 1,000 sets of control loci were generated by matching SNPs to sentinel variants from the AF combined-ancestry analysis, with the SNPSnap tool.', {'entities': [(1, 6, 'Total SNPs')]}),
 (' For each SNP set, 2,000 sets of matched SNPs were obtained via SNPsnap with its default settings.', {'entities': [(19, 24, 'Total SNPs')]}),
 ('05), a total of 5,400,957 and 4,983,952\nSNPs were evaluated in the PAGE study and the meta-analysis, respectively.', {'entities': [(16, 25, 'Total SNPs')]}),
 (' For this purpose, we used a subset of 22,897 SNPs that were uncorrelated (r _2  < 0.', {'entities': [(39, 45, 'Total SNPs')]}),
 ('0 microarray (Illumina, San Diego, California) containing 988,306 autosomal SNPs.', {'entities': [(58, 65, 'Total SNPs')]}),
 (', Santa Clara, CA), with 897,981 SNPs passing study-specific quality control ().', {'entities': [(25, 32, 'Total SNPs')]}),
 (' Data for\n2,155,369 autosomal SNPs were available for analysis of circulating HDL-c\nlevels, 2,154,923 for LDL-c and 2,155,784 SNPs for TG.', {'entities': [(10, 19, 'Total SNPs')]}),
 (' The number of SNPs significantly associated with change in LVEF assigned to each evaluated KEGG pathway were compared to the number of significantly associated SNPs in 3,500 randomly generated pathways.', {'entities': [(169, 174, 'Total SNPs')]}),
 ('_,  Illumina HumanCoreExome SNP array data for additional 91 CRC patients and 14,187 Finnish cancer-free controls were obtained from the National FINRISK Study (https://www.', {'entities': [(78, 84, 'Total SNPs')]}),
 (' In total, 2,762,059 SNPs were analyzed.', {'entities': [(11, 20, 'Total SNPs')]}),
 ('2–9.5 million SNP', {'entities': [(2, 13, 'Total SNPs')]}),
 (' We studied 481,281 SNP genotypes after excluding 51,271 SNPs because of a low minor-allele frequency (<1%) or poor call rate (<95%).', {'entities': [(12, 19, 'Total SNPs')]}),
 (' Imputation of 2,416,663 SNPs from the HapMap release 22 build 36 Chinese Han of Beijing and Japanese of Tokyo (CHB+JPT) reference panel was conducted using MACH software (version 1.', {'entities': [(15, 24, 'Total SNPs')]}),
 (' Our final hybrid dataset contained 2,543,887 SNPs of which 584,029 were genotyped.', {'entities': [(60, 67, 'Total SNPs'), (36, 45, 'Total SNPs')]}),
 (' This left 254,457 autosomal SNPs for imputation.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' Of 405,555 SNPs attempted for genotyping, 381,212 were released by CIDR and 299,873 of these remained after removing SNPs that were monomorphic (n\u2009= \u200970,761), were positional duplicates, were on the Y chromosome, had Hardy-Weinberg Equilibrium (HWE) P\u2009< \u200910\u2009_− \u2009_4 , had call rate\u2009<\u20090.', {'entities': [(4, 11, 'Total SNPs')]}),
 ('5 genotypes contained 5034 individuals and 2,337,794 SNPs.', {'entities': [(43, 52, 'Total SNPs')]}),
 (' We imputed genotypes for ~70 million SNP', {'entities': [(27, 37, 'Total SNPs')]}),
 ('We genotyped GOLDN participants at 906,600 loci using the Affymetrix Genome Wide Human SNP Array 6.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' In all, we identified 257,035 SNP markers that overlap across the Add Health sibling pairs subsample, the HGDP sample and the HapMap sample.', {'entities': [(23, 30, 'Total SNPs')]}),
 ('Our initial sample consisted of 1,817 DSM-IV OCD cases, 504 controls and 663 complete trios, genotyped using the\nIllumina Human610-Quadv1_B SNP array.', {'entities': [(32, 37, 'Total SNPs')]}),
 (' This Stage 2 dataset included 431 SLE cases (97% women) and 2,155 database controls (50% women) successfully genotyped for 311,238 SNPs on Affy 5.', {'entities': [(61, 66, 'Total SNPs')]}),
 ('htm) using 16,819 SNPs that are in the linkage disequilibrium (LD)-pruned SNP set provided by The Gene, Environment Association Studies consortium (GENEVA) coordinating center [].', {'entities': [(11, 17, 'Total SNPs')]}),
 (' After filtering out SNPs with a call rate <95% (SNP call rate is the percentage of patients who have a confident genotype call for each SNP according to Affymetrix quality control criteria) and minor allele frequency <1%; the remaining SNPs (484,623 typed SNPs and 1,091,393 imputed SNPs) were assessed in a GWAS for their association with vincristine-induced neuropathy, in St.', {'entities': [(266, 275, 'Total SNPs')]}),
 (' Following quality control, 483,359 SNPs were available in all data sets for analysis.', {'entities': [(28, 35, 'Total SNPs')]}),
 (' Only SNPs which were available in >50% of the total sample size over all studies were analyzed, resulting in a total number of 2,362,330 SNPs in the meta-analysis.', {'entities': [(128, 137, 'Total SNPs')]}),
 (' Common variants are defined by over 1% of a minor allele frequency with decent sample size such as 1,000 (), but we selected common SNPs having 5% or greater because at least 5 out of 100 samples were needed for a suitable statistical analysis due to our sample size of 96.', {'entities': [(100, 105, 'Total SNPs')]}),
 (' The data were then merged, resulting in one data set consisting of 5,971 samples genotyped at a total of 1,240,656 individual SNPs, and another with an additional 2,083 samples genotyped at 583,613 SNPs.', {'entities': [(68, 73, 'Total SNPs'), (106, 115, 'Total SNPs')]}),
 (' 251 individuals were removed after kinship estimates identified related individuals using identity-by-descent sharing from a random selection of 100,000 autosomal SNPs.', {'entities': [(146, 153, 'Total SNPs')]}),
 (' After QC, there were 546,561 SNPs remaining for the combined initial study.', {'entities': [(22, 29, 'Total SNPs')]}),
 (' We tested ~2.7 million SNP', {'entities': [(12, 23, 'Total SNPs')]}),
 (' A total of 47,582 SNPs\nhad a non-call rate > 2.', {'entities': [(12, 18, 'Total SNPs')]}),
 ('DNA samples of panel A were genotyped using the Immunochip, comprising a total of 196,524 SNP assays ().', {'entities': [(82, 89, 'Total SNPs')]}),
 (' After all rounds of quality control filtering, the ADNI dataset had 2,449,382 SNPs and the QTIM dataset had 2,439,807 SNPs.', {'entities': [(69, 78, 'Total SNPs')]}),
 (' After these exclusions, 2,116,365 SNP remained.', {'entities': [(25, 34, 'Total SNPs')]}),
 ('Germline DNA was genotyped using the Exome-24 BeadChip (Illumina, San Diego, CA) (689 patients in SJCRH cohort and 2,382 in AALL0232 trial) and either the Affymetrix Genome-Wide Human SNP Array 6.', {'entities': [(115, 120, 'Total SNPs')]}),
 (' In the original GWAS study design, our goal of a discovery sample size of 2,500 (which we exceeded) was chosen so as to have high power to detect risk-associated SNPs with realistic effect sizes.', {'entities': [(75, 80, 'Total SNPs')]}),
 (' Proportion of variance accounted for by covariates, and estimates of variance components (95% CI) from GCTA and biometric analysis of the five covariate-adjusted clinical phenotypes Each of the five clinical phenotypes was regressed on each of the 527,828 autosomal SNPs, using the demographic and principal component scores described above as covariates.', {'entities': [(249, 256, 'Total SNPs')]}),
 ('30, MAF<1% and HWE P<1×10_−6 , 2,216,774 SNPs remained for analysis.', {'entities': [(31, 40, 'Total SNPs')]}),
 (' Following the exclusion there remained 372,193 SNPs for further analysis.', {'entities': [(40, 47, 'Total SNPs')]}),
 (' Exclusion criteria for SNP performance included call rate < 95% (n=972), SNPs with 5 or fewer observances (n=204,273) and Hardy-Weinberg Equilibrium (HWE) p-value <1×10_−6  (n=26); 41,961 SNPs were retained for analysis.', {'entities': [(182, 188, 'Total SNPs')]}),
 (' Once the data from the multiple sites and different Illumina arrays were merged, there were 983,441 SNPs genotyped across the complete sample of 737 trios.', {'entities': [(93, 100, 'Total SNPs')]}),
 (' The V1 and V2 platforms were variants of the Illumina HumanHap550+ BeadChip, including about 25,000 custom SNPs selected by 23andMe, with a total of about 560,000 SNPs.', {'entities': [(94, 100, 'Total SNPs')]}),
 ('01 were used to impute the approximately 2.5 million SNP', {'entities': [(41, 52, 'Total SNPs')]}),
 (' Genotyping data from 459 patients, 382 Canadian historical controls, and 1,124 US historical controls were merged, and the same missingness settings were applied to all of the samples and SNPs.', {'entities': [(74, 79, 'Total SNPs')]}),
 (' These quality scores and minor allele frequencies for up to ∼2.5 million SNP', {'entities': [(62, 73, 'Total SNPs')]}),
 (' () (for additional quality control steps and imputation using MACH, see the ), yielding 1,954,455 SNPs in 1,273 subjects.', {'entities': [(107, 112, 'Total SNPs'), (89, 98, 'Total SNPs')]}),
 (' After QC, a total of 1,633,452 SNPs were available for final analysis using the imputed dosages.', {'entities': [(22, 31, 'Total SNPs')]}),
 (' Approximately 34 million markers (SNPs and insertion–deletion polymorphisms), including the 191,777 functional variants identified through whole-genome sequencing, were imputed in the Icelandic cases and controls.', {'entities': [(93, 100, 'Total SNPs'), (15, 25, 'Total SNPs')]}),
 (' Using the International HapMap Project genotype data (phase 3 release #3, National Center for Biotechnology Information [NCBI] build 36, SNP Database (dbSNP) b126, 2010-05-28, minor allele frequency [MAF]>5%) for CEU, JPT/CHB, and YRI , we seeded 10,195 high-quality markers from our dataset (r_2  < 0.', {'entities': [(248, 254, 'Total SNPs')]}),
 ('0 array included 906,600 SNP probes and 946,000 CNV probes.', {'entities': [(17, 24, 'Total SNPs')]}),
 (' The initial SLEGEN GWA samples were genotyped as detailed above, and the top 13,000 SNPs from Set 1 were considered for the LLAS replication study.', {'entities': [(78, 84, 'Total SNPs')]}),
 (' To detect population group outliers, we analyzed each of the four HAPO populations separately with and without 89 HapMap samples (CEU, CHB, JPT and YRI samples genotyped external to the HapMap control samples genotyped with the HAPO study participants) with a subset of autosomal SNPs [160,189 (AC), 90,712 (NE), 109,901 (MA), and 96,836 (TH) SNPs] ().', {'entities': [(301, 307, 'Total SNPs')]}),
 (' Each study independently imputed its genotype data to the ≈2.6 million SNP', {'entities': [(60, 71, 'Total SNPs')]}),
 (' After imputation and quality control analyses, a total of about 2.7 million SNP', {'entities': [(65, 76, 'Total SNPs')]}),
 ('We imputed genotypes for ~70 million SNP', {'entities': [(26, 36, 'Total SNPs')]}),
 ('5–8 BeadChip, which measures nearly 2.4 million SNP', {'entities': [(36, 47, 'Total SNPs')]}),
 (' As a sampling dataset, we chose the 655,658 SNP from the Affymetrix 6.', {'entities': [(37, 44, 'Total SNPs')]}),
 (', San Diego, CA), which includes ~2.5 million SNP', {'entities': [(34, 45, 'Total SNPs')]}),
 (' Before quality control (QC), we imputed 56,389 SNPs with the help of IMPUTE2 ().', {'entities': [(41, 47, 'Total SNPs')]}),
 (' After QC, results were available for 4,972,397 SNPs, of which 57.', {'entities': [(38, 47, 'Total SNPs')]}),
 (' For imputation of genotypes to the HapMap set of 2.5 million SNP', {'entities': [(50, 61, 'Total SNPs')]}),
 (' Conditional logistic regression was used to fit models with the binary pesticide exposure variable and the SNP genotype coded as the minor allele count (0,1,2 for observed SNPs or the imputed “dosage”), with and without the interaction term between these two variables.', {'entities': [(154, 159, 'Total SNPs')]}),
 (' A total of 2,379,855 SNP probes were attempted in Illumina HumanOmni2.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' The V4 had a fully customized array of approximately 570,000 SNPs.', {'entities': [(54, 61, 'Total SNPs')]}),
 (' We used as inputs for MetaXcan the ND meta-analysis association result in the trans-population merged cohort for 12,768,612 common SNPs that appeared in at least one single data set.', {'entities': [(114, 124, 'Total SNPs')]}),
 ('0% across the merged data set of 17,150 unique subjects (532,566 → 482,985 SNPs).', {'entities': [(33, 39, 'Total SNPs')]}),
 (' Analyses in this report focused first on the 13,276 SNPs proposed by the ER-negative breast cancer GWAS.', {'entities': [(46, 52, 'Total SNPs')]}),
 (' After removal of 44,237 monomorphic SNPs, 3,638 SNPs due to deviations from Hardy-Weinberg Equilibrium (HWE P<1×10_−6 ), 1 SNP with all missing data, and 265 SNPs with missing rate > 25% and MAF<1%, a total of 820,017 SNPs remained.', {'entities': [(18, 24, 'Total SNPs')]}),
 (' Principal components were estimated using 19,059 randomly selected autosomal SNPs with frequency ≥ 2% in the combined multiethnic sample ().', {'entities': [(43, 49, 'Total SNPs')]}),
 (' The final analyses were based on data from 199,961 SNPs.', {'entities': [(44, 51, 'Total SNPs')]}),
 (' After\nimputation, 11,314,818 SNPs in GSA and 11,351,136 SNPs in MEGA were obtained.', {'entities': [(19, 29, 'Total SNPs')]}),
 (' The discovery GWAS (DAG cohort) included 294,932 SNPs and were analysed using a logistic regression with an additive genetic model, and GWAS I and II were meta-analysed using Plink v1.', {'entities': [(42, 49, 'Total SNPs')]}),
 (' Age-dependent effects were assessed using a meta-regression approach for 1,464 SNPs obtained after this selection procedure.', {'entities': [(74, 79, 'Total SNPs')]}),
 ('5 × 10_−123 ), we estimate ~1,007 of the 1,909 SNPs represent true BMI associations.', {'entities': [(41, 46, 'Total SNPs')]}),
 (' a, The estimated variance in BMI explained by SNPs selected at a range of P  values using unrelated individuals from the QIMR (n  = 3,924; purple) and TwinGene (n  = 5,668; gold), their weighted average (cyan), inferred from within-family prediction (red; ), and by all HapMap phase III SNPs in 16,275 unrelated individuals from the QIMR, TwinGene and ARIC studies (orange).', {'entities': [(296, 302, 'Total SNPs')]}),
 (' After the initial genome-wide imputation had identified the FTO region as a candidate region, further imputation of this region (1Mb either side of rs16953002, Chr16: 53,114,824–55,114,824) was conducted based on the 1000 Genomes Phase 1 integrated variant set (March 2012 release, excluding SNPs with MAF<0.', {'entities': [(168, 178, 'Total SNPs')]}),
 ('05 were considered to maintain stability of effect estimates and statistical validity for hypothesis tests at interaction terms, resulting in the removal of 84,674 SNPs in African-Americans and 130,820 SNPs in Hispanics and a total of 786,776 SNPs in African-Americans and 706,791 SNPs in Hispanics available for analysis.', {'entities': [(157, 163, 'Total SNPs')]}),
 ('01 (n\u2009= \u200928,851 SNPs), not in Hardy-Weinberg Equilibrium (n\u2009= \u200915), SNPs with\u2009>3 Mendelian errors (n\u2009= \u200915), SNPs showing a genotyping ‘plate’ effect (n\u2009= \u20091530), or perfectly correlated with gender (n\u2009= \u20095) were excluded, leaving 559,400 SNPs.', {'entities': [(231, 238, 'Total SNPs')]}),
 ('and obtained a total of 1,574,154 SNPs for final analysis.', {'entities': [(24, 33, 'Total SNPs')]}),
 (' A total of 676,913 autosomal SNPs were typed using Illumina SNP chips.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('5–8 SNP array contained 2,315,673 autosomal sites, 273,074 of which overlapped with the HumanCoreExome SNP array (https://support.', {'entities': [(51, 58, 'Total SNPs'), (24, 33, 'Total SNPs')]}),
 (' The RPGEH imputed >25 million SNP', {'entities': [(20, 30, 'Total SNPs')]}),
 (' Our GWAS consisted of examining the impact on the different startle indices of each of the 527,829 genotyped SNPs that survived quality control.', {'entities': [(92, 99, 'Total SNPs')]}),
 (' There were 9,830 SNPs in common between the PDGene and the PDWBS data sets.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' All imputations were done on the forward (+)-strand using 562,554 genotyped SNPS that had passed quality control filters.', {'entities': [(59, 66, 'Total SNPs')]}),
 (' Genotypes for 1,006,422 SNPs and 133,997 CNV probes were released.', {'entities': [(34, 41, 'Total SNPs'), (15, 24, 'Total SNPs')]}),
 (' A total of 731,458 SNPs were genotyped in 1,497 cases and 1,008 controls.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' A total of 1,632,526 SNPs were excluded, leaving 2,668,805 SNPs for statistical analyses.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' In two large cohorts included in the meta-analysis, the Netherlands Twin Register (NTR, N = 3,599 unrelated individuals) cohort and the QIMR Berghofer Medical Research Institute (QIMR, N= 3,369) adult cohort, Genomic-relatedness-matrix Restricted Maximum Likelihood (GREML) analysis in the GCTA software was applied to estimate the proportion of variance in neuroticism that can be explained by common SNPs.', {'entities': [(93, 98, 'Total SNPs')]}),
 (' We excluded 65,288 SNPs in the neonatal data for failing the Hardy-Weinberg disequilibrium test.', {'entities': [(13, 19, 'Total SNPs')]}),
 ('A total of 2,418 current smokers were genotyped using the Illumina Human1M-Duo BeadChip (1,199,187 SNPs).', {'entities': [(11, 16, 'Total SNPs'), (89, 98, 'Total SNPs')]}),
 (' A fixed-effects meta-analysis of the cohort-specific results was performed using the inverse variance-weighted method in METAL [], with a total of 2,033,301 single nucleotide polymorphisms (SNPs) tested.', {'entities': [(148, 157, 'Total SNPs')]}),
 (' The final 2013 PGC MDD GWAS comprised results for 1,232,794 SNPs.', {'entities': [(51, 60, 'Total SNPs')]}),
 (' We analysed data on a common set of 314,861 SNPs successfully genotyped by both arrays.', {'entities': [(37, 44, 'Total SNPs')]}),
 ('We imputed all known SNPs across the genome on the basis of the genotyped SNPs in the 1,161 cases and 1,353 controls used in the initial GWAS and haplotype data from HapMap Phase 2 CHB and JPT subjects (release 24) using the IMPUTE program (v2.', {'entities': [(86, 91, 'Total SNPs')]}),
 ('Genotyping of 130 SNPs was carried out for the 3,614 cases and 5,924\ncontrols forming the Chinese replication set, using the Sequenom platform.', {'entities': [(47, 52, 'Total SNPs')]}),
 (' SNPs were further excluded if they had sample size less than 10,000 or showed evidence of heterogeneity across studies (P  for Cochrane’s Q-test<1×10_−6 ).', {'entities': [(62, 68, 'Total SNPs')]}),
 (' Genotypes in all four GWAS were imputed for ~2.6 million SNP', {'entities': [(46, 57, 'Total SNPs')]}),
 (' A total of 13,341,935 SNPs was retained after filtering and excluding chromosome X, Y and mitochondria.', {'entities': [(12, 22, 'Total SNPs')]}),
 (' For the association analysis, we used 523,420 SNPs; the other SNPs were excluded based on a missing rate >5%, deviation from Hardy-Weinberg equilibrium in controls (P<10_−3 ), minor allele frequency <1%, or discrepancies (P<10_−7 ) in allele frequencies between the two genotyping rounds.', {'entities': [(39, 46, 'Total SNPs')]}),
 (' PCA was performed using 13,012 LD-pruned SNPs with allele frequency >5% and IMPUTE2 info score >0.', {'entities': [(25, 31, 'Total SNPs')]}),
 (' Stage 1 comprised a meta-analysis of directly genotyped and imputed SNPs in 7,467 patients diagnosed with BD by direct interview and 27,303 controls drawn from published BD case-control studies, dbGaP, and WTCCC2.', {'entities': [(77, 82, 'Total SNPs')]}),
 (' To compare both populations using the same SNP density, we re-ran the\nanalysis on the overlap of genotyped SNPs (267,005 SNPs with minor allele\nfrequency > 1% in Chinese and 264,833 with minor allele frequency\n> 1% in Europeans) and found that the heritability explained was higher\nin the data for the Chinese population: h _2  = 30.', {'entities': [(175, 182, 'Total SNPs')]}),
 (' For a discovery analysis in 110,000 individuals (urate), there was >80% power to detect a SNP explaining 0.', {'entities': [(29, 36, 'Total SNPs')]}),
 (' Quality controls (QCs) were performed on the 234 samples and 624,297 single-nucleotide polymorphisms (SNPs) using PLINK().', {'entities': [(62, 69, 'Total SNPs')]}),
 ('Genotyping for 500,568 SNPs in 9,354 subjects from three generations was conducted with Affymetrix 500K mapping plus Affymetrix 50K supplemental arrays and was additionally checked for sex accordance and consistency with family structure resulting 9,237 participants.', {'entities': [(15, 22, 'Total SNPs')]}),
 (' The remaining 2,074,734 SNPs were used in all subsequent analyses.', {'entities': [(15, 24, 'Total SNPs')]}),
 (' After conversion of genomic coordinates to GRCh37/hg19, exclusion of SNPs with duplicates, call rates < 97%, MAFs < 1%, and without chromosome and base pair position, and exclusion of 44 subjects with genotype call rates < 90%, 642,766 were available for imputation in 2,972 participants.', {'entities': [(229, 236, 'Total SNPs')]}),
 (' The reported pedigree structure was assessed using a pruned set of 1,519,440 SNPs.', {'entities': [(68, 77, 'Total SNPs')]}),
 ('  On the basis of the genotyped single-nucleotide polymorphisms (SNPs) and haplotype information in the National Center for Biotechnology Information build 35 of phase II Hapmap CEU data, we imputed genotypes for >2.5 million SNP', {'entities': [(214, 225, 'Total SNPs')]}),
 (' Utilizing a set of 12,000 un-linked SNPs (pair-wise r2<0.', {'entities': [(20, 26, 'Total SNPs')]}),
 (' We examined the combined effects of lead SNPs at the 97 loci in an independent sample of 8,164 European-descent individuals from the Health and Retirement Study.', {'entities': [(90, 95, 'Total SNPs')]}),
 (' Here, we used the QIMR cohort as the reference, which included 3,924 unrelated individuals with European ancestry and with genotypes available for 2,410,957 SNPs_, .', {'entities': [(64, 69, 'Total SNPs'), (148, 157, 'Total SNPs')]}),
 (' Classical HLA  alleles, variant amino acids within HLA proteins, and additional SNPs in the MHC were imputed using the SNP2HLA pipeline, with a reference panel consisting of 5,225 individuals of European ancestry from the Type 1 Diabetes Genetics Consortium ().', {'entities': [(175, 180, 'Total SNPs')]}),
 ('8) in the region increased from 1,245 to 4,874, although the most significant three SNPs remained the same.', {'entities': [(32, 37, 'Total SNPs')]}),
 ('3 (March 2012) reference panel, yielding ∼30,000,000 SNPs for analysis.', {'entities': [(42, 52, 'Total SNPs')]}),
 (' The Immunochip is an Illumina Infinium microarray comprising 196,524 SNPs and small indel markers selected based on results from genome-wide association studies of 12 different immune-mediated diseases.', {'entities': [(62, 69, 'Total SNPs')]}),
 (' A total of 3546 samples and 549,530 SNPs remained after quality control.', {'entities': [(29, 36, 'Total SNPs')]}),
 (' Minimac software was used to perform targeted imputation of the 3 Mb region surrounding each identified SNP based on the ALL ancestry panel from the 1000G Phase I Integrated Release Version 3 Haplotypes, which contains haplotypes of 1,092 individuals of all ethnic background.', {'entities': [(234, 239, 'Total SNPs')]}),
 (' In Stage I, two separate GWA analyses for CHD across 2,543,016 genotyped or imputed SNPs (with imputed SNPs expressed as allele dosage) were performed in the NHS and HPFS sets by means of logistic regression under an additive genetic model using the ProbABEL package.', {'entities': [(54, 63, 'Total SNPs')]}),
 (' Data were available 855 Northern European and 117 African American patients with breast cancer who were treated with taxanes typed at 521,600 SNPs using the HumanHap610-Quad Genotyping BeadChip (Illumina) [].', {'entities': [(135, 142, 'Total SNPs')]}),
 (' A total of 2,090,256 SNPs with a minor allele frequency ≥1% and directly genotyped or imputed with sufficient quality (see  Supplementary Table 3 under “Supplemental data” in the online issue) were included in the meta-analysis.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' Consequently, data for 2,450,547 genotyped or imputed autosomal SNPs were available for the primary analysis of serum urate concentrations, and data for 2,538,056 SNPs were available for the primary gout analysis.', {'entities': [(24, 33, 'Total SNPs')]}),
 (' Participants had either been genotyped on a custom designed SNP chip (iCOGS) with 211,155 markers or on standard genome-wide arrays ().', {'entities': [(83, 90, 'Total SNPs')]}),
 (' After genotyping QC and imputation, a total number of 2,380,486 SNPs were included.', {'entities': [(55, 64, 'Total SNPs')]}),
 (' Genotyped SNPs that passed quality control () were included, resulting in 324,895 SNPs for analysis.', {'entities': [(75, 82, 'Total SNPs')]}),
 (' GWAS data from the seven studies were imputed to >10 million SNP', {'entities': [(51, 61, 'Total SNPs')]}),
 ('The associations of the 36 sentinel blood pressure SNPs with DNA methylation were first examined among 1,904 South Asian individuals from the LOLIPOP cohort.', {'entities': [(103, 108, 'Total SNPs')]}),
 (' Results for the most significantly associated SNPs for CSF tau, ptau_181 , and Aβ_42  are reported here from the largest previously published two-stage meta-analysis of GWAS for AD risk consisting of a total 25,580 cases and 48,466 controls [], and a recently published genome-wide survival analysis of AAO consisting of 39,855 individuals (personal communication: Huang & Goate).', {'entities': [(209, 215, 'Total SNPs')]}),
 ('0001), resulting in 7,738,399 bi-allelic SNPs for further analysis.', {'entities': [(20, 29, 'Total SNPs')]}),
 ('8 × 10_−6  (Bonferroni correction for 13,275 SNP–CpG marker tests).', {'entities': [(38, 44, 'Total SNPs')]}),
 (' This resulted in 604,255 SNPs.', {'entities': [(18, 25, 'Total SNPs')]}),
 (' A total of 707,557 autosomal SNPs passed quality control ().', {'entities': [(12, 19, 'Total SNPs')]}),
 (' The final SNP count for MTAG was 7,333,576.', {'entities': [(34, 43, 'Total SNPs')]}),
 (' Quality control and imputation using MACH () are described in the original reports (summarized in the  accompanying the online version of this article), yielding 1,922,309 single nucleotide polymorphisms (SNPs) in 3,117 subjects.', {'entities': [(215, 220, 'Total SNPs'), (163, 172, 'Total SNPs')]}),
 ('0V software, resulting in 2,543,887 and 1,387,466 SNPs respectively.', {'entities': [(26, 35, 'Total SNPs')]}),
 (' Briefly, genome-wide genotyping was performed by Affymetrix Axiom array from which 618,793 SNPs passed genotyping quality control.', {'entities': [(84, 91, 'Total SNPs')]}),
 ('025 were excluded, leaving 7,276,170 SNPs for further analyses.', {'entities': [(27, 36, 'Total SNPs')]}),
 (' 2013 (who generated a 573 SNP classifier from 10,799 SNPs with P < 1 x 10-4  in a cohort of ~17,000 CD cases and ~22,000 controls; ).', {'entities': [(47, 53, 'Total SNPs')]}),
 (' This extended our SNP association testing to a total of 11,892,802 genome wide variants post quality control checks (1,131,426 genotyped and 10,761,376 imputed SNPs/indels).', {'entities': [(57, 67, 'Total SNPs')]}),
 (' Before imputation, SNPs with <95% call rate, concordance <95% with 1,000 Genomes in samples genotyped for QC, or Hardy-Weinberg equilibrium P <10_−4  in controls were excluded.', {'entities': [(68, 73, 'Total SNPs')]}),
 (' Analyses were restricted to 519,655 SNPs meeting the following criteria; call rate ≥95% if MAF ≥5%, (or ≥99% if MAF<5%), HWE P >10_−12  (cases), or HWE P >10_−7  with no difference in frequency between the two WTCCC2 control groups at P <10_−6  (controls).', {'entities': [(29, 36, 'Total SNPs')]}),
 (' Our analyses were restricted to SNPs that had a minor allele frequency of at least 1%, which left 9,955,952 SNPs after quality control.', {'entities': [(99, 108, 'Total SNPs')]}),
 (' This resulted in a total of ~2,261,000 SNPs that were either genotyped or imputed with high confidence in all three samples.', {'entities': [(30, 39, 'Total SNPs')]}),
 (' 15,483 SNPs with low minor allele frequencies and 96,260 SNPs exceeding the Hardy-Weinberg disequilibrium cutoff were excluded.', {'entities': [(1, 7, 'Total SNPs')]}),
 (' After QC, there were 1,726 subjects and 270,630 SNPs (263,345 autosomal SNPs).', {'entities': [(22, 27, 'Total SNPs')]}),
 (' A total of 2,416,663 SNPs from the HapMap release 22 build 36 CHB+JPT samples were imputed using MACH software.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' Significance of GO categories was assessed by false discovery rate (FDR) based on 10,000 SNP permutations.', {'entities': [(83, 89, 'Total SNPs')]}),
 ('The 5,055 SNPs that were included for BMI replication on Metabochip included 1,909 independent SNPs (r _2  < 0.', {'entities': [(4, 9, 'Total SNPs')]}),
 (' A total of 50,255 SNPs were removed due to severe deviation from Hardy-Weinberg equilibrium (P<1.', {'entities': [(12, 18, 'Total SNPs')]}),
 (' Genome-wide associations on asthma (2,004,043 SNPs) and COPD (1,872,289 SNPs) were performed using χ_2 - test using a genetic additive model (0, 1, and 2).', {'entities': [(37, 46, 'Total SNPs')]}),
 ('For SNPs identified as associated with β diversity and/or single bacterial traits, a cis - and trans -eQTL analysis was performed using data on 2,360 individuals.', {'entities': [(144, 149, 'Total SNPs')]}),
 (' After quality control checks, there were 2088 participants (1036 males, 1052 females) with data for 549,281 SNPs, with a mean genotyping call rate of 99.', {'entities': [(101, 108, 'Total SNPs')]}),
 (' Price, Department of Genetics, Harvard Medical School, Boston, MA) () on the genotyping data in the pediatric samples and the imputed data in the adults (using 35,324 SNPs common to all Illumina and Affymetrix genotyping platforms).', {'entities': [(161, 167, 'Total SNPs')]}),
 (' A total of 476,395 SNPs were available for analysis after applying the following QC criteria: SNP call rate >98%, sample call rate >98%, minor allele frequency >0.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' There were 561,303 unique measured SNPs, of which 508,199 SNPs passed QC.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' With the sample size of the Stage I cohorts (241 cases, 1,998 controls), the probability of determining a “true-positive” SNP associated with HS-Aging pathology, i.', {'entities': [(57, 62, 'Total SNPs')]}),
 (' For CAS in the discovery stage, a total of\n1,034 cases of CAD and 4,245 controls were genotyped with the\nAxiom_™  Genome-Wide CHB 1 Array Plate, which was designed\nfor Chinese population and includes 657,124 SNPs.', {'entities': [(67, 72, 'Total SNPs')]}),
 (' The SNP genotype-VTE association results were generated in 3,208 VTE cases and 46,167 controls from the French MARTHA and the CHARGE studies.', {'entities': [(60, 65, 'Total SNPs')]}),
 (' We determined all the most significantly associated SNPs (or an appropriate surrogate) in the GWAS results from METASTROKE, a study of 12,389 individuals with ischemic stroke and 62,004 controls with imputation to the Hapmap2 reference panel.', {'entities': [(136, 142, 'Total SNPs')]}),
 (' Significance was estimated by examining the relative proximity and specificity of the test SNP set with 10,000 sets (permutation) of matched background.', {'entities': [(105, 111, 'Total SNPs')]}),
 (' After pruning the GWAS SNPs for linkage disequilibrium () greater than 80%, 145,472 SNPs that were common to the GWAS dataset and HapMap panel were analyzed to characterize the underlying genetic architecture of the samples.', {'entities': [(77, 84, 'Total SNPs')]}),
 (' A total of 605,718 SNPs were included for association analyses.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' A total of 6,090,031 SNPs were included in the meta-analysis.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' Genotyped SNPs that passed quality control procedures were then imputed to approximately 2.5 million ', {'entities': [(90, 101, 'Total SNPs')]}),
 (' For meta-analyses of gout, only cohorts with >50 gout cases were included, and SNPs with an effect size of |β | > 1,000 were excluded to remove only a minimum number of SNPs with implausibly large effects that could systematically influence the results.', {'entities': [(115, 120, 'Total SNPs')]}),
 (' After quality control analysis, a total of 1,417 cases and 1,008 controls with 587,292 SNPs remained.', {'entities': [(44, 49, 'Total SNPs')]}),
 ('2) and 1,070 healthy individuals from Japan (1KJPN panel, which contains > 20 million SNP', {'entities': [(7, 12, 'Total SNPs'), (75, 85, 'Total SNPs')]}),
 (' Association testing for AKI was performed on 9,076,120 SNPs, using the additive model in SNPTEST v2.', {'entities': [(46, 55, 'Total SNPs')]}),
 ('9 software was utilized to conduct univariate linear mixed model associations between the loci from each strata (10 a priori  loci, 8,762 HVA loci, and 4,873,750 genome-wide SNPs) and response inhibition, adjusting for the significant candidate covariates and the top three genetic principal components from the PCA.', {'entities': [(132, 137, 'Total SNPs'), (152, 161, 'Total SNPs')]}),
 ('5–8v1–1) and the remaining 109,571 are custom SNPS including the APOL1  alleles G1 (rs73885319 and rs60910145) and G2 (rs71785313).', {'entities': [(27, 34, 'Total SNPs')]}),
 (' Finally, 303 cases were used for the Nanjing study, and 225 cases for the Beijing study with 576,351 overlapped SNPs.', {'entities': [(94, 101, 'Total SNPs')]}),
 (' Imputation was performed using MACH (), IMPUTE (,) or BEAGLE () for ∼2.5 million SNP', {'entities': [(70, 81, 'Total SNPs')]}),
 ('  In addition to this GWAS providing a broad atheoretical test of the effect of all 527,829 SNPs, we tested 1,180 SNPs identified from a variety of publications that examined SNPs in relation to various disorders such as schizophrenia, depression, substance use, etc.', {'entities': [(84, 91, 'Total SNPs')]}),
 (' Before QC, 546 subjects met inclusion criteria for pharmacokinetic (1,212 for CrCl) association analyses as described in the statistical analyses section, and with ~1.2 million SNP', {'entities': [(166, 177, 'Total SNPs')]}),
 (' We used VEGAS () to conduct gene-based tests of all 17,601 genes identified by VEGAS, to parallel our genome-wide scan of individual SNPs.', {'entities': [(53, 59, 'Total SNPs')]}),
 (' We retained 18,564,419 SNPs with derived information content > 0.', {'entities': [(13, 23, 'Total SNPs')]}),
 ('We performed Principal Component Analysis (PCA) on a subset of 205,842 post-QC SNPs (none from the MHC), selected so as to minimize the contribution from regions of extensive strong linkage disequilibrium and to ensure that only genome-wide effects are detected.', {'entities': [(63, 70, 'Total SNPs')]}),
 (' Firstly, explore the extent to which the effects of genome-wide significant SNPs were regionally specific, additional GWAs were performed on FA values in each of the 119,563 voxels within the TBSS skeleton, using the same model as above, for the genome-wide significant SNPs only.', {'entities': [(167, 174, 'Total SNPs')]}),
 (' After quality control, 69,108 SNPs were retained for subsequent analyses.', {'entities': [(24, 30, 'Total SNPs')]}),
 (' After filtering we had 437,652 SNPs that were used for imputation.', {'entities': [(24, 31, 'Total SNPs')]}),
 ('0, using a set of 100,864 SNPs common to all three studies, and pruned to reduce pairwise LD – this SNP set was selected using the ‘indep’ option of PLINK (http://pngu.', {'entities': [(18, 25, 'Total SNPs')]}),
 ('001 (Afro-Caribbean, n=4616; European ancestry, n=1529; and Hispanic, n=4390) were excluded, leaving 979,693 (Afro-Caribbean), 541,023 (European ancestry), and 964,533 (Hispanic) SNPs.', {'entities': [(101, 108, 'Total SNPs')]}),
 ('PLINK was also used for testing the association between each of the 1,067,955 SNPs and left STG thickness.', {'entities': [(68, 77, 'Total SNPs')]}),
 (' Call rates for SNPs were determined for\nthe 3,045,301 genotyped SNPs on the autosomes and chromosome X, in subsets of\nSNPs based on which platform produced the genotypes ().', {'entities': [(45, 54, 'Total SNPs')]}),
 (' Genotype data from each study had been imputed to the HapMap phase 2 reference panel [], except for JUPITER which was imputed to the 1000genomes pilot data, using either MACH, Impute, or BIMBAM software [–], resulting in a total of approximately 2.5 million SNP', {'entities': [(247, 258, 'Total SNPs')]}),
 ('3 were retained, which resulted in a total number of 2,380,486 SNPs.', {'entities': [(53, 62, 'Total SNPs')]}),
 (' After excluding subjects with >5 % missing genotypes, and SNPs with: missingness >2 %, extreme deviations from Hardy–Weinberg equilibrium, and minor allele frequency <1 %, there were 943 subjects and ~ 1.9 million SNP', {'entities': [(203, 214, 'Total SNPs')]}),
 (' After quality control, 671,422 autosomal and 25,069 X-chromosome SNPs were selected for analysis ().', {'entities': [(24, 31, 'Total SNPs')]}),
 (' SNPs were coded according to the number of minor alleles [0,1,2] for each person); covariates included age; sex; and an ordinal variable representing education level.', {'entities': [(59, 64, 'Total SNPs')]}),
 ('01 in cases or\ncontrols (n  = 100,865, including 46,048 monomorphic SNPs);\ngenotype call rates below 95% in cases or controls (n  =\n20,030); or deviations from Hardy-Weinberg equilibrium (P  value\n< 10_−4 , n  = 12,544).', {'entities': [(49, 55, 'Total SNPs')]}),
 (' In our region of interest on chromosome 15, there were 2,818 SNPs available for imputation.', {'entities': [(56, 61, 'Total SNPs')]}),
 (' Out of the initial full-set of 909,622 SNPs, 21,247 SNPs’ allele frequencies deviated from Hardy-Weinberg equilibrium (P  < 0.', {'entities': [(32, 39, 'Total SNPs')]}),
 (' We identified and removed 107 subjects who overlapped between these studies using a set of 1,000 random non-AT/GC SNPs with MAF>5%.', {'entities': [(92, 97, 'Total SNPs')]}),
 ('Imputation of classical HLA genotypes was performed using published statistical methodology and a reference panel of over 1,500 samples with classical HLA and SNP genotype data from the 1958 Birth Cohort and the International HapMap Project.', {'entities': [(122, 127, 'Total SNPs')]}),
 (' We also investigated 1,712 additional Mexican subjects (1,056 hypertriglyceridemia cases and controls and 656 family members from 77 Mexican dyslipidemic families) for the follow-up of the novel SNPs that did not pass the genome-wide significance level but provided P-values ≤5×10_−05  in the combined analysis of stage 1 and 2.', {'entities': [(22, 27, 'Total SNPs')]}),
 ('Primary analyses were conducted in GWAF (Genome-Wide Association analyses with Family) on 12,972,748 SNPs, of which 1,519,440 were genotyped directly, using a generalized estimating equation (GEE) framework to control for the relatedness in the family sample (Chen and Yang, 2010).', {'entities': [(90, 100, 'Total SNPs')]}),
 ('0 contains 988,306 autosomal SNPs, and genotypes were called using Illumina Genome Studio software v2011.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' Association of immunoglobulin heavy chain (IGHC) SNPs with susceptibility to MS was investigated in a data set of 1,854 MS cases and 5,175 controls from the United Kingdom (further details of this data set are described in Sawcer et al).', {'entities': [(115, 120, 'Total SNPs')]}),
 (' After the above quality control parameters, 576,798 SNPs remained for further analysis.', {'entities': [(45, 52, 'Total SNPs')]}),
 (' After stringent quality control, 492,900 SNP genotypes remained for analysis.', {'entities': [(34, 41, 'Total SNPs')]}),
 (' For all five personality traits, the correlation structure of SNPs was determined by an LD matrix of 9,270,523 autosomal SNPs generated from European reference sample in 1000 Genomes Project phase 1 v3 within 1,000,000 base pairs (1 Mb)_,  using Plink 1.', {'entities': [(102, 111, 'Total SNPs')]}),
 (' [] Since only the top 10,000 most significant SNPs (P  value\u2009≤\u20091\u2009×\u200910_−5 ) were available for the 2016 23andMe MDD GWAS, we utilized SECA to examine the genetic overlap between the 2016 IHGC migraine GWAS and 2016 23andMe MDD GWAS.', {'entities': [(23, 29, 'Total SNPs')]}),
 (' On the basis of the genotyped single-nucleotide polymorphisms (SNPs) and haplotype information in the National Center for Biotechnology Information build 35 of phase II Hapmap CEU data, we imputed genotypes for >2.5 million SNP', {'entities': [(213, 224, 'Total SNPs')]}),
 (' We then used the 382 935 genotyped SNPs to impute all autosomal SNPs on HapMap (∼2.5 million SNP', {'entities': [(82, 93, 'Total SNPs')]}),
 ('Each participating study performed a GWAS of approximately 2.5 million SNP', {'entities': [(59, 70, 'Total SNPs')]}),
 (' GWAS analysis was done using logistic regression on 6,162,479 imputed SNP dosages under an additive genetic model using PLINK v1.', {'entities': [(53, 62, 'Total SNPs')]}),
 (' To identify genomic regions containing variants that may influence the antibody traits, genome-wide linkage analysis was run based on multipoint identity-by-descent estimations that were calculated with LOKI_,   using 28,388 SNPs with very low linkage disequilibrium between them.', {'entities': [(219, 225, 'Total SNPs')]}),
 (' For the Exome set, exclusion criteria for SNP performance included call rate <99% (n=972), monomorphic SNPs (n=157,754) and Hardy-Weinberg Equilibrium p-value <1×10-6  (n=26); 88,483 SNPs were retained for analysis.', {'entities': [(177, 183, 'Total SNPs')]}),
 ('001, a total of 929,187 SNPs remained for further analysis.', {'entities': [(16, 23, 'Total SNPs')]}),
 (' This took the top 2,079 SNPs associated with breast size in a previous GWAS in an independent sample () at a p -value of ≤.', {'entities': [(19, 24, 'Total SNPs')]}),
 (' Germline DNA for the CFR1 study was extracted from peripheral blood samples and genotyped in two batches using three different platforms – the Illumina Human1M or Human1M-Duo (CFR1-Set1) and the Illumina HumanOmni1-Quad (CFR1-Set 2) – each containing ~1.2 million SNP', {'entities': [(253, 264, 'Total SNPs')]}),
 (', Santa Clara, CA), with 897,981 single-nucleotide polymorphisms (SNPs) passing study-specific quality control.', {'entities': [(25, 32, 'Total SNPs')]}),
 (' After quality control and filtering processes, genotype data for 568,280 SNPs in 1,161 cases and 1,353 controls were used for the GWAS analysis.', {'entities': [(66, 73, 'Total SNPs')]}),
 ('We obtained the 697 SNPs shown to be robustly associated with overall height (p < 5\xa0× 10_−8 ) and analyzed the summary statistics of SHR from a GWAS of 21,590 individuals of European ancestry.', {'entities': [(152, 158, 'Total SNPs')]}),
 (' After application of these filters,\nthere were 492,900 SNPs for analysis (44 SNPs were excluded for multiple\nreasons).', {'entities': [(48, 55, 'Total SNPs')]}),
 ('Data on 909,622 SNPs and 12,008 individuals were available prior to implementation of quality control.', {'entities': [(8, 15, 'Total SNPs')]}),
 (' To calculate the genomic-inflation factor (λ) while overcoming the skewed nature of the SNP selection process in the Immunochip design, we used a set of 3,120 “null” SNPs not associated with autoimmune diseases (originated by J.', {'entities': [(154, 159, 'Total SNPs')]}),
 ('  GOLDN-FamHS participants were genotyped on one of three Illumina platforms: (i) Illumina HumMap 550K chip with 547,353 SNP markers, (ii) Illumina Human 610-Quadv1 chip with 576,888 SNP markers, or (iii) Illumina Human 1M-Duov3 chip with 1,111,639 SNP markers [].', {'entities': [(113, 120, 'Total SNPs'), (239, 248, 'Total SNPs')]}),
 (' 559,977 SNPs were available for analysis in one or more studies.', {'entities': [(1, 8, 'Total SNPs')]}),
 (' For the KORA S4 replication sample, SNP genotypes were imputed against the 1,000 g phase1 integrated haplotypes reference set.', {'entities': [(76, 81, 'Total SNPs')]}),
 (' After excluding 17,888 SNP with allele frequencies deviating from Hardy-Weinberg equilibrium (p  < 0.', {'entities': [(17, 23, 'Total SNPs')]}),
 (' For combined analyses, 94,595 European ancestry individuals from 23 studies genotyped with SNP arrays were included.', {'entities': [(24, 30, 'Total SNPs')]}),
 (' For this analysis we utilised data on 314,861 SNPs that were successfully genotyped on both arrays.', {'entities': [(39, 46, 'Total SNPs')]}),
 (' Principal components analysis (PCA) was used to determine genetic ancestry using 41,871 autosomal independent SNPs, excluding regions known to be associated with ethnicity, such as the extended HLA  region and the lactase  gene.', {'entities': [(82, 88, 'Total SNPs')]}),
 (' For the CIMBA samples 33,661 weakly correlated autosomal SNPs (pair-wise r2 less than 0.', {'entities': [(23, 29, 'Total SNPs')]}),
 ('06 mg/dl per allele with 80% power (or 15,201 samples for a SNP with MAF of 0.', {'entities': [(39, 45, 'Total SNPs')]}),
 (' We additionally analysed the association between BW and directly genotyped SNPs on the X chromosome: for this analysis, we used 57,715 unrelated individuals with BW available and identified by UK Biobank as white British.', {'entities': [(129, 135, 'Total SNPs')]}),
 (' Principal-components analyses were carried out separately for the European and African-American subgroups on the basis of a subset of 37,000 uncorrelated SNPs.', {'entities': [(135, 141, 'Total SNPs')]}),
 (' In total, replication genotypes (in silico  and de novo ) of 76 prioritized SNPs and 27 AIMs were available from 2,677 AN cases and 8,629 controls of European ethnicity and 458 AN cases and 421 controls from Japan.', {'entities': [(114, 119, 'Total SNPs')]}),
 ('  Our GWAS consisted of examining the impact on the different startle indices of each of the 527,829 genotyped SNPs that survived quality control.', {'entities': [(93, 100, 'Total SNPs')]}),
 ('Each cohort was genotyped as specified in  and performed ancestry-specific imputation up to ~2.6 million SNP', {'entities': [(93, 104, 'Total SNPs')]}),
 (' These criteria yielded a final set of 506,679 SNPs and 484,176 SNPs for NEIGHBOR and GLAUGEN, respectively.', {'entities': [(39, 46, 'Total SNPs')]}),
 (' Principal components were estimated using 19,059 randomly selected autosomal SNPs with frequency ≥ 2% in the combined multiethnic sample.', {'entities': [(43, 49, 'Total SNPs')]}),
 (' Genotyping was performed at the Broad Institute of MIT and Harvard using Illumina Human610-Quad (European ancestry) and Illumina Human1M-Duo (Afro-Caribbean and Hispanic) BeadChip microarray platforms (Illumina, San Diego, CA), interrogating over 601,000 and 1.1 million SNP', {'entities': [(248, 255, 'Total SNPs'), (260, 271, 'Total SNPs')]}),
 (' Specifically, in samples from Germany (64 LS, 413 non-LS, and 4,498 control subjects) and from African Americans (781 non-LS and 876 control subjects), SNPs identified at P _GC   less than 5\u2009×\u200910_−5  in the discovery cohort were extracted from an available dataset typed on the Immunochip.', {'entities': [(63, 68, 'Total SNPs')]}),
 (' In order to obtain empirical p  values, we permuted the ranks of each SNP 100,000,000 times and counted the number of times the permuted RP was equal to or higher than the observed RP.', {'entities': [(75, 86, 'Total SNPs')]}),
 (' There were 660,755 unique measured SNPs, of which 630,240 passed QC.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' Following marker QC 125,141 SNPs remained in the East Asian dataset, 145,857 SNPs in the Indian dataset, 152,232 in the Iranian dataset and 144,245 in the Caucasian dataset.', {'entities': [(21, 28, 'Total SNPs')]}),
 (' A total of 28,032,917 SNPs were successfully imputed (i.', {'entities': [(12, 22, 'Total SNPs')]}),
 (' Approximately 79,000 SNPs were selected specifically for their relevance to PrCa, on the basis of prior evidence of association with overall or subtype-specific disease, fine-mapping of known PrCa regions, and candidate submissions (survival, exome sequencing, and so forth).', {'entities': [(15, 21, 'Total SNPs')]}),
 (' In this study, 7,918 randomly selected autosomal ImmunoChip SNPs with MAF>1%, low pairwise LD ( < 0.', {'entities': [(16, 21, 'Total SNPs')]}),
 (' 2,222 SNPs within ±10 kb from the 15 gene boundaries existed in the data and were analyzed.', {'entities': [(1, 6, 'Total SNPs')]}),
 (' The thyroid cancer GWAS data set used in the current study comprises results from 222 individuals with thyroid cancer and 24,198 controls genotyped using Illumina Human Hap300, HapCNV370, Hap610, 1M, or Omni-1 Quad BeadChips (Illumina), as well as results from 627 individuals with thyroid cancer and 71,613 unaffected individuals with genotypes inferred using an imputation method making use of the Icelandic genealogy to propagate genotypic information into individuals for whom we have neither SNP chip nor sequence data, a process we refer to as genealogy-based imputation, the combined method of imputing sequence-derived data into Illumina chip–typed individuals and using genealogy-based imputation to infer the DNA sequence of ungenotyped individuals as two-way imputation (see ).', {'entities': [(123, 129, 'Total SNPs')]}),
 (' We genotyped 909,622 SNPs with 1308 total samples (this does not include 14 HapMap samples genotyped making the total 1322).', {'entities': [(14, 21, 'Total SNPs')]}),
 (' Results were obtained for 10,641,224 single nucleotide polymorphisms (SNPs) and insertion-deletion variants with minor allele frequency > 1% and imputation quality scores > 0.', {'entities': [(27, 37, 'Total SNPs')]}),
 (' Finally, for the 1,047 SNPs examined at the second stage, an\ninverse-variance weighted meta-analysis was performed to combine association\nparameter from the discovery and second-stage studies.', {'entities': [(18, 23, 'Total SNPs')]}),
 (' We used ~ 700,000 SNPs to calculate principal components, and ten default main eigenvectors generated by EIGENSTRAT were used as covariates to adjust population stratification in GWAS analyses by PLINK.', {'entities': [(11, 18, 'Total SNPs')]}),
 ('M arrays) and up to 874,733 SNPs depending on the dataset (HumanHap300: 303,940, HumanHap610Q: 553,487, HumanHap1M and 1.', {'entities': [(20, 27, 'Total SNPs')]}),
 (' We used the MACH program () to impute 2,543,887 autosomal SNPs based on haplotypes from the HapMap () database phase II data build 35 (CEU) in all of the four component sets, including T2D_NHS, T2D_HPFS, CHD_NHS and CHD_HPFS ().', {'entities': [(39, 48, 'Total SNPs')]}),
 (' Among 299,140 genotyped SNPs, we implemented the following quality control (QC) exclusion criteria for SNPs using PLINK[]: (i) SNPs without rs numbers; (ii) SNP call rate <95%; (iii) monomorphic SNPs; (iv) Hardy-Weinberg P <1 × 10_−10 .', {'entities': [(7, 14, 'Total SNPs')]}),
 (' In addition, SNPs not directly genotyped in the top region(s) of interest were imputed using all populations from the 1,000 Genomes Project (phase I v3) as reference for phasing and imputation with SHAPE-IT and IMPUTE2, respectively.', {'entities': [(119, 124, 'Total SNPs')]}),
 (' The genotyped SNPs from the discovery cohort were categorized into 17 categories according to P -values, and risk scores for each category were calculated in the ANZRAG study consisting of 1,155 glaucoma cases and 1,992 controls and NEIGHBOR consisting of 2,131 glaucoma cases and 2,290 controls as target cohorts (see ).', {'entities': [(190, 195, 'Total SNPs')]}),
 (' These men were genotyped at over 650,000 SNPs on four race/ethnicity-specific Affymetrix Axiom arrays optimized for individuals of European (EUR), African-American (AFR), East Asian (EAS), and Latino (LAT) race/ethnicity.', {'entities': [(34, 41, 'Total SNPs')]}),
 (' Imputation of 2,416,663 SNPs from the HapMap release 22 build 36 CHB+JPT samples was conducted using MACH software.', {'entities': [(15, 24, 'Total SNPs')]}),
 (' After SNP filtering, the final 2016 IHGC migraine GWAS included association results for 8,045,569 SNPs.', {'entities': [(89, 98, 'Total SNPs')]}),
 (' For each of these loci, we then re-assessed the amount of association signals through fixed-effects inverse variance meta-analysis of the two cohorts for all 37,000 available traits using imputed SNPs relative to HapMap2 data (see Online Methods for details).', {'entities': [(159, 165, 'Total SNPs')]}),
 (' Across all platforms, a total of 1,030,430 SNPs were genotyped.', {'entities': [(34, 43, 'Total SNPs')]}),
 ('Blood leukocyte DNA samples were genotyped using the Illumina Human1M-Duo BeadChip (1,199,187 SNPs).', {'entities': [(84, 93, 'Total SNPs')]}),
 (' This array captures 951,117 single nucleotide polymorphisms (SNPs).', {'entities': [(21, 28, 'Total SNPs')]}),
 (' After these quality control\nprocedures, 5,008 samples and 613,724 autosomal SNPs were retained for\nsubsequent analyses.', {'entities': [(41, 46, 'Total SNPs')]}),
 (' The iCOGS chip included a total of 211,155 SNPs selected in collaboration with other consortia of BRCA1  and BRCA2  mutation carriers (CIMBA), ovarian cancer (OCAC) and prostate cancer (PRACTICAL).', {'entities': [(36, 43, 'Total SNPs')]}),
 (' Of the 561,490 non-intensity SNP markers on the array, 527,829 (94.', {'entities': [(8, 15, 'Total SNPs')]}),
 ('Genome-wide significant SNPs in the discovery stage were directly genotyped in 1,783 individuals from the UKGPCS1 study () using TaqMan assays to verify imputation quality, evaluated as the concordance rate between imputed and genotyped data (percentage of individuals correctly classified by imputation).', {'entities': [(79, 84, 'Total SNPs')]}),
 ('001), 198,345 SNPs remained.', {'entities': [(6, 13, 'Total SNPs')]}),
 (' We considered studies with a sample size greater than 1,000 and retained SNPs with association P  < 5 × 10_−8 .', {'entities': [(55, 60, 'Total SNPs')]}),
 ('  To investigate whether any of the 527,829 successfully genotyped SNPs exerted a significant effect on the antisaccade error rate, we used generalized least squares regression.', {'entities': [(36, 43, 'Total SNPs')]}),
 (' Fourth, we used the method of Zhang et al to test associations between BW and the maternal untransmitted, maternal transmitted and inferred paternal transmitted haplotype score of 422 height SNPs, 30 SBP SNPs_,  and 84 T2D SNPs in 5,201 mother-child pairs from the ALSPAC study.', {'entities': [(232, 237, 'Total SNPs')]}),
 (' Single-locus tests of association were performed using linear regression assuming an additive genetic model for all 528,508 SNPs in a total of 5,272 individuals with a normal QRS duration.', {'entities': [(117, 124, 'Total SNPs')]}),
 (' After the QC steps, 563,599 SNPs and 2,240 Mexican individuals were available for the analysis of stage 1.', {'entities': [(21, 28, 'Total SNPs')]}),
 (' Samples were genotyped with the Affymetrix Axiom® LAT1 array (World Array 4, Affymetrix, Santa Clara, CA), which includes 817,810 SNPs.', {'entities': [(123, 130, 'Total SNPs')]}),
 (' After stringent quality control, there were 474,231 directly genotyped SNPs in 1616 subjects available for further analysis and used for the basis of imputation.', {'entities': [(45, 52, 'Total SNPs')]}),
 ('Principal component analysis for the OncoArray data was carried out using data from 33,661 uncorrelated SNPs (pair-wise r2 less than 0.', {'entities': [(84, 90, 'Total SNPs')]}),
 (' We performed a meta-analysis of the UCSF and Mayo Clinic results on a total of 6,026,834 SNPs in common from both GWAS that met the allele frequency and imputation quality thresholds.', {'entities': [(80, 89, 'Total SNPs')]}),
 ('Germline DNA of 183 cancer patients treated with monotherapy paclitaxel stored in Biobank Japan (University of Tokyo) were genotyped using Illumina OmniExpress BeadChip that contained 733,202 SNPs ().', {'entities': [(184, 191, 'Total SNPs')]}),
 ('  Participants’ genomic DNA was genotyped for >2.5 million SNP', {'entities': [(47, 58, 'Total SNPs')]}),
 (' Genomic DNA samples from the MGH and WASH-U were genotyped using the Illumina Human1M BeadChip (N=1,057,265 SNPs) while the UCLA samples were genotyped using the Illumina Human 1M-Duo array (N=1,151,846 SNPs).', {'entities': [(99, 108, 'Total SNPs')]}),
 (' Imputation was performed via combination with 3.96 million SNP', {'entities': [(47, 59, 'Total SNPs')]}),
 (' Genome-wide SNP genotyping was conducted on approximately 5000 subjects using Illumina’s Omni1-Quad BeadChip, which interrogates 1,011,219 individual SNPs.', {'entities': [(130, 139, 'Total SNPs')]}),
 (' Quality control excluded 67,819 SNPs and 143 individuals from analysis.', {'entities': [(26, 32, 'Total SNPs')]}),
 (' An additional round of QC performed on the merged GAIN and TGEN samples resulted in 703,012 passing SNPs.', {'entities': [(85, 92, 'Total SNPs')]}),
 (' A total of 364,336 informative autosomal SNPs that passed quality-control were included in the analysis.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('  The meta-analysis for adiponectin association with ∼2.5 million SNP', {'entities': [(54, 65, 'Total SNPs')]}),
 (' In total, 12,106,458 SNPs passed quality control (minor allele count [MAC]\n>5 in individual cohorts; imputation quality >0.', {'entities': [(11, 21, 'Total SNPs')]}),
 (' Before imputation, 806,466 SNPs pass QC in at least one batch (>99% of the array content).', {'entities': [(20, 27, 'Total SNPs')]}),
 (' The number of SNPs used as input for the meta-analysis was as follows: 23andMe: 15,607,353 SNPs; CONVERGE: 5,992,772 SNPs; PGC 1,235,109 SNPs.', {'entities': [(81, 91, 'Total SNPs')]}),
 (' After quality control steps including filtering for MAF ≥ 5% on the imputed SNPs were applied, 1,575 of 1,716 ADNI participants and 5,574,300 SNPs remained for subsequent analyses.', {'entities': [(96, 101, 'Total SNPs'), (133, 142, 'Total SNPs')]}),
 (' On the basis of the original GWA data including 352,228 SNPs, we included only cohort members who underwent a polysomnography during the period between February 22, 2011, and February 28, 2013, at the Korea University Ansan Hospital; thus data for 1,763 participants were available for GWA analysis.', {'entities': [(49, 56, 'Total SNPs')]}),
 (' After all subject and marker quality control steps were completed, we had ~1.83 million SNP', {'entities': [(76, 88, 'Total SNPs')]}),
 (' In the end, 237 SNPs on 2,041 Stage 2 participants (891 cases, 1150 controls) were retained for association analysis.', {'entities': [(25, 30, 'Total SNPs')]}),
 (' A second sample of 1,198 bipolar cases and 403 controls was similarly genotyped at the Translational Genomics Institute (TGEN) and underwent a comparable QC process that resulted in 728,187 SNPs available for analysis ().', {'entities': [(20, 25, 'Total SNPs')]}),
 ('3) with at least one other SNP in a 150 SNP window (step size 15 SNPs) were eliminated using Plink [], leaving 50,745 SNPs.', {'entities': [(111, 117, 'Total SNPs')]}),
 (' To define population stratification adjustment factors, principal component analysis was performed (EIGENSTRAT) using a pruned set of 30,956 SNPs defined based on pairwise linkage disequilibrium (r_2 <0.', {'entities': [(135, 141, 'Total SNPs')]}),
 (' A total of 16,732 SNPs exhibiting an Illumina score superior or equal to 0.', {'entities': [(12, 18, 'Total SNPs')]}),
 (' All DNA samples from the 10,004 participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 5.', {'entities': [(26, 32, 'Total SNPs')]}),
 (' (A) QQ plot of RTL GWAS of the Sikh discovery cohort after quality control of directly genotyped (474,231), and (B) imputed variants 5,904,251 (MAF≥5%) from the 1kG reference panel of 1092 world-wide subjects In addition to analysis of directly genotyped SNPs, we performed imputation using the Impute 2 program_– .', {'entities': [(134, 143, 'Total SNPs')]}),
 (' The BPC3 GWAS included 2,188 ER-negative cases and 26,477 controls from 8 studies (CPSII, EPIC, MEC, NHS, NHSII, PLCO, PBCS and WGHS), geno-typed using different versions of Illumina SNP arrays_, .', {'entities': [(24, 29, 'Total SNPs')]}),
 ('To estimate the total number of newly associated loci selected for the iCOGS array, we first used the set of 29,807 SNPs selected from the GWAS and not selected for fine mapping, to exclude previously known loci.', {'entities': [(109, 115, 'Total SNPs')]}),
 ('4 yielding 299,140 single nucleotide polymorphisms (SNPs).', {'entities': [(11, 18, 'Total SNPs')]}),
 (' analysis of GWA data imputed with missing genotypes from the HapMap2 reference panel (total 2,646,472 SNPs).', {'entities': [(93, 102, 'Total SNPs')]}),
 (' For the 1,062 subjects in the Rochester cohort with valid data, 10 subjects were removed due to high SNP missing rates.', {'entities': [(9, 14, 'Total SNPs')]}),
 (' The array contains 659,253 SNPs, including tag SNPs for imputation, as well as SNPs related to phenotypes from previously reported GWAS and pharmacogenomics studies.', {'entities': [(20, 27, 'Total SNPs')]}),
 (' A total of 79,893 SNPs were omitted because their minor allele frequency was lower than 0.', {'entities': [(12, 18, 'Total SNPs')]}),
 ('  Replication of associated SNPs was conducted in four independent cohorts, three of white European descent and one of black African descent, totaling 7,766 subjects.', {'entities': [(151, 156, 'Total SNPs')]}),
 (' Of note, of the 7,086 SNPs that we were unable to successfully genotype, only 471 were not tagged by another successfully genotyped variant (±100 kb) and associated with a P  value at least 10 times higher than that of the missing SNP.', {'entities': [(17, 22, 'Total SNPs')]}),
 (' A total of 581,023 autosomal SNPs passed quality filters for call rate and minor allele frequency (see Methods) and were included for further analysis.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('8–1.1 million SNP', {'entities': [(2, 13, 'Total SNPs')]}),
 (' After QC,\nthe Chinese replication consisted of 3,043 cases and 5,074 controls with\ngenotyping on 64 SNPs.', {'entities': [(48, 53, 'Total SNPs')]}),
 (' To the end, a total of 266,944 SNPs were involved in the analysis.', {'entities': [(24, 31, 'Total SNPs')]}),
 (' We examined 6 SNP markers at the 5 most significantly associated loci from the genotyped panel (P  < 1 × 10_−5  in the GWAS) in the 659 CeAD and 2,648 control samples available for follow-up.', {'entities': [(146, 151, 'Total SNPs')]}),
 (' This resulted in a final analysis of 462,499 autosomal and 9,922 X-linked SNPs in a sample of 340 i/fPAH patients and 1,068 healthy individuals.', {'entities': [(38, 45, 'Total SNPs')]}),
 (' A total of 2,217,748 SNPs were subjected to QC filters as follows: 1) call rate ≤ 90% (excluded 22,509 SNPs), Hardy-Weinberg p-value < 10_−6  (excluded 10,282), MAF < 0.', {'entities': [(97, 103, 'Total SNPs'), (12, 21, 'Total SNPs')]}),
 (' After exclusion, genotype data of 4,198,245 SNPs from 98 Japanese CD cases were used for further analysis.', {'entities': [(35, 44, 'Total SNPs')]}),
 ('05% were excluded, leaving 11,133,794 SNPs for analyses.', {'entities': [(27, 37, 'Total SNPs')]}),
 (' For the Exome set, exclusion criteria for SNP performance included call rate <99% (n = 972), monomorphic SNPs (n = 157,754), and Hardy–Weinberg equilibrium p  < 1 × 10_−6  (n = 26); 88,483 SNPs were retained for analysis.', {'entities': [(183, 189, 'Total SNPs')]}),
 (' To estimate imputation accuracy, imputed genotype calls at 99,124 SNPs were compared with direct genotyping data in 880 cases (Illumina Immunochip).', {'entities': [(60, 66, 'Total SNPs')]}),
 (' Meta-analysis of the 2016 IHGC migraine GWAS and 2016 23andMe MDD GWAS (for the top 10,000 SNPs) was performed using the METASOFT (URL: http://genetics.', {'entities': [(85, 91, 'Total SNPs')]}),
 (' The final analysis incorporated genotype data from 1,008,655 SNPs.', {'entities': [(52, 61, 'Total SNPs')]}),
 (' 2064 samples and 677,171 SNPs passed all QC tests.', {'entities': [(18, 25, 'Total SNPs')]}),
 (' 534,665 autosomal SNPs were used for the analysis of this study (basically 610K SNPs extracted from the final merged data set).', {'entities': [(1, 8, 'Total SNPs')]}),
 (' The numbers and percentages of non-rare allele SNPs vary among different chromosomes and range from 4,417 to 28,771 and from 0.', {'entities': [(101, 106, 'Total SNPs')]}),
 (' Therefore, to avoid excessive false positive associations we focused subsequent association analyses on a very conservative subset of 2,819,700 SNPs that had an RSQ>0.', {'entities': [(135, 144, 'Total SNPs')]}),
 (' Subsequently, we evaluated significantly associated SNPs in 6,841 subjects of Asian origin including four different studies (stage 2) and performed a meta-analysis on all individual studies from stage 1 and stage 2 (stage 3).', {'entities': [(61, 66, 'Total SNPs')]}),
 (' Each case was then matched with four controls based on PCAs performed using 25,914 selected SNPs shared across platforms (both sets 1 and 2) using EIGEN-SOFT v5 ().', {'entities': [(77, 83, 'Total SNPs')]}),
 ('  VEGAS (versatile gene-based association study) analysis software () was used to assess the degree to which SNPs in 17,601 autosomal genes and their surrounding regions were associated with antisaccade error.', {'entities': [(117, 123, 'Total SNPs')]}),
 (' Before frequency and genotyping pruning, there were 516,512 SNPs.', {'entities': [(53, 60, 'Total SNPs')]}),
 (' To impute classic HLA  alleles, we used a reference data set from the Type 1 Diabetes Genetics Consortium, which includes genotype data for 7,261 SNPs selected across the entire MHC, high-resolution 4-digit typing data for 424 classic alleles at HLA–A, B, C, DRB1, DQA1, DBQ1, DPA1 , and DPB1 , and 1,276 amino acids corresponding to serologically defined antigens in 5,225 individuals of European descent (–).', {'entities': [(141, 146, 'Total SNPs')]}),
 ('05/(22 SNPs × 43,465 probe sets) = P value\n< 5.', {'entities': [(14, 20, 'Total SNPs')]}),
 (' After quality control, which consisted of Mendelian error checks, Hardy-Weinberg equilibrium (p>1E-06 included), and minor allele frequency (>1% included), a total of 369,241 SNPs remained for use in the imputation to the HapMap population (release 22, build36, CEU, http://hapmap.', {'entities': [(168, 175, 'Total SNPs')]}),
 (' The association results of the three datasets were combined in a meta-analysis for the shared set of 466,573 SNPs, using the inverse sample size-weighted approach in METAL  (), implemented in a fixed-effects model, with study-specific genomic control correction.', {'entities': [(102, 109, 'Total SNPs')]}),
 (' In total, 318,237 SNPs were genotyped on the BeadChips.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' Monomorphic SNPs and those with a call rate < 95% were excluded, leaving 786,950 observed SNPs.', {'entities': [(74, 81, 'Total SNPs')]}),
 (' After QC, 33,622 SNPS and 58 individuals (29 cases and 29 controls) were removed for low call rates, and 16,548 SNPs were removed for minor allele frequencies below 1%.', {'entities': [(11, 17, 'Total SNPs')]}),
 (' A total of 1,001 bipolar cases, 1,033 controls, and 724,067 SNPs were available for analysis following an extensive quality control (QC) process to eliminate subjects with ≥5% missing data and SNPs with ≥5% missing data, minor allele frequencies (MAF) <0.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' 76,816 SNPs with call rates < 98% were dropped, along with 206,970 SNPs with MAF ≤ 0.', {'entities': [(1, 7, 'Total SNPs')]}),
 (' A total of 2,239 study participants with complete genotype and phenotype data, and 11,892,802 SNPs/indels (1,131,426 genotyped and 10,761,376 imputed) were included in the GWAS analysis of CYP2A6 activity (ratio of total 3HCOT to COT).', {'entities': [(12, 17, 'Total SNPs'), (84, 94, 'Total SNPs')]}),
 (' In stage 1, 20 studies each imputed approximately 2.5 million SNP', {'entities': [(51, 62, 'Total SNPs')]}),
 (' The UK biobank array is a high-density custom designed array with 7,348 SNPs across the HLA region (~24,000 high-quality imputed SNPs) and over 830,115 established SNPs across the genome (~4 million high-quality imputed SNPs).', {'entities': [(67, 72, 'Total SNPs')]}),
 (' An additional 2,616 SNPs with MAF <0.', {'entities': [(15, 20, 'Total SNPs')]}),
 (' Approximately 72,000 SNPs were selected specifically for their relevance to breast cancer, on the basis of prior evidence of association with overall or subtype-specific disease, with breast density or with breast- tissue-specific gene expression.', {'entities': [(15, 21, 'Total SNPs')]}),
 (' The total number of genotyped SNPs was 2,440,283 in OAI and 1,199,187 in JoCo.', {'entities': [(40, 49, 'Total SNPs')]}),
 (' 9,048 subjects and 526,688 SNPs passed these quality-control filters.', {'entities': [(1, 6, 'Total SNPs')]}),
 ('\nThere were 370,704 pairs of SNPs (168,299,616 genotypes) that passed quality\ncontrol at both genotyping centers.', {'entities': [(12, 19, 'Total SNPs'), (35, 46, 'Total SNPs')]}),
 (' Of the 2,449,708 SNPs successfully genotyped, a total of 1,545,328 SNPs were included in the final analysis after exclusion from either a low call rate < 90% (65,469), deviation from Hardy-Weinberg Equilibrium with a P  value for HWE test < 0.', {'entities': [(8, 17, 'Total SNPs')]}),
 (' On the Omni 1 genotyping array, there were 1,134,514 unique measured SNPs, of which 887,889 passed QC.', {'entities': [(85, 92, 'Total SNPs'), (44, 53, 'Total SNPs')]}),
 ('5%, resulting in 93,339 SNPs from the Human-1 and 295,912 SNPs from the HumanHap300 chip.', {'entities': [(17, 23, 'Total SNPs')]}),
 ('8, the resulting data set comprised 417,563 overlapping SNPs.', {'entities': [(36, 43, 'Total SNPs')]}),
 ('0, 906,602 SNPs) for Shanghai-1 cases and controls; Illumina HumanOmniExpress BeadChip (Illumina OmniExpress, 729,462 SNPs) for Shanghai-2 cases and controls, Guangzhou-1 cases and Aichi-1 cases; Illumina Human610-Quad BeadChip (620,901 SNPs) for Guangzhou-1 controls; and Illumina Infinium HumanHap610 BeadChip (592,044 SNPs) for Aichi-1 controls.', {'entities': [(3, 10, 'Total SNPs')]}),
 (' Unobserved genotypes were imputed in the family-based study leading to 7,467,568 combined genotyped and imputed SNPs across autosomes, and 5,390,648 autosomal SNPs retained after quality control filtering ().', {'entities': [(72, 81, 'Total SNPs')]}),
 (' Similarly, we addressed potential plate batch issues for 1,308 men genotyped with the AFR array through a GWAS of the association between SNPs and whether a subject was typed in the originally genotyped GERA cohort versus later in additional PCa batches separately among cases and controls, adjusting for PCs.', {'entities': [(58, 63, 'Total SNPs')]}),
 ('07) was used to carry out quality-control measures on an initial set of 10,015 subjects and 557,124 directly genotyped SNPs.', {'entities': [(72, 78, 'Total SNPs')]}),
 (' _–  Genotypes were imputed to the ~2.5 million SNP', {'entities': [(36, 47, 'Total SNPs')]}),
 ('[] In total, 670,176 SNPs, 801,830 SNPs, 877,845 SNPs, and 708,134 SNPs in the NHW, Latinos, African Americans, and East Asians, respectively, passed initial QC.', {'entities': [(13, 20, 'Total SNPs')]}),
 (' We analyzed the set of overlapping SNPs present in both datasets, totaling 2,380,200 SNPs.', {'entities': [(76, 85, 'Total SNPs')]}),
 ('5 chip (2.5 million SNP', {'entities': [(8, 19, 'Total SNPs')]}),
 (' Of these, 157,048 SNPs failed\nPerlegen’s quality control (20.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' if the constraint of correlation with the reference SNP was ignored), giving a total of 896,831 primary tests of association with bipolar disorder.', {'entities': [(89, 96, 'Total SNPs')]}),
 ('015 were excluded, resulting in 328,928 SNPs for analysis.', {'entities': [(32, 39, 'Total SNPs')]}),
 ('015, resulting in 19,423 SNPs for analysis in Plink v1.', {'entities': [(18, 24, 'Total SNPs')]}),
 (' Finally, a total of 1,777,244 SNPs were included in the Harvard GWAS.', {'entities': [(21, 30, 'Total SNPs')]}),
 (' DNA from the subjects was genotyped for over 600,000 SNPs using the Ilumina Human610-Quad BeadChip.', {'entities': [(46, 53, 'Total SNPs')]}),
 (' These samples also underwent exome-wide genotyping using the Illumina Human Exome BeadChip, which assays for 247,870 SNP markers enriched in the coding exome, following the manufacturer’s specifications.', {'entities': [(110, 117, 'Total SNPs')]}),
 (' By this mapping rule, a total of 454,993 SNPs were mapped to 23,765 genes (with the number of SNPs mapping to a gene ranging from 1 to 1,204, median=11, interquartile range=25).', {'entities': [(34, 41, 'Total SNPs')]}),
 (' Of the remaining 274,935 SNPs, 28,925 were excluded because they had call rates < 95% (n = 6,456), generated ≥5 Mendelian errors (n = 15,912), or deviated from Hardy-Weinberg expectations at P  < 10_−3  (correcting for inbreeding and relatedness) (n = 6,557), yielding a final set of 246,010 autosomal markers with a median inter-marker spacing of 5.', {'entities': [(18, 25, 'Total SNPs')]}),
 ('01), >1 Mendelian error detected in a set of duplicated samples, and a missing call rate ≥2 %, which led to the removal of approximately 45 % of markers (of which a large proportion was monomorphic), leaving 2,567,713 SNPs to serve as the imputation basis.', {'entities': [(208, 217, 'Total SNPs')]}),
 (' To check for cryptic relatedness and population stratification, 92,867 independent SNPs were selected based on a pair-wise inter-marker linkage disequilibrium r2 < 0.', {'entities': [(65, 71, 'Total SNPs')]}),
 (' For the replication analyses, 40,546 samples were estimated to be required to independently replicate a SNP with MAF of 10% and effect of 0.', {'entities': [(31, 37, 'Total SNPs')]}),
 (' After quality control, 8,229\ncase and 36,329 control samples were included in the analysis, and\n436,746 SNPs were available for imputation in the USA and Italy cohorts,\nand 420,131 SNPs were available in the UK, French and Belgium\ncohorts.', {'entities': [(39, 45, 'Total SNPs')]}),
 (' Standard quality control (QC) measures were applied to both samples and SNPs, giving a total of 1,353 cases and 3,571 controls.', {'entities': [(97, 102, 'Total SNPs')]}),
 (' 1,972,057 SNPs in the MI cases and 1,980,188 SNPs in the MI controls were available for statistical analyses after QC procedures (Supplementary Table\xa02).', {'entities': [(1, 10, 'Total SNPs')]}),
 (' Between the autosomes and X chromosome SNPs, the dataset included 685,281 SNPs for the association analysis.', {'entities': [(67, 74, 'Total SNPs')]}),
 (' Each array contains 567,097 SNPs.', {'entities': [(21, 28, 'Total SNPs')]}),
 (' Additionally, 40,631 SNPs failed genotyping and 250,843 were rare SNPs with MAF<0.', {'entities': [(15, 21, 'Total SNPs')]}),
 ('edu/wiki/Minimac), resulting in a total of 8,248,570 and 8,349,255 imputed SNPs in the OAI and JoCo, respectively, available for analyses after removal of SNPs with low minor allele frequencies (<1%) and poor imputation quality scores (<0.', {'entities': [(43, 52, 'Total SNPs')]}),
 (' The Biobank array has more than 650,000 variants, including 265,000 exome coding snps and indels, 70,000 novel loss-of-function SNPs and indels, 23,000 eQTLs, 2000 markers of pharmacogenomic relevance and 246,000 genome-wide association markers designed to ensure good genome-wide coverage in major populations, which make it possible to carry out imputation in order to increase the number of markers in the statistical analyses.', {'entities': [(33, 40, 'Total SNPs')]}),
 ('A total of 1,457 subjects included in the current study were genotyped for 906,600 SNPs using the Human SNP Array 6.', {'entities': [(11, 16, 'Total SNPs')]}),
 (' This reduced the number of SNPs available for analysis to 914,402 autosomal SNPs and 905 pseudo-autosomal SNPs.', {'entities': [(59, 66, 'Total SNPs')]}),
 ('3, resulted in 9,012,028 autosomal SNPs that were available for analysis in 1,297 GeneBank subjects for whom plasma TML levels were also available.', {'entities': [(76, 81, 'Total SNPs'), (15, 24, 'Total SNPs')]}),
 ('We performed a meta-analysis on directly genotyped and imputed SNPs from individuals of European ancestry in 27 studies, with a total of 37,382 individuals.', {'entities': [(137, 143, 'Total SNPs')]}),
 (' After imputation and quality control (QC), a total of 2,708,280 SNPs were used in the meta-analysis of GECCO studies and CCFR.', {'entities': [(55, 64, 'Total SNPs')]}),
 (' Plate effects were examined [] and three plates were identified as having an excess of SNPs with low plate-association p  values (132, 413, and 1,080 SNPs with p  value > 1×10_−7  on these plates).', {'entities': [(145, 150, 'Total SNPs')]}),
 (' After quality control, high-quality genotypes for 586,178 SNPs were available for GW imputation using all populations of release 1 of phase 3 of the 1000 Genomes Project.', {'entities': [(51, 58, 'Total SNPs')]}),
 (' Of the 951,117 SNPs assayed, 29% had minor allele frequencies of 1% or less.', {'entities': [(8, 15, 'Total SNPs')]}),
 (' In the initial screening stage we assessed associations of approximately 600,000 genotyped SNPs with over 37,000 metabolic traits (concentrations and their ratios) by fitting linear models separately in both cohorts to log-transformed metabolic traits, adjusting for age, gender and family structure (Supplemental Figure 2 & Supplemental Table 2).', {'entities': [(74, 81, 'Total SNPs')]}),
 (' Of the 533,631 manufactured SNPs on the OncoArray, we retained 498,417 SNPs among our samples of European ancestry after QC.', {'entities': [(8, 15, 'Total SNPs')]}),
 (' We discovered a total of 46,429 SNPs and indels with a MAF > 1% that passed our quality control filters, resulting in a Bonferoni threshold of 1.', {'entities': [(26, 32, 'Total SNPs')]}),
 (' Genome-wide association analyses were run in SOLAR [] using 944,565 SNPs.', {'entities': [(61, 68, 'Total SNPs')]}),
 (' From the 597,320 SNPs on the Axiom array, 464,632 were retained following this quality review.', {'entities': [(10, 17, 'Total SNPs')]}),
 (' After quality control, 1,526 samples and 367,129 autosomal SNPs\nremained for the subsequent analyses.', {'entities': [(24, 29, 'Total SNPs')]}),
 ('0 microarray containing 988,306 autosomal SNPs, at the Center for Inherited Disease Research (CIDR) and the Yale Center for Genome Analysis.', {'entities': [(24, 31, 'Total SNPs')]}),
 (' The final dataset retained 672,210 autosome SNPs for analysis.', {'entities': [(28, 35, 'Total SNPs')]}),
 ('_,  The data sets were imputed to a common panel of 2.56 million SNP', {'entities': [(52, 64, 'Total SNPs')]}),
 (' Genotyping of the 1,326 stage 2 SNPs was performed using the Illumina Goldengate custom panel at the Southern California Genotyping Consortium.', {'entities': [(19, 24, 'Total SNPs')]}),
 (' After quality assessment, 1163 subjects with 1,599,980 SNPs remained in the genetic association analysis ().', {'entities': [(46, 55, 'Total SNPs')]}),
 (' For stage 2 genotyping, we selected 1,326 SNPs as described in .', {'entities': [(37, 42, 'Total SNPs')]}),
 (' To estimate the number of Metabochip SNPs truly associated with BMI, we counted the number of SNPs with directional consistency (DC) between  and a meta-analysis of non-overlapping samples for these 1,909 SNPs.', {'entities': [(200, 205, 'Total SNPs')]}),
 ('57\u2009×\u200910_−8  was determined based on a Bonferroni correction for multiple comparisons for 546,355 SNPs.', {'entities': [(89, 96, 'Total SNPs')]}),
 (' Beginning with\nthe 508,286 SNPs delivered by Perlegen, 76 duplicated SNPs, 3,803 SNPs with\nminor allele frequencies <0.', {'entities': [(20, 27, 'Total SNPs')]}),
 (' The imputation of 11,572,501 autosomal SNPs was conducted using the MACH (http://www.', {'entities': [(19, 29, 'Total SNPs')]}),
 ('Two of the selected samples lacked sufficient DNA, and the remaining 1,542 subjects were genotyped with the Illumina Omni 1 array, containing probes for 1,008,624 SNPs.', {'entities': [(69, 74, 'Total SNPs'), (153, 162, 'Total SNPs')]}),
 (' After quality control exclusions, 584,029 genotyped SNPs remained as described by Aslibekyan et al.', {'entities': [(35, 42, 'Total SNPs')]}),
 ('For the Icelandic data set, we extended the classical case-control association analysis to include in silico  genotypes of affected individuals who were not genotyped but who had genotyped relatives among the 40,000 Icelanders (about 13% of all living Icelanders) genotyped with the Illumina SNP chips at deCODE Genetics.', {'entities': [(209, 215, 'Total SNPs')]}),
 (' Similarly, IBD was computed for all pairs of individuals in data from each country separately, using 6,764 autosomal SNPs with MAF of >1% and selected to minimize LD.', {'entities': [(102, 107, 'Total SNPs')]}),
 (' A total of 948,658 SNPs passed data-cleaning procedures and further within sample filtering for autosomal and X-chromosome markers yielded 948,142 markers.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' A total of 324,748 SNPs were genotyped in 602 subjects and available for analyses.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' In total, 93,508 autosomal SNPs passed all quality control measures and proceeded to further analysis.', {'entities': [(11, 17, 'Total SNPs')]}),
 (' Genotyping calls were generated after clustering all available data within platform at Genizon and then merged into a single file of 1,172,613 SNPs.', {'entities': [(134, 143, 'Total SNPs')]}),
 (' Assuming a 2% population prevalence of gout, there was >80% power to detect a risk variant conferring 30% increased odds of gout in 3,000 cases and ~67,000 controls at P  < 5 × 10_−8  for a SNP with minor allele frequency (MAF) of 10%.', {'entities': [(133, 138, 'Total SNPs')]}),
 ('\n4,683,137 SNPs in GSA and 5,477,977 SNPs in MEGA were analyzed.', {'entities': [(1, 10, 'Total SNPs')]}),
 (' Q-Q plots and the inflation factor (λ) were evaluated for confounding by population stratification (Appendix Table 2, Appendix Figures 1 and 2)Using principal components and a random subset of 21,710 SNPs across the genome, we genetically determined ethnicity across the studies.', {'entities': [(194, 200, 'Total SNPs')]}),
 ('00001 (N=288) were discarded, leaving 932,214 SNPs for analysis.', {'entities': [(38, 45, 'Total SNPs')]}),
 (' Of the 533,631 SNPs which were manufactured on the array, 494,813 SNPs passed the initial QC and 470,825 SNPs were used for imputation.', {'entities': [(8, 15, 'Total SNPs')]}),
 (' A total of 247,725 SNPs were included in the final GWA.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' We used a subset of 28,174 SNPs with CR>99% common to all arrays (dbGaP phs000674.', {'entities': [(21, 27, 'Total SNPs')]}),
 ('  A pruned version of the dataset, containing 56,919 LD-independent SNPs was merged with the 1000 Genomes Project dataset.', {'entities': [(46, 52, 'Total SNPs')]}),
 (' For scenario c), the single causal SNP was replaced with polygenic contributions from 10,000 simulated independent SNPs.', {'entities': [(87, 93, 'Total SNPs')]}),
 (' Lastly, we used 6852 markers (SNPs or HLA alleles) of two alleles from 12,983 people as reference data in HLA imputation _– .', {'entities': [(72, 78, 'Total SNPs')]}),
 (' Complete data on refractive error and genome-wide SNPs were available on 5,328 persons, 99% of whom were of European ancestry.', {'entities': [(74, 79, 'Total SNPs')]}),
 (' In total, the sample and SNP exclusions described above resulted in the association analysis of 3,023 cases and 8,779 controls at 2,223,620 autosomal SNPs.', {'entities': [(97, 102, 'Total SNPs'), (131, 140, 'Total SNPs')]}),
 (' The primary analysis comprised meta-analysis of association results for men and women combined, at the 568,976 SNPs that had been directly genotyped.', {'entities': [(104, 111, 'Total SNPs')]}),
 (' We then defined a set of 10,668 SNPs that were uncorrelated (r _2  < 0.', {'entities': [(26, 32, 'Total SNPs')]}),
 (' Genotyped SNPs passing quality control metrics described\nabove and reference haplotypes from HapMap Phase 2 (release 22 on NCBI build 36)\nwere used to impute approximately 2.5 million SNP', {'entities': [(173, 184, 'Total SNPs')]}),
 (' In brief, samples from 19 observational studies genotyped with high-density SNP arrays and imputed to the 1,000 Genomes Project March 2012 reference panel contributed to the discovery meta-analysis.', {'entities': [(107, 112, 'Total SNPs')]}),
 (' Finally, several quality control measures were applied to the remaining 12,446 SNPs to detect potential biases in genotyping.', {'entities': [(73, 79, 'Total SNPs')]}),
 ('0) and predicted (mirSNP) miRNA target sites (R), or SNPs that tag regions containing common copy-number variation regions reported by the database of genomic variants (DGV) (V) Conserved: conserved nucleotide sequences based on GERP++/phastCon (C) or known CpG islands that correlate with epigenetic methylation patterns (M) Literature-supported: published association with immune or inflammatory diseases or immune-related endophenotypes from candidate studies or GWASs catalogued in the Genetic Association Database, NHGRI GWAS catalog, dbGAP, or Immunochip studies (L) \n In addition to determining whether the 27 GWS pAID-associated SNPs were enriched for a given annotation type, we performed Monte Carlo simulations to resample 10,000 times the SNPs (MAF > 0.', {'entities': [(734, 740, 'Total SNPs')]}),
 (' After QC, 528,508 SNPs were used for analysis based on the following QC criteria: SNP call rate >99%, sample call rate >99%, minor allele frequency > 0.', {'entities': [(11, 18, 'Total SNPs')]}),
 (' After quality control procedures, 797,128 single nucleotide polymorphisms (SNPs) were available for analysis in a total of 1,227 (812 asthma cases, 415 controls) individuals with complete measurements of global African ancestry, age, and sex.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' We conducted a permutation resampling analysis to test for an enrichment of the 34,095 SNPs within 50kb of 84 Mendelian nonsyndromic deafness genes (,) among the CAO-associated SNPs (GWAS).', {'entities': [(81, 87, 'Total SNPs')]}),
 (' A test for population stratification with 10,000 random SNPs as genomic controls showed no evidence for admixture.', {'entities': [(43, 49, 'Total SNPs')]}),
 (' After these procedures, a maximum of 8,133,148 SNPs were retained that were present in at least 1 data set.', {'entities': [(38, 47, 'Total SNPs')]}),
 (' Using the same QC as above, 13,071 chromosome X SNPs were used.', {'entities': [(29, 35, 'Total SNPs')]}),
 ('01), 202,984 SNPs with minor allele frequency (MAF) <1% and 618 with both.', {'entities': [(5, 12, 'Total SNPs')]}),
 (' Participants’ genomic DNA was genotyped for >2.5 million SNP', {'entities': [(46, 57, 'Total SNPs')]}),
 (' A total of 5,815,690 SNPs passed the QC process.', {'entities': [(12, 21, 'Total SNPs')]}),
 (' The final combined data set contained 1,962 subjects (459 patients with GPA, 380 controls from Canada, and 1,123 controls from the US), with 287,802 common SNPs.', {'entities': [(39, 44, 'Total SNPs')]}),
 (' This resulted in a total of 2,649,157 SNPs which were tested for association with protein C concentration.', {'entities': [(29, 38, 'Total SNPs')]}),
 (' The total number of SNPs, directly genotyped, that remained\nfor further analysis in PAGE and the combined (meta-analysis) PAGE and PAPE\nstudies were 232,960 and 205,100, respectively.', {'entities': [(150, 157, 'Total SNPs')]}),
 (' After sampling and annotating 100-SNP sets 10,000 times, we use the permutation- derived distribution of annotation percentages for each annotation type to calculate an enrichment P  value such that\n Penrich=1−N(fpAID>Fconclusive)10,000 Penrich=1−N(fpAID>Fconclusive)10,000 Penrich=1−N(fpAID>Fconclusive)10,000 Penrich=1−N(fpAID>Fconclusive)10,000 Penrich=1−N(fpAID>Fconclusive)10,000 Penrich=1−N(fpAID>Fconclusive)10,000 Penrich Penrich P P   enrich enrich  = 1 − N(fpAID>Fconclusive)10,000 N(fpAID>Fconclusive)10,000 N(fpAID>Fconclusive) N(fpAID>Fconclusive) N  ( fpAID fpAID f f   pAID pAID p A I D  > Fconclusive Fconclusive F F   conclusive conclusive  )  10,000 10,000     \nwhere N  is the number of permutations, f  is the percentage of SNPs in the pAID set that are annotated and F  is the distribution of the percentage of SNPs annotated across 10,000 sets of 100 SNPs resampled from the 1KGP-RP using only markers with MAF > 0.', {'entities': [(44, 50, 'Total SNPs')]}),
 (' The original 13,341,935 SNPs were reduced into 9,270,523 SNPs in our subsequent analyses (e.', {'entities': [(14, 24, 'Total SNPs')]}),
 (' 832 controls were run on the Omni-5 microarray which contains approximately 4.3 million SNP', {'entities': [(77, 88, 'Total SNPs')]}),
 (' In total, genotypes for 559,390 SNPs were released in both genotyping rounds.', {'entities': [(25, 32, 'Total SNPs')]}),
 ('01) and 202,984 SNPs with minor allele frequencies (MAF) < 1% (618 SNP were included by both exclusion criteria), a final total of 689,368 SNPs were retained for subsequent analyses, yielding an average marker spacing of ~4 kb throughout the human genome.', {'entities': [(8, 15, 'Total SNPs')]}),
 ('01 in 1,618 Starr County Mexican-Americans to the full panel of CEU (Centre d’Etude du Polymorphisme [Utah residents with northern and western European ancestry]), YRI (Yoruba in Ibadan, Nigeria), and JPT (Japanese in Tokyo, Japan) + CHB (Han Chinese in Beijing, China) HapMap2 phased polymorphic SNPs from release 22 [].', {'entities': [(6, 11, 'Total SNPs')]}),
 (' PCA of approximately 150,000 SNPs identified a relatively homogeneous subset of the cases, and 53 outliers were removed.', {'entities': [(22, 29, 'Total SNPs')]}),
 (' As previously described (), we imputed classical alleles and amino acid polymorphisms in HLA-A , HLA-B , HLA-C , HLA-DPA1 , HLA-DPB1 , HLA-DQA1 , HLA-DQB1  and HLA-DRB1  at a four-digit resolution, as well as an additional 3,117 SNPs across the MHC, using a large reference panel of 2,767 individuals of European descent.', {'entities': [(224, 229, 'Total SNPs')]}),
 (' We then conducted a meta-analysis to combine results across datasets for 2,554,714 SNPs with high quality genotype data in one or more collections (see  online) by summing inverse variance-weighted β  and z -scores, and again genomic-control corrected our results.', {'entities': [(74, 83, 'Total SNPs')]}),
 (' 248 samples were genotyped on the Illumina Infinium HumanCoreExome beadchip (Illumina, USA), which contains 264,909 tagging SNP markers, and 244,593 exome focused markers by the Broad Institute (Boston, USA).', {'entities': [(109, 116, 'Total SNPs')]}),
 (' In total, 894 HapMap SNPs were successfully imputed in the interval between 130,051,729 bp and 131,225,253 bp using available SNP genotype data from GWA scans (225 SNPs).', {'entities': [(77, 88, 'Total SNPs')]}),
 (' The\xa0number of SNPs that entered the imputation process were 525,752, 795,240, and 532,149 for GOCHA, GERFHS, and ESs, respectively.', {'entities': [(83, 90, 'Total SNPs')]}),
 (' The final analyses were based on data from 201,598 SNPs.', {'entities': [(44, 51, 'Total SNPs')]}),
 ('05) 1000 Genomes SNPs (Interim Phase I release, 1,092 subjects) covered by the genome-wide array with r_2 >0.', {'entities': [(48, 53, 'Total SNPs')]}),
 (' After applying the marker map corresponding to human genome build 37 (GRCh37/hg19), a total of 905,420 successfully mapped SNPs (excluding duplicates) were advanced into quality control (QC) filtering process prior to GWA analysis.', {'entities': [(96, 103, 'Total SNPs')]}),
 (' 76% of the 9,412,474 SNPs with MAF>1% frequency was imputed at RSQ>0.', {'entities': [(12, 21, 'Total SNPs')]}),
 ('Because different genotyping arrays were used in the COGA and SAGE studies, there were only 483,037 common SNPs across both datasets after quality control.', {'entities': [(92, 99, 'Total SNPs')]}),
 (' This procedure yielded a total of 780,650 high-quality genotyped or imputed SNPs, which were used for all analyses.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' For selected SNPs, we estimated per-allele odds ratios by ER status using all available BCAC data for 82,263 cases with known ER status and 87,962 controls from the iCOGS and OncoArray studies.', {'entities': [(103, 109, 'Total SNPs')]}),
 (' The IMPUTE2 program was used for imputing untyped SNPs using the post-QCed PEGASUS genotype dataset (960 samples with 561,091 markers) and phased haplotypes from the 1000 genome CEU reference panel.', {'entities': [(119, 126, 'Total SNPs')]}),
 (' A total of 662,282 and 662,807 SNPs passed the quality filter for the ARV drugs alone and ARV-ATD co-treatment groups, respectively.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' An independent cohort of 7,138 AA participants from the NHLBI Candidate-gene Association Resource (CARe) Study was used to validate those SNP-trait associations identified in WHI, which have not been reported in previous GWASs.', {'entities': [(26, 31, 'Total SNPs')]}),
 (' There were 1,564 strand ambiguous SNPs (A/T and C/G polymorphism) out of the 532,566 total intersecting SNPs.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' Evaluation was restricted to the ~2.7 million SNP', {'entities': [(35, 46, 'Total SNPs')]}),
 (' A total of 397,704 SNPs passed quality control standards, were called per each calling algorithm, were in common on both arrays and had a minor allele frequency (MAF) ≥ 1%.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' In total, we performed 372,193 single SNP tests, 340,925 unique multi-marker tests, 200 pSNP tests and 183,513 pHAP tests (which represents approximately 10% of all possible haplotypes, i.', {'entities': [(24, 31, 'Total SNPs')]}),
 (' Data were imputed for all scans for ~2.6 million SNP', {'entities': [(38, 49, 'Total SNPs')]}),
 (' The array contains a total of 2,536,661 SNPs of which 2,427,090 are from a standard Illumina Omni2.', {'entities': [(31, 40, 'Total SNPs')]}),
 ('0 chip containing 906,600 SNP markers.', {'entities': [(18, 25, 'Total SNPs')]}),
 (' In step 2 we calculated a gene-based P-value for each of the 19,684 genes by combining the EOBC-association P-values for all its putative functional SNPs using methods described elsewhere ().', {'entities': [(62, 68, 'Total SNPs')]}),
 (' To examine the joint effect of multiple variants within known genes, gene-based tests were performed on the top 10\xa0% of the SNPs within the gene and the p  value was assessed based on 1,000,000 permutations using HCS GWAS results and VEGAS software (Liu et al.', {'entities': [(185, 194, 'Total SNPs')]}),
 (' We excluded SNPs with a call rate <95%, SNPs deviating from Hardy-Weinberg equilibrium (P <10-7  in controls or unrelated samples in CIMBA and P  <10-12  in cases) and SNPs with concordance<98% among 5,280 duplicate pairs.', {'entities': [(201, 206, 'Total SNPs')]}),
 ('9) a total of 215,607 SNPs remained.', {'entities': [(14, 21, 'Total SNPs')]}),
 (' From 1,411,821 SNPs after imputation, 165,433 SNPs were dropped due to QC reasons.', {'entities': [(39, 46, 'Total SNPs'), (6, 15, 'Total SNPs')]}),
 (' For sets 1 and 2, a total of 280,929 and 1,406,133 SNPs, respectively, passed all data filters.', {'entities': [(30, 37, 'Total SNPs'), (42, 51, 'Total SNPs')]}),
 (' Summary of SNPs that showed genome-wide significant (P  < 5 × 10_−8 ) association with cup area (adjusted for disc area) in the combined analysis (n  = 23,831 subjects with European and Asian descent) We tested for heterogeneous effects, for which P -values and I_2  are shown.', {'entities': [(153, 159, 'Total SNPs')]}),
 ('3 M autosomal SNPs and short in-dels (release v2) in 1,092 individuals from Africa, Asia, Europe and the Americas.', {'entities': [(53, 58, 'Total SNPs')]}),
 ('\nGWAS summary statistics results for all tested SNPs and identified SNVs from\nour 1,138 FALS cohort used for the RVB analysis can be viewed through our\nweb based ALS Variant Server (http://als.', {'entities': [(82, 87, 'Total SNPs')]}),
 (' In addition to the genotyped SNPs, we imputed genotypes for 2.54 million SNP', {'entities': [(61, 73, 'Total SNPs')]}),
 (' Of these 38 SNPs, 36 were successfully genotyped and evaluated in an independent sample of 6,532 cases and 8,140 controls (replication stage 1).', {'entities': [(92, 97, 'Total SNPs')]}),
 (' After EasyQC quality control, 8,040,131 SNPs were available for analysis.', {'entities': [(31, 40, 'Total SNPs')]}),
 (' A total of 3,277 SNPs were selected based on the interaction with overall breast cancer and 1,723 selected based on their association with lobular breast cancer.', {'entities': [(12, 17, 'Total SNPs')]}),
 (' A total of 12,896,220 variants (11,933,700 SNPs) were analyzed.', {'entities': [(12, 22, 'Total SNPs')]}),
 (' We initially used 90 individuals from JPT and CHB founders in HapMap as a reference panel comprising 3.99 million SNP', {'entities': [(102, 114, 'Total SNPs')]}),
 (' All individuals that met the inclusion criteria (n = 501) were genotyped for >1.1 million SNP', {'entities': [(79, 90, 'Total SNPs')]}),
 (' Sets could be comprised of up to 5 SNPs and gene-wide statistical significance was estimated with 50,000 permutations.', {'entities': [(99, 105, 'Total SNPs')]}),
 (' Briefly, samples were genotyped for 589,945 SNPs on the Illumina Human610-Quadv.', {'entities': [(37, 44, 'Total SNPs')]}),
 (' Principal components (PC) analysis was conducted in the entire GWAS sample using Eigensoft (, ) and 145,472 SNPs that were common to the GWAS dataset and HapMap panel (after pruning the GWAS SNPs for linkage disequilibrium (LD) (r_2 ) >80%) to characterize the underlying genetic architecture of the samples.', {'entities': [(101, 108, 'Total SNPs')]}),
 (' After quality control as described previously, 474,231 directly genotyped SNPs (MAF ≥5%) in 1,616 subjects (842 cases and 774 controls) from 1,850 total subjects were available for association testing after removing samples showing cryptic relatedness through identity by descent sharing.', {'entities': [(48, 55, 'Total SNPs')]}),
 (' A total of 128,935 SNPs were analyzed.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' PCA was performed using EIGENSTRAT  on a set of 15,552 Immunochip SNPs that had a pairwise r2 < 0.', {'entities': [(49, 55, 'Total SNPs')]}),
 ('0001 – this left 396,255 (Crohn’s disease) and 727,195 (Ulcerative Colitis) autosomal SNPs.', {'entities': [(17, 24, 'Total SNPs')]}),
 (' We mapped the credible set variants at each migraine locus to these enhancer sites and compared the overlap observed with tissue-specific enhancers relative to a background of 10,000 randomly selected sets of SNPs of equal size.', {'entities': [(177, 183, 'Total SNPs')]}),
 ('The stage 1 genotyping of 592,394 bi-allelic SNPs was performed using the Illumina Human 610 BeadChip (Illumina Inc.', {'entities': [(26, 33, 'Total SNPs')]}),
 (' All SNPs overlapping 1,000 Genomes were matched to the forward strand.', {'entities': [(22, 27, 'Total SNPs')]}),
 (' This resulted in 2,421,770 autosomal SNPs in 2054 subjects in whom plasma aspirin hydrolytic activity was available for analysis.', {'entities': [(18, 27, 'Total SNPs')]}),
 ('To explore the possible functional consequences of identified SNPs, we tested whether they were associated with expression of nearby genes in adult human lung tissue using a previously published dataset of 1,111 tissue samples with both genotyping and gene expression data ().', {'entities': [(206, 211, 'Total SNPs')]}),
 (' We used the program GCTA to compute a genetic relatedness matrix using these 19,059 SNPs and to output the top 10 leading eigenvectors from this matrix to adjust for population stratification in the analyses described below (, ).', {'entities': [(78, 84, 'Total SNPs')]}),
 ('  HAPI Heart Study participants were genotyped using the Affymetrix GeneChip_®  Human Mapping 500K Array Set which consisted of 500,568 SNP genotyping calls on each participant using the BRLMM genotype-calling algorithm.', {'entities': [(128, 135, 'Total SNPs')]}),
 (' π̂  Following quality control, 484,724 SNPs were available in all data sets for analysis.', {'entities': [(32, 39, 'Total SNPs')]}),
 (' This initial pruning was done in PLINK (), and 260,402 SNPs met these criteria (the full set of SNPs is available upon request).', {'entities': [(48, 55, 'Total SNPs')]}),
 (' Following imputation, 8.38 million SNP', {'entities': [(23, 35, 'Total SNPs')]}),
 ('01), and additional 141,666 SNPs had minor allele frequencies (MAF) less than 1.', {'entities': [(20, 27, 'Total SNPs')]}),
 (' To identify related samples, 119,811 LD-independent SNPs were selected and pairwise identity-by-descent was estimated using Plink (pi-hat threshold 0.', {'entities': [(30, 37, 'Total SNPs')]}),
 ('A total of 186 GD1 patients confirmed to be homozygous for N370S mutation were genotyped on Illumina 650 SNP array, which contains 620,901 SNPs.', {'entities': [(131, 138, 'Total SNPs')]}),
 (' After QC filtering, 40,647 SNPs with an MAF of 5% or higher remained for the analysis.', {'entities': [(21, 27, 'Total SNPs')]}),
 (' 334,631 SNPs remained for\nimputation.', {'entities': [(1, 8, 'Total SNPs')]}),
 (' Therefore, a final set of 746,709 SNPs was retained for subsequent association analyses, and yielded an average spacing of ~4.', {'entities': [(27, 34, 'Total SNPs')]}),
 (' 44,644 SNPs on the microarray and 135 individuals with call rates < 98% were excluded, and 62,076 additional SNPs were removed due to minor allele frequencies (MAF) <1%.', {'entities': [(1, 7, 'Total SNPs')]}),
 (' Genotype data for a total of 34,985,077 SNPs were available after imputation, including both fully imputed SNPs as well as genotyped SNPs for which sporadic missingness was imputed.', {'entities': [(30, 40, 'Total SNPs')]}),
 (' We combined 477,482 SNP genotypes of these subjects with genotype data of a sample of 9,115 children, removed SNPs with a missingness above 1% due to poor quality (n\xa0= 11,396), and removed a further 321 subjects due to potential ID mismatches.', {'entities': [(13, 20, 'Total SNPs')]}),
 (' Following the same SNP filtering criteria as above, 169,995 SNPs survived the filters and were used to generate the pairwise IBS matrix.', {'entities': [(53, 60, 'Total SNPs')]}),
 (' After the initial quality control processing, the genotype datasets contained 521,687 single nucleotide polymorphisms (SNPs) for 4,514 subjects in NEIGHBOR, and 495,161 SNPs for 2,116 subjects in GLAUGEN (dbGaP Study Accession: phs000308.', {'entities': [(79, 86, 'Total SNPs')]}),
 ('05), p-value of Hardy-Weinberg distribution <10-8  or non-autosomal loci, leaving 498,081 SNPs for analysis ().', {'entities': [(82, 89, 'Total SNPs')]}),
 (' In total, 596,032 SNPs remained in the analytic data set.', {'entities': [(11, 18, 'Total SNPs')]}),
 ('50, 1,695,815 genotyped or imputed SNPs remained for meta-analyses.', {'entities': [(4, 13, 'Total SNPs')]}),
 (' The European replication data comprised 1,478 cases and\n6,925 controls genotyped for 18 SNPs with an FDR of 1% in the Chinese\nreplication study.', {'entities': [(41, 46, 'Total SNPs')]}),
 (' An additional 2,363 SNPs located on the X chromosome were not included in this analysis.', {'entities': [(15, 20, 'Total SNPs')]}),
 ('2012-08-15) to impute ~31 million SNP', {'entities': [(23, 33, 'Total SNPs')]}),
 ('16()) and phased haplotype data from CEU individuals (HapMap release 22, Phase II NCBI B36, dbSNP 126) on 514,432 autosomal SNPs.', {'entities': [(106, 113, 'Total SNPs')]}),
 (' Manhattan and quantile-quantile plots were generated from the resulting data of 1,246,388 SNPs ().', {'entities': [(81, 90, 'Total SNPs')]}),
 (' We also used data from 5,654 unscreened controls, previously genotyped on\ntwo different Illumina SNP arrays ().', {'entities': [(24, 29, 'Total SNPs')]}),
 ('01 were also excluded, dropping 14,528 SNPs in African-Americans and 47,845 SNPs in Hispanics.', {'entities': [(32, 38, 'Total SNPs')]}),
 (' Sixty-three percent (2,444) of the controls are female, and 3,620 have genotyping data available for at least 317,503 SNPs (range: 243,991–561,466 SNPs).', {'entities': [(61, 66, 'Total SNPs')]}),
 (' To investigate whether any of the 527,829 successfully genotyped SNPs exerted a significant effect on the antisaccade error rate, we used generalized least squares regression.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' Additionally, we removed any SNPs based on the number of families with Mendel errors as follows: 1,486 SNPs with minor allele frequency (MAF)>20% and Mendel errors in 3+ families, 1,338 SNPs with 20%≥MAF>10% and Mendel errors in 2+ families, 1,767 SNPs with 20%≥MAF>10% and Mendel errors in 1+ family, and 9,592 SNPs with MAF<5% and any Mendel errors.', {'entities': [(98, 103, 'Total SNPs')]}),
 (' Quality-control filtering of SNPs resulted in a total of 325,624 and 912,765 high-quality SNPs, respectively.', {'entities': [(58, 65, 'Total SNPs')]}),
 (' 718,542 SNPs remained in the analysis following the quality control procedures described above.', {'entities': [(1, 8, 'Total SNPs')]}),
 (' For the 8,762 HVA loci, we were adequately powered to detect SNPs with effects accounting for ≥ 2.', {'entities': [(9, 14, 'Total SNPs')]}),
 (' To check the rank of eQTL p-values of six LD-independent SNPs in the Braineac database, we randomly selected 50,000 SNPs and queried the database to extract the lowest p-value for each SNP, resulting in a total of 36,190 SNPs with eQTL results.', {'entities': [(110, 116, 'Total SNPs')]}),
 (' Genotypes were imputed to approximately 2.5 million SNP', {'entities': [(41, 52, 'Total SNPs')]}),
 (' HumanOmni1-Quad BeadChips contain approximately 1,140,419 SNPs.', {'entities': [(49, 58, 'Total SNPs')]}),
 (' Adjusted and stratified analyses were performed only on the binary  and duration F0-1/F3-4  phenotypes, for the 140,797 SNPs giving P -values<0.', {'entities': [(113, 120, 'Total SNPs')]}),
 (' For each dataset we performed GWA-testing for each trait across ~31 million SNP', {'entities': [(66, 76, 'Total SNPs')]}),
 (' A total of 247,463 SNPs available in both EGEA and Hutterites were examined.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('2 million SNPs were tested, of which over 900,000 (91%) were successfully genotyped.', {'entities': [(42, 49, 'Total SNPs')]}),
 (' The analysis was restricted to 302,140 SNPs that passed quality filters and were deemed usable due to yield, Hardy-Weinberg equilibrium and consistency in genotype frequencies between the two arrays.', {'entities': [(32, 39, 'Total SNPs')]}),
 (' The GWAS included 5,060,354 SNPs and 511 individuals with full phenotypic data (i.', {'entities': [(19, 28, 'Total SNPs')]}),
 (' Principal-component and identity-by-descent analyses were performed via a pruned subset of independent SNPs (61,325 SNPs in GOCHA, 95,013 in GERFHS, and 64,728 in ESs) to account for potential biases introduced by LD structure.', {'entities': [(132, 138, 'Total SNPs')]}),
 (' Each study imputed the allele dosages for ∼2.5 million SNP', {'entities': [(44, 55, 'Total SNPs')]}),
 (' After applying quality controls, 430,198 SNPs were subject to analysis.', {'entities': [(34, 41, 'Total SNPs')]}),
 (' Additionally, a filtering criteria was applied to 776,463 autosomal SNPs to exclude those with genotyping call rate <0.', {'entities': [(51, 58, 'Total SNPs')]}),
 (' Lead SNP associations with stroke were explored in data generated from four large cohorts composing the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, including 1544 incident strokes (1164 ischemic strokes) developed over an average follow-up of 11 years, and 18,058 controls, and in data generated from four cohorts comprising the Welcome Trust Case Control Consortium (WTCCC), including 3,548 cases with ischemic stroke and 5,972 controls.', {'entities': [(296, 302, 'Total SNPs')]}),
 (' A total of 930,450 SNPs (call rate > 0.', {'entities': [(12, 19, 'Total SNPs')]}),
 ('For each of the 14 fatty acids considered here, a linear mixed model was fit for each of the 2.5 million SNP', {'entities': [(93, 104, 'Total SNPs')]}),
 ('01 )  2 2   ((p1+p0)(2−p1−p0)) ((p1+p0)(2−p1−p0)) ((p1+p0)(2−p1−p0)) ( (p1+p0)(2−p1−p0) (p1+p0) ( p1+p0 p1 p1 p p  1 1  + p0 p0 p p  0 0  ) (2−p1−p0) ( 2−p1−p0 2 − p1 p1 p p  1 1  − p0 p0 p p  0 0  ) )     > C  Our QC pipeline for ELLIPSE excluded SNPs with a call rate <95% by study, not in Hardy-Weinberg equilibrium (P <  10_−7  in controls or P <  10_−12  in cases) or with concordance <98% among 11,260 duplicate pairs.', {'entities': [(401, 407, 'Total SNPs')]}),
 (' In total, 6,942,916 SNPs present in both NHW and AAs at a\nminor allele frequency greater than 1% were analyzed.', {'entities': [(11, 20, 'Total SNPs')]}),
 (" The 23andMe's V4 platform in current use is a fully custom array, including a lower redundancy subset of V2 and V3 SNPs with additional coverage of lower-frequency coding variation, and about 570,000 SNPs.", {'entities': [(193, 200, 'Total SNPs')]}),
 ('01; 3,071 markers were excluded because they failed a test of Hardy-Weinberg equilibrium at p < 10_−7 ; and 3,922 SNPs were dropped because of a missingness greater than 3%.', {'entities': [(4, 9, 'Total SNPs')]}),
 (' We used linear regression with an additive model to conduct the association analysis of the delta log PCSK9 phenotype from 562 self-reported Caucasians with the 570,422 remaining SNPs using the third genome-wide ancestry axis as a covariate in Plinkv1.', {'entities': [(162, 169, 'Total SNPs')]}),
 ('The iSelect microarray contained 33,368 SNPs, of which 11,632 were devoted to stage 2.', {'entities': [(33, 39, 'Total SNPs')]}),
 (' Associations of SNPs with T2D amongst Europeans were tested in silico  using results from the GWA phase of the DIAGRAM+ study, which comprises 8,130 T2D cases and 38,987 controls of European ancestry.', {'entities': [(144, 149, 'Total SNPs')]}),
 (' The first stage GWAS revealed 1,372 SNPs in 268 loci associated with ischemic stroke or a specific subtype in any of the CCS or TOAST traits at p < 1 × 10_−6 .', {'entities': [(31, 36, 'Total SNPs')]}),
 (" After SNP and sample QC, the Crohn's disease data consisted of 5,956 cases and 14,927 controls, the ulcerative colitis data consisted of 6,968 cases and 20,464 controls, and Crohn's disease+ulcerative colitis combined (IBD) data consisted of 12,882 cases and 21,770 controls.", {'entities': [(64, 69, 'Total SNPs')]}),
 (' Following SNP and sample QC, genotype data of 643,496 SNPs from 98 CD cases were available for further analysis.', {'entities': [(47, 54, 'Total SNPs')]}),
 (' For dedicated imputation of the HLA region we used SNP2HLA  and imputed into the T1DGC reference panel of 5,224 individuals that have had classical HLA alleles typed as well as SNPs and indels by the immunochip.', {'entities': [(107, 112, 'Total SNPs')]}),
 ('20), 103,699 SNPs remained.', {'entities': [(5, 12, 'Total SNPs')]}),
 (' This resulted in 568,496 SNPs.', {'entities': [(18, 25, 'Total SNPs')]}),
 (' Replication set 2 (stage 2b, examining 12 non-HLA  SNPs) included 528 cases (279 from the WGGER and 249 from the VCRC) and 1,228 controls (300 from the WGGER and 928 “historical” controls from the MIRAGE study) ( and ).', {'entities': [(124, 129, 'Total SNPs')]}),
 (' Markers with low genotyping efficiency (<95%) were also excluded, 6,020 SNPs in African-Americans and 6,967 SNPs in Hispanics.', {'entities': [(67, 72, 'Total SNPs')]}),
 ('01 and passing stringent quality control criteria, for a total of ~2.6 million SNP', {'entities': [(67, 78, 'Total SNPs')]}),
 ('Of the 196,475 autosomal Metabochip loci, 75,820 were not genotyped in all 839 individuals and 46,044 had a minor allele frequency less than 1%, leaving 112,218 completely genotyped common SNPs.', {'entities': [(7, 14, 'Total SNPs')]}),
 (' After QC, 843 subjects and 563,980 SNPs remained for the subsequent genome-wide association and interaction analyses.', {'entities': [(28, 35, 'Total SNPs')]}),
 ('2[] was used to compute principal components (PC) separately for individuals on the four different arrays using 144,799 high-quality SNPs common to all arrays.', {'entities': [(112, 119, 'Total SNPs')]}),
 (' Genotype-CAD association results for the selected SNPs were obtained from the Coronary ARtery DIsease Genome-wide Replication And Meta-analysis (CARDIoGRAM) and Europe South Asia Coronary Artery Disease Genetics (C4D) consortia, including a total of 40,695 CAD cases and 85,582 controls.', {'entities': [(251, 257, 'Total SNPs')]}),
 (' The 660 W array included 561,490 SNPs and 95,876 intensity-only probes, and the 1 M array consisted of a total of 1,199,187 loci.', {'entities': [(26, 33, 'Total SNPs'), (115, 124, 'Total SNPs')]}),
 (' Gene-level analysis of all 283 genes and SNP-based analysis of 9,229 SNPs in the 42 pancreatitis-associated genes was performed using the same methods as in the initial GWAS (Data Supplement).', {'entities': [(64, 69, 'Total SNPs')]}),
 (' After removing 25,814 monomorphic SNPs along with 174,075 SNPs with r_2 <0.', {'entities': [(16, 22, 'Total SNPs')]}),
 (' In four trials, DICE, IMPACT, SOCS, and SLIC, subjects were genotyped for 909,622 SNPs throughout the entire genome.', {'entities': [(75, 82, 'Total SNPs')]}),
 (' SNPs are coloured in reference to LD with the particular index SNP according to a blue to red scale from  = 0 to 1, based on pairwise  values estimated from a reference of 5,000 individuals of white British origin, randomly selected from the UK Biobank.', {'entities': [(173, 178, 'Total SNPs')]}),
 (' Genotyping was performed by Illumina Microarray Services with a custom array [>2.5 million SNP', {'entities': [(80, 91, 'Total SNPs')]}),
 (' After all of these QC and filtering steps, 782,456 SNPs remained before imputation.', {'entities': [(44, 51, 'Total SNPs')]}),
 (' After the quality control (QC) process, a total of 513,460 and 266,727 SNPs were available in EGEA and Hutterites respectively.', {'entities': [(52, 59, 'Total SNPs')]}),
 ('To evaluate the potential functional significance of our findings, we related each replicated SNP to the expression levels of genes in three sets of tissues: human whole blood samples from n  = 5,311 individuals evaluated by Westra et al.', {'entities': [(194, 199, 'Total SNPs')]}),
 ('Each study used ProbABEL () or PLINK () to perform GWA-testing for natural log-transformed Se concentrations across ∼2.5 million SNP', {'entities': [(117, 128, 'Total SNPs')]}),
 ('Genome-wide associations between 4,313,801 imputed autosomal single nucleotide polymorphisms (SNPs) (with minor allele frequency (MAF) >5%, imputation information >0.', {'entities': [(33, 42, 'Total SNPs')]}),
 (' In our GWAS analysis we used\nlogistic regression to examine the association of the 840,354 SNPs with ED using\nPLINK (v1.', {'entities': [(84, 91, 'Total SNPs')]}),
 ('3(), a total of 14,620,866 SNPs were excluded.', {'entities': [(16, 26, 'Total SNPs')]}),
 (' In SAGE we did not have the advantage of family based cleaning; therefore, we based our analysis on 4,058,415 common SNPs that met imputation quality control criteria across both SAGE and COGA datasets.', {'entities': [(101, 110, 'Total SNPs')]}),
 (' After meta-analyses, results were filtered to remove SNPs and indels that were missing in either dataset for a total of 6,982,258 variants in common between the two studies (of those, 650,503 were indels).', {'entities': [(185, 192, 'Total SNPs'), (121, 130, 'Total SNPs')]}),
 (' The final set of 1,047 SNPs was also\nsubmitted to the MARTHA and EOVT studies, where results were obtained using\nin silico  analysis.', {'entities': [(18, 23, 'Total SNPs')]}),
 (' A total of 11,892,802 SNPs/indels with a frequency >1% in any single ethnic population (1,131,426 genotyped and 10,761,376 imputed) were included in the analysis.', {'entities': [(12, 22, 'Total SNPs')]}),
 (' A total of 173,882 SNPs were within 20kb of 29,418 genes or pseudo-genes.', {'entities': [(12, 19, 'Total SNPs')]}),
 (' Out of the initial full-set of 909,622 SNPs, there are 17,888 SNPs with allele frequencies extremely deviating from Hardy–Weinberg equilibrium (P  < 0.', {'entities': [(32, 39, 'Total SNPs')]}),
 ('3 million SNPs on 10,292 individuals (3,008 Tibetans, 2,098 Han, and 5,186 EAS) included in analysis.', {'entities': [(18, 24, 'Total SNPs')]}),
 ('18 software (), 38 million SNP', {'entities': [(16, 26, 'Total SNPs')]}),
 (' After quality control assessment, 510,856 SNPs were advanced in our survival analysis.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' We performed a within-family prediction analysis using full-sib pairs selected from independent families (1,622 pairs from the QIMR cohort and 2,758 pairs from the TwinGene cohort) and then SNPs at each threshold were used to calculate the percentage of phenotypic variance explained and predict risk ( and ).', {'entities': [(144, 149, 'Total SNPs')]}),
 ('We imputed classical HLA alleles and corresponding amino acid polymorphisms using a combined Asian and European reference panel with high-density SNP genotypes and 4-digit classical HLA allele genotypes (530 Asian individuals and 5,225 European individuals) using SNP2HLA software (see URLs), as described elsewhere.', {'entities': [(230, 235, 'Total SNPs')]}),
 (' After the series of QC, 98 European samples with 266,820 common SNPs remained for further statistical analysis ().', {'entities': [(50, 57, 'Total SNPs')]}),
 (' We also investigated a specific set of 1,180 endophenotype-general candidate SNPs selected from meta-analyses and related studies of interest examining the molecular genetic bases of disorders and traits likely related to the startle response, such as depression, schizophrenia, and antisocial behavior (see notes for  for a list of the sources used).', {'entities': [(40, 45, 'Total SNPs')]}),
 (' To allow for the\ntwo-stage testing of the 1,047 SNPs in the meta-analysis, we adjusted the\nsignificance threshold downward by a factor of two\n(p<2.', {'entities': [(43, 48, 'Total SNPs')]}),
 (' This resulted in 149,817 analyzable SNPs in 433 PD cases and 428 sibling controls.', {'entities': [(18, 25, 'Total SNPs')]}),
 ('01, 9,279 SNPs with missingness\n>0.', {'entities': [(4, 9, 'Total SNPs')]}),
 (' For confirming thyroid cancer GWAS results for SNPs under investigation in the present study, we used the Centaurs genotyping platform (see ) to attempt genotyping all 572 samples available from affected individuals and a minimum of 1,500 unaffected individuals.', {'entities': [(234, 239, 'Total SNPs')]}),
 (' In the SNP level quality control analysis, 32,192 SNPs with technical errors, 119,924 SNPs with minor allele frequency\u2009=\u20090 and 5,631 duplicate SNPs were excluded.', {'entities': [(44, 50, 'Total SNPs')]}),
 (' Variants with an imputed MAF ≥ 2% were used in association analyses, for a final analyzed SNP count of 2,193,082.', {'entities': [(104, 113, 'Total SNPs')]}),
 (' From the association summary statistics of LS and non-LS, we extracted 48,740 SNPs tagging 6,840 genes across the genome and used the genomic-controlled P  value (P _GC  ) as P  value entry.', {'entities': [(72, 78, 'Total SNPs')]}),
 (' Specifically, for the VTI1A  regional plot, genotypes of 70 SNPs spanning chr10: 114,362,000 - 114,593,000 (UCSC Genome Build hg18) were phased using PHASE v2.', {'entities': [(82, 93, 'Total SNPs')]}),
 (' In order to correctly apply the Bonferroni correction to our dataset, we calculated the number of effectively independent tests among our 797,128 genotyped SNPs (independent tests = 116,105) using the protocol published by .', {'entities': [(139, 146, 'Total SNPs')]}),
 (' After this extensive QC, 798 samples and 622,812 SNPs were available for analysis.', {'entities': [(42, 49, 'Total SNPs')]}),
 (' 655,658 autosomal SNPs satisfied these criteria.', {'entities': [(1, 8, 'Total SNPs')]}),
 (' We filtered imputed SNPs and indels based on minor allele frequency (MAF)<1% in the 1000 Genomes populations of African (AFR) or European (EUR) descent, leaving 6,809,218 SNPs and 739,119 indels in the AAs and 6,727,359 SNPs and 729,634 indels in the EAs.', {'entities': [(181, 188, 'Total SNPs'), (162, 171, 'Total SNPs')]}),
 ('5–4v1-H BeadChip (Illumina, San Diego, CA) was used to genotype 2,450,000 SNPs in 1200 Caucasian smokers from the LSC.', {'entities': [(64, 73, 'Total SNPs')]}),
 (' 514,008 single nucleotide polymorphisms (SNPs) passed the QC testing and were used in the association analysis.', {'entities': [(1, 8, 'Total SNPs')]})] ('[] The GERA cohort comprises a sample of 110,266 adult members of Kaiser Permanente Medical Care Plan, Northern California Region (KPNC) with high-density single nucleotide polymorphism (SNP) markers linked to comprehensive electronic health records (EHR) containing information on pharmacy utilization, laboratory test results, clinical diagnoses, and other clinical utilization.', {'entities': [(41, 48, 'Total SNPs')]}),
 (' After applying previously implemented quality control procedures (), we performed GWA analyses of 729,454 single nucleotide polymorphism (SNP) markers using 1001 European American bipolar cases and 1034 mentally healthy European American controls, genotyped on the Affymetrix Genome-Wide Human SNP Array 6.', {'entities': [(99, 106, 'Total SNPs')]}),
 ('In GOLDN, a total of 906,600 single nucleotide polymorphisms (SNPs) were genotyped using the Affymetrix Genome-Wide Human 6.', {'entities': [(21, 28, 'Total SNPs')]}),
 (' Because not all versions of 1000 Genomes that were used included copy number variations, we only analyzed single nucleotide polymorphisms (SNPs), which totaled 14,227,402.', {'entities': [(161, 171, 'Total SNPs')]}),
 (' Briefly, we combined summary statistics from 24 studies for up to 2,766,983 autosomal single nucleotide polymorphisms (SNPs) using an inverse-variance fixed-effects meta-analysis for each QRS trait.', {'entities': [(67, 76, 'Total SNPs')]}),
 (' High-density genotyping results were also available in the FHS and MESA for approximately 50,000 single nucleotide polymorphisms (SNPs) in approximately 2000 cardiovascular candidate genes from the Candidate Gene Association Resource (CARe).', {'entities': [(91, 97, 'Total SNPs')]}),
 ('All of the contributed samples were genotyped on 1 of the Illumina (San Diego, CA, USA) single nucleotide polymorphism (SNP) chips (see ); 254,145 SNPs common across the various SNP genotyping arrays and that passed quality control were analyzed in these cohorts.', {'entities': [(139, 146, 'Total SNPs')]}),
 (' A fixed-effects meta-analysis of the cohort-specific results was performed using the inverse variance-weighted method in METAL [], with a total of 2,033,301 single nucleotide polymorphisms (SNPs) tested.', {'entities': [(148, 157, 'Total SNPs')]}),
 (' Quality control and imputation using MACH () are described in the original reports (summarized in the  accompanying the online version of this article), yielding 1,922,309 single nucleotide polymorphisms (SNPs) in 3,117 subjects.', {'entities': [(215, 220, 'Total SNPs'), (163, 172, 'Total SNPs')]}),
 (' Quantile-quantile plot of the 591,610 single nucleotide polymorphisms from the genome-wide association study scan (n  = 1380; λ_GC  = 1.', {'entities': [(31, 38, 'Total SNPs')]}),
 (' Results were obtained for 10,641,224 single nucleotide polymorphisms (SNPs) and insertion-deletion variants with minor allele frequency > 1% and imputation quality scores > 0.', {'entities': [(27, 37, 'Total SNPs')]}),
 (' This array captures 951,117 single nucleotide polymorphisms (SNPs).', {'entities': [(21, 28, 'Total SNPs')]}),
 ('4 yielding 299,140 single nucleotide polymorphisms (SNPs).', {'entities': [(11, 18, 'Total SNPs')]}),
 (' After quality control procedures, 797,128 single nucleotide polymorphisms (SNPs) were available for analysis in a total of 1,227 (812 asthma cases, 415 controls) individuals with complete measurements of global African ancestry, age, and sex.', {'entities': [(35, 42, 'Total SNPs')]}),
 (' After the initial quality control processing, the genotype datasets contained 521,687 single nucleotide polymorphisms (SNPs) for 4,514 subjects in NEIGHBOR, and 495,161 SNPs for 2,116 subjects in GLAUGEN (dbGaP Study Accession: phs000308.', {'entities': [(79, 86, 'Total SNPs')]}),
 ('Genome-wide associations between 4,313,801 imputed autosomal single nucleotide polymorphisms (SNPs) (with minor allele frequency (MAF) >5%, imputation information >0.', {'entities': [(33, 42, 'Total SNPs')]}),
 (' 514,008 single nucleotide polymorphisms (SNPs) passed the QC testing and were used in the association analysis.', {'entities': [(1, 8, 'Total SNPs')]})]